

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

D7

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 September 2001 (20.09.2001)

PCT

(10) International Publication Number
WO 01/68882 A2

(51) International Patent Classification⁷: C12N 15/63

(21) International Application Number: PCT/US01/07870

(22) International Filing Date: 13 March 2001 (13.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/525,160 14 March 2000 (14.03.2000) US

(71) Applicant (for all designated States except US): TRAN-SKARYOTIC THERAPIES, INC. [US/US]; 195 Albany Street, Cambridge, MA 02139 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): IVANOV, Evguenii [RU/US]; 390 East Foxboro Street, Sharon, MA 02067 (US).

(74) Agents: MYERS, P., Louis et al.; Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110-2804 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



A2

WO 01/68882

(54) Title: METHODS OF IMPROVING HOMOLOGOUS RECOMBINATION

(57) Abstract: The invention features a method of promoting an alteration at a selected site in a target DNA, e.g., in the chromosomal DNA of a cell. The method includes providing, at the site: (a) a double stranded DNA sequence which includes a selected DNA sequence; (b) an agent which enhances homologous recombination, e.g., a Rad52 protein or a functional fragment thereof; and (c) an agent which inhibits non-homologous end joining, e.g., an agent which inactivates Ku such as an anti-Ku antibody or a Ku-binding oligomer or polymer, and allowing the alteration to occur. The agent which inhibits non-homologous end joining, e.g., a Ku inactivating agent such as an anti-Ku antibody, is preferably provided locally. Component (a), (b), and (c) can be introduced together, which is preferred, or separately.

BEST AVAILABLE COPY

5 **METHODS OF IMPROVING HOMOLOGOUS RECOMBINATION***Background of the Invention*

Current approaches to treating disease by administering therapeutic proteins include *in vitro* production of therapeutic proteins for conventional pharmaceutical delivery (e.g. intravenous, subcutaneous, or intramuscular injection) and, more recently, gene therapy.

10 Proteins of therapeutic interest can be produced by introducing exogenous DNA encoding the protein of therapeutic interest into appropriate cells. For example, a vector which includes exogenous DNA encoding a therapeutic protein can be introduced into cells and the encoded protein expressed. It has also been suggested that endogenous cellular genes and their expression may be modified by gene targeting. See for example, U.S. Patent No.:
15 5,272,071, U.S. Patent No.: 5,641,670, WO 91/06666, WO 91/06667 and WO 90/11354.

Summary of the Invention

The invention is based, in part, on the use of homologous recombination between a double stranded DNA sequence and a selected target DNA, e.g., chromosomal DNA in a cell, promoted by providing an agent which enhances homologous recombination, e.g., Rad52, and an agent which inhibits non-homologous end joining, e.g., a Ku inactivating agent, in sufficiently close proximity to the DNA sequence at the targeted site. It is predicted that a higher rate of homologous recombination occurred in the presence of both Rad52 and a Ku inactivating agent than in their absence. In addition, it is predicted that gene targeting aimed at altering a targeted site in a DNA, e.g., a targeted site in the chromosomal DNA in a cell, using a selected DNA sequence as a template can be promoted by providing a Rad52 protein and a Ku inactivating agent, e.g., an anti-Ku antibody. By providing a Rad52 protein and a Ku inactivating agent in close proximity to the selected DNA sequence and the target site, a higher rate of alteration by gene targeting occurs than in the absence of a Rad52 protein and a Ku inactivating agent, e.g., an anti-Ku antibody.
30

Accordingly, in one aspect, the invention features, a method of promoting an alteration at a selected site in a target DNA, e.g., in the chromosomal DNA of a cell. The method includes providing, at the site: (a) a double stranded DNA sequence which includes a selected DNA sequence; (b) an agent which enhances homologous recombination, e.g., a Rad52 protein or a functional fragment thereof, or a DNA sequence which encodes Rad52 or
35

5 a functional fragment thereof; and (c) an agent which inhibits non-homologous end joining, e.g., an agent which inactivates Ku, and allowing the alteration to occur. In a preferred embodiment, components (a), (b), and (c) are provided, e.g., introduced into the cell, such that, at the site of an interaction between the selected DNA sequence and the target DNA, the concentration of the agent which enhances homologous recombination and of the agent which inhibits non-homologous end joining are sufficient that an alteration of the site, e.g.,
10 homologous recombination or gene correction between the selected DNA sequence and the target DNA, occurs at a higher rate than would occur in the absence of the supplied agent which enhances homologous recombination and the agent which inhibits non-homologous end joining. The agent which inhibits non-homologous end joining is preferably provided locally. Preferably the agent which inhibits non-homologous end joining is a Ku inactivating
15 agent such as an anti-Ku antibody.

Components (a), (b), and (c) can be introduced together, which is preferred, or separately. In addition, two of the components can be introduced together and the third can be introduced separately. For example, the DNA sequence and the agent which enhances homologous recombination, e.g., Rad52, can be introduced together or the DNA sequence and the agent which inhibits non-homologous end joining, e.g., a Ku inactivating agent, can be introduced together. In another preferred embodiment, the agent which enhances homologous recombination and the agent which inhibits non-homologous end joining can be introduced together.
20

25 Two, or preferably all, of the components can be provided as a complex. In a preferred embodiment, the method includes contacting the target DNA, e.g., by introducing into the cell, a complex which includes: (a) a double stranded DNA sequence which includes the selected DNA sequence; (b) an agent which enhances homologous recombination, e.g., a Rad52 protein or functional fragment thereof; and (c) an agent which inhibits non-homologous end joining, e.g., a Ku inactivating agent such as an anti-Ku antibody or a Ku-binding oligomer or polymer.
30

In a preferred embodiment, one, or more, preferably all of the components are provided by local delivery, e.g., microinjection, and are not expressed from the target genome or another nucleic acid. In a particularly preferred embodiment, the agent which inhibits non-homologous end joining, e.g., a Ku inhibiting agent, is provided by local delivery, e.g.,
35 microinjection, and is not expressed from the target genome or another nucleic acid.

5 In a preferred embodiment, the agent which inhibits non-homologous end joining is: an agent which inactivates hMre11, e.g., an anti-hMre11 antibody or a hMre11-binding oligomer or polymer; an agent which inactivates hRad50, e.g., an anti-hRad50 antibody or a hRad50-binding oligomer or polymer; an agent which inactivates Nbs1, e.g., an anti-Nbs1 antibody or a hNbs1-binding oligomer or polymer; an agent which inactivates human ligase 4 (hLig4), e.g., an anti-hLig4 antibody or a hLig4-binding oligomer or polymer; an agent which inactivates hXrcc4, e.g., an anti-hXrcc4 antibody or a hXrcc4-binding oligomer or polymer; an agent which inactivates a human homolog of Rap1, e.g., an antibody to a human homolog of Rap1 or an oligomer or polymer which binds a human homolog of Rap1; an agent which inactivates a human homolog of Sir2304, e.g., an antibody to a human homolog of Sir2304 or an oligomer or polymer which binds a human homolog of Sir2304; an agent which inactivates Ku, e.g., an anti-Ku antibody or a Ku-binding oligomer or polymer. Any of the agents which inhibit non-homologous end joining can be administered alone or can be administered in combination with one or more of the other agents which inhibit non-homologous end joining.

20 In a preferred embodiment, the DNA sequence is a linear DNA sequence. In a preferred embodiment, the linear DNA sequence can have one or more single stranded overhang(s).

25 In a preferred embodiment, the selected DNA sequence is flanked by a targeting sequence. The targeting sequence is homologous to the target, e.g., homologous to DNA adjacent to the site where the target DNA is to be altered or to the site where the selected DNA sequence is to be integrated. Such flanking sequence can be present at one or more, preferably both ends of the selected DNA sequence. If two flanking sequences are present, one should be homologous with a first region of the target and the other should be homologous to a second region of the target.

30 In a preferred embodiment, the DNA sequence has one or more protruding single stranded end, e.g., one or both of the protruding ends are 3' ends or 5' ends.

 In a preferred embodiment, the agent which enhances homologous recombination is: a Rad52 protein or a functional fragment thereof; a Rad51 protein or a functional fragment thereof; a Rad54 protein or a functional fragment thereof; or a combination thereof.

35 In a preferred embodiment, the agent which enhances homologous recombination is adhered to, e.g., coated on, the DNA sequence. In a preferred embodiment, the Rad52 protein or functional fragment thereof is adhered to, e.g., coated on, the DNA sequence.

5 In a preferred embodiment, the Rad52 protein or fragment thereof is human Rad52 (hRad52).

In a preferred embodiment, the anti-Ku antibody is: an anti-Ku70 antibody; an anti-Ku80 antibody. In a preferred embodiment, the anti-Ku antibody is: a humanized antibody; a human antibody; an antibody fragment, e.g., a Fab, Fab', F(ab')² or F(v) fragment.

10 In a preferred embodiment, at least one anti-Ku antibody is covalently linked to: the DNA sequence; the Rad52 protein or fragment thereof. In another preferred embodiment, at least one anti-Ku antibody is non-covalently linked to: the DNA sequence; the Rad52 protein or fragment thereof.

15 In a preferred embodiment, an anti-Ku70 antibody and an anti-Ku80 antibody is provided, e.g., as components of a complex.

In a preferred embodiment, the cell is: a eukaryotic cell. In a preferred embodiment, the cell is of fungal, plant or animal origin, e.g., vertebrate origin. In a preferred embodiment, the cell is: a mammalian cell, e.g., a primary or secondary mammalian cell, e.g., a fibroblast, a hematopoietic stem cell, a myoblast, a keratinocyte, an epithelial cell, an endothelial cell, a glial cell, a neural cell, a cell comprising a formed element of the blood, a muscle cell and precursors of these somatic cells; a transformed or immortalized cell line. Preferably, the cell is a human cell. Examples of immortalized human cell line useful in the present method include, but are not limited to: a Bowes Melanoma cell (ATCC Accession No. CRL 9607), a Daudi cell (ATCC Accession No. CCL 213), a HeLa cell and a derivative of a HeLa cell (ATCC Accession Nos. CCL2 CCL2.1, and CCL 2.2), a HL-60 cell (ATCC Accession No. CCL 240), a HT1080 cell (ATCC Accession No. CCL 121), a Jurkat cell (ATCC Accession No. TIB 152), a KB carcinoma cell (ATCC Accession No. CCL 17), a K-562 leukemia cell (ATCC Accession No. CCL 243), a MCF-7 breast cancer cell (ATCC Accession No. BTH 22), a MOLT-4 cell (ATCC Accession No. 1582), a Namalwa cell (ATCC Accession No. CRL 1432), a Rafji cell (ATCC Accession No. CCL 86), a RPMI 8226 cell (ATCC Accession No. CCL 155), a U-937 cell (ATCC Accession No. 1593), WI-28VA13 sub line 2R4 cells (ATCC Accession No. CLL 155), a CCRF-CEM cell (ATCC Accession No. CCL 119) and a 2780AD ovarian carcinoma cell (Van Der Blick et al., Cancer Res. 48:5927-5932, 1988), as well as heterohybridoma cells produced by fusion of human cells and cells of another species. In another embodiment, the immortalized cell line can be cell line other than a human cell line, e.g., a CHO cell line, a COS cell line.

5 In a preferred embodiment, the components, e.g., the components of a complex, are introduced into the cell by microinjection.

10 In one preferred embodiment, the selected DNA sequence differs from the target DNA by less than 10, 8, 6, 5, 4, 3, 2, or by a single nucleotide, e.g., by a substitution, or a deletion, or an insertion.

In a preferred embodiment, the target DNA includes a mutation, e.g., the target sequence differs from wild-type sequence by about 10, 8, 6, 5, 4, 3, 2 or by a single nucleotide. Preferably, the mutation is a point mutation, e.g., a mutation due to an insertion, deletion or a substitution.

15 In a preferred embodiment, the target DNA includes a mutation and the mutation is associated with, e.g., causes, contributes to, conditions or controls, a disease or a dysfunction. Preferably, the disease or dysfunction is: cystic fibrosis; sickle cell anemia; hemophilia A; hemophilia B; von Willebrand disease type 3; xeroderma pigmentosa; thalassaemias; Lesch-Nylan syndrome; protein C resistance; a lysosomal storage disease, e.g., Gaucher disease, Fabry disease; mucopolysaccharidosis (MPS) type 1 (Hurley-Scheie syndrome), MPS type II (Hunter syndrome), MPS type IIIA (Sanfilio A syndrome), MPS type IIIB (Sanfilio B syndrome), MPS type IIIC (Sanfilio C syndrome), MPS type IIID (Sanfilio D syndrome), MPS type IVA (Morquio A syndrome), MPS type IVB (Morquio B syndrome), MPS type VI (Maroteaux-Larry syndrome), MPS type VII (Sly syndrome).

20 25 In a preferred embodiment, the target DNA includes a mutation and the selected DNA sequence includes a normal wild-type sequence which can correct the mutation.

In a preferred embodiment, the target DNA includes a mutation and the mutation is in the cystic fibrosis transmembrane regulator (CFTR) gene. Preferably, the mutation is one which alters the amino acid at codon 508 of the CFTR protein coding region, e.g., the mutation is a 3 base pair in-frame deletion which eliminates a phenylalanine at codon 508 of the CFTR protein. This deletion of phenylalanine-508 in the CFTR protein is found in a high percentage of subjects having cystic fibrosis. Thus, in a preferred embodiment, a selected DNA sequence including sequence encoding phenylalanine-508 as found in the wild-type CFTR gene can be used to target and correct the mutated CFTR gene.

30 35 In a preferred embodiment, the target DNA includes a mutation and the mutation is in the human β-globin gene. Preferably, the mutation is one which alters the amino acid at the sixth codon of the β-globin gene, e.g., the mutation is an A to T substitution in the sixth

5 codon of the β -globin gene. This mutation leads to a change from glutamic acid to valine in the β -globin protein which is found in subjects having sickle cell anemia. Thus, in a preferred embodiment, a selected DNA which encodes a wild-type amino acid residue at codon 6, e.g., a selected DNA sequence including an A as found within the sixth codon of wild-type β -globin gene, can be used to target and correct the mutated β -globin gene.

10 In a preferred embodiment, the target DNA includes a mutation and the mutation is in the Factor VIII gene. For example, a mutation can be in exon 23, 24, and/or exon 25 of the Factor VIII gene. Preferably, the mutation is one which alters the amino acid at codon 2209 of the coding region of the Factor VIII protein coding region, e.g., the mutation is a G to A substitution in exon 24 of the Factor VIII gene which leads to a change from an arginine to a glutamine at amino acid 2209 of Factor VIII. Preferably, the mutation is one which alters the amino acid at codon 2229 of the coding region of the Factor VIII protein coding region, e.g., the mutation is a G to T substitution in exon 25 of the Factor VIII gene which leads to a change from a tryptophan to a cysteine at amino acid 2229 of Factor VIII. These mutations have been associated with moderate to severe hemophilia A. Thus, in a preferred embodiment, a selected DNA sequence including either DNA which encodes a wild-type amino acid at codon 2209 of the coding region of Factor VIII gene or DNA which encodes a wild-type amino acid at codon 2229 of the coding region of the Factor VIII gene, or both, can be used to target and correct the mutated Factor VIII gene.

20 In a preferred embodiment, the target DNA includes a mutation and the mutation is in the Factor IX gene. For example, in subjects having hemophilia B, most of the mutations are point mutations in the Factor IX gene. Thus, in a preferred embodiment, the selected DNA sequence can include one or more nucleotides having at least one nucleotide from the wild-type Factor IX gene, to target and correct one or more of the point mutations in the Factor IX gene associated with hemophilia B.

25 In a preferred embodiment, the target DNA includes a mutation and the mutation is in the von Willebrand factor gene. Preferably, the mutation is a single cytosine deletion in a stretch of 6 cytosines at positions 2679-2684 in exon 18 of the von Willebrand gene. This mutation is found in a significant percentage of subjects having von Willebrand disease type 3. Other mutations, e.g., point mutations, associated with von Willebrand disease type 3 can also be altered as described herein. Thus, in a preferred embodiment, a selected DNA sequence including sequences found in the wild-type von Willebrand gene, e.g., the six

5 cytosines at positions 2679-2684 of the von Willebrand gene, can be used to target and correct the mutated von Willebrand gene.

In a preferred embodiment, the target DNA includes a mutation and the mutation is in the Xeroderma pigmentosum group G (XP-G) gene. Preferably, the mutation is a deletion of a single adenine in a stretch of three adenines at positions 19-21 of a 245 base-pair exon 10 found in the XP-G gene. This deletion leads to xeroderma pigmentosum. Thus, in a preferred embodiment, a selected DNA including the wild-type sequence of the XP-G gene, e.g., three adenines at positions 19-21 of the 245 base-pair exon, can be used to target and correct the mutated XP-G gene.

15 Preferably, an agent which inactivates a mismatch repair protein such as Msh2, Msh6, Msh3, Mlh1, Pms2, Mlh3, Pms1, is also provided. The agent can be included in a complex.

In another preferred embodiment, the alteration includes homologous recombination between the selected DNA sequence and the target DNA, e.g., a chromosome.

20 In preferred embodiment, the selected DNA sequence differs from the target DNA by more than one nucleotide, e.g., it differs from the target by a sufficient number of nucleotides such that the target, or the selected DNA sequence has an unpaired region, e.g., a loop-out region. In such an application, Msh2, Msh6, Msh3, Mlh1, Pms2, Mlh3, Pms1 can also be provided, e.g., as part of a complex.

25 In a preferred embodiment, the alteration includes integration of the selected sequence into the target DNA and the selected DNA is integrated such that it is in a preselected relationship with a preselected element on the target, e.g., if one is a regulatory element and the other is a sequence which encodes a protein, the regulatory element functions to regulate expression of the protein encoding sequence. Flanking sequences which promote the selected integration can be used. The selected DNA sequence can be integrated 5', 3', or within, a 30 selected target sequence, e.g., a gene or coding sequence.

35 In a preferred embodiment, the alteration includes integration of the selected DNA sequence and the selected DNA sequence is a regulatory sequence, e.g., an exogenous regulatory sequence. In a preferred embodiment, the regulatory sequence includes one or more of: a promoter, an enhancer, an upstream activating sequence (UAS), a scaffold-attachment region or a transcription factor-binding site. In a preferred embodiment, the regulatory sequence includes: a regulatory sequence from a metallothionein-I gene, e.g., a mouse metallothionein-I gene, a regulatory sequence from an SV-40 gene, a regulatory

5 sequence from a cytomegalovirus gene, a regulatory sequence from a collagen gene, a regulatory sequence from an actin gene, a regulatory sequence from an immunoglobulin gene, a regulatory sequence from the HMG-CoA reductase gene, a regulatory sequence from γ actin gene, a regulatory sequence from transcription activator YY1 gene, a regulatory sequence from fibronectin gene, or a regulatory sequence from the EF-1 α gene.

10 In a preferred embodiment, the selected DNA sequence includes an exon. Preferably, the exogenous exon includes: a CAP site, the nucleotide sequence ATG, and/or encoding DNA in-frame with the targeted endogenous gene.

In a preferred embodiment, the selected DNA sequence includes a splice-donor site.

15 In a preferred embodiment, the selected DNA sequence includes an exogenous regulatory sequence which when integrated into the target functions to regulate an endogenous coding sequence. The selected DNA sequence can be integrated upstream of the coding region of an endogenous gene in the target or upstream of the endogenous regulatory sequence of an endogenous gene in the target. In another preferred embodiment, the selected DNA sequence can be integrated downstream of an endogenous gene or coding region or within an intron or an endogenous gene. In another preferred embodiment, the selected DNA sequence can be integrated such that the endogenous regulatory sequence of the endogenous gene is inactive, e.g., is wholly or partially deleted.

20 In a preferred embodiment, the selected DNA sequence is upstream of an endogenous gene and is linked to the second exon of the endogenous gene.

25 In a preferred embodiment, the endogenous gene encodes: a hormone, a cytokine, an antigen, an antibody, an enzyme, a clotting factor, a transport protein, a receptor, a regulatory protein, a structural protein or a transcription factor. In a preferred embodiment, the endogenous gene encodes any of the following proteins: erythropoietin, calcitonin, growth hormone, insulin, insulinotropin, insulin-like growth factors, parathyroid hormone, α 2-interferon (IFNA2), β -interferon, γ -interferon, nerve growth factors, FSH β , TGF- β , tumor necrosis factor, glucagon, bone growth factor-2, bone growth factor-7, TSH- β , interleukin 1, interleukin 2, interleukin 3, interleukin 6, interleukin 11, interleukin 12, CSF-granulocyte (GCSF), CSF-macrophage, CSF-granulocyte/macrophage, immunoglobulins, catalytic antibodies, protein kinase C, glucocerebrosidase, superoxide dismutase, tissue plasminogen activator, urokinase, antithrombin III, DNase, α -galactosidase, tyrosine hydroxylase, blood clotting factor V, blood clotting factor VII, blood clotting factor VIII, blood clotting factor IX, blood clotting factor X, blood clotting factor XIII, apolipoprotein E, apolipoprotein A-I,

5 globins, low density lipoprotein receptor, IL-2 receptor, IL-2 antagonists, α -1-antitrypsin, immune response modifiers, β -glucoceramidase, α -iduronidase, α -L-iduronidase, glucosamine-N-sulfatase, α -N-acetylglucosaminidase, acetylcoenzymeA: α -glucosamine-N-acetyltransferase, N-acetylglucosamine-6-sulfatase, β -galactosidase, β -glucuronidase, N-acetylgalactosamine-6-sulfatase, and soluble CD4.

10 In a preferred embodiment, the endogenous gene encodes follicle stimulating hormone β (FSH β) and the selected DNA sequence includes a regulatory sequence, e.g., a regulatory sequence which differs in sequence from the regulatory sequence of the FSH β gene. Preferably, the selected DNA sequence is flanked by a targeting sequence, e.g., such targeting sequence is present at one or more, preferably both ends of the selected DNA
15 sequence. In a preferred embodiment, the targeting sequence is homologous to a region 5' of the FSH β coding region (SEQ ID NO:1). In a preferred embodiment, the targeting sequence directs homologous recombination within the FSH β coding sequence or upstream of the FSH β coding sequence. In a preferred embodiment, the targeting sequence includes at least 20, 30, 50, 100 or 1000 contiguous nucleotides from SEQ ID NO:2, which corresponds to
20 nucleotides -7454 to -1417 of human FSH β sequence (numbering is relative to the translation start site), or SEQ ID NO:3, which corresponds to nucleotides -696 to -155 of human FSH β sequence.

25 In a preferred embodiment, the endogenous gene encodes interferon α 2 (IFNa2) and the selected DNA sequence includes a regulatory sequence, e.g., a regulatory sequence which differs in sequence from the regulatory sequence of the IFNa2 gene. Preferably, the selected DNA sequence is flanked by a targeting sequence, e.g., such targeting sequence is present at one or more, preferably both ends of the selected DNA sequence. In a preferred embodiment, the targeting sequence is homologous to a region 5' of the IFNa2 coding region. In a preferred embodiment, the targeting sequence directs homologous recombination within a region upstream of the IFNa2 coding sequence. In a preferred embodiment, the targeting sequence includes at least 20, 30, 50, 100 or 1000 contiguous nucleotides from SEQ ID
30 NO:4, which corresponds to nucleotides -4074 to -511 of human IFNa2 sequence (numbering is relative to the translation start site). For example, it can include: at least 20, 30, 50, or 100 nucleotides from SEQ ID NO:7, which corresponds to nucleotides -4074 to -3796 of human IFNa2 sequence; at least 20, 30, or 50 nucleotides from SEQ ID NO:8, which corresponds to nucleotides -582 to -510 of human IFNa2 sequence; at least 20, 30, 50, 100,
35

5 or 1000 nucleotides from SEQ ID NO:9, which corresponds to nucleotides -3795 to -583 of human IFN α 2 sequence.

In a preferred embodiment, the endogenous gene encodes granulocyte colony stimulating factor (GCSF) and the selected DNA sequence includes a regulatory sequence, e.g., a regulatory sequence which differs in sequence from the regulatory sequence of the GCSF gene. Preferably, the selected DNA sequence is flanked by a targeting sequence, e.g., such targeting sequence is present at one or more, preferably both ends of the selected DNA sequence. In a preferred embodiment, the targeting sequence is homologous to a region 5' of the GCSF coding region. In a preferred embodiment, the targeting sequence directs homologous recombination within the GCSF coding sequence or upstream of the GCSF coding sequence. In a preferred embodiment, the targeting sequence includes at least 20, 30, 50, 100 or 1000 contiguous nucleotides from SEQ ID NO:5, which corresponds to nucleotides -6,578 to 101 of human GCSF sequence (numbering is relative to the translation start site). For example, the target sequence can include 20, 30, 50, 100 or 1000 nucleotides from SEQ ID NO:6, which corresponds to nucleotides -6,578 to -364 of the human GCSF gene.

In another preferred embodiment, the DNA sequence includes a coding region, e.g., the selected DNA sequence encodes a protein. In a preferred embodiment, the coding region encodes: a hormone, a cytokine, an antigen, an antibody, an enzyme, a clotting factor, a transport protein, a receptor, a regulatory protein, a structural protein or a transcription factor.

25 In a preferred embodiment, the coding region encodes any of the following proteins: erythropoietin, calcitonin, growth hormone, insulin, insulinotropin, insulin-like growth factors, parathyroid hormone, α 2-interferon (IFN α 2), β -interferon, γ -interferon, nerve growth factors, FSH β , TGF- β , tumor necrosis factor, glucagon, bone growth factor-2, bone growth factor-7, TSH- β , interleukin 1, interleukin 2, interleukin 3, interleukin 6, interleukin 11, interleukin 12, CSF-granulocyte (GCSF), CSF-macrophage, CSF-granulocyte/macrophage, immunoglobulins, catalytic antibodies, protein kinase C, glucocerebrosidase, superoxide dismutase, tissue plasminogen activator, urokinase, antithrombin III, DNase, α -galactosidase, tyrosine hydroxylase, blood clotting factor V, blood clotting factor VII, blood clotting factor VIII, blood clotting factor IX, blood clotting factor X, blood clotting factor XIII, apolipoprotein E, apolipoprotein A-I, globins, low density lipoprotein receptor, IL-2 receptor, IL-2 antagonists, α -1-antitrypsin, immune response modifiers, β -glucoceramidase,

5 α -iduronidase, α -L-iduronidase, glucosamine-N-sulfatase, α -N-acetylglucosaminidase, acetylcoenzymeA: α -glucosamine-N-acetyltransferase, N-acetylglucosamine-6-sulfatase, β -galactosidase, β -glucuronidase, N-acetylgalactosamine-6-sulfatase, and soluble CD4.

10 In a preferred embodiment, the selected DNA sequence can be integrated into the target such that it is under the control of an endogenous regulatory element. The selected DNA can be integrated downstream of an endogenous regulatory sequence or upstream of a coding region of an endogenous gene and downstream of the endogenous regulatory sequence of the gene. In another preferred embodiment, the selected DNA can be integrated downstream of an endogenous regulatory sequence such that the coding region of the endogenous gene is inactivated, e.g., is wholly or partially deleted.

15 In a preferred embodiment, the method further includes introducing an agent which inhibits a mismatch-repair protein, e.g., Msh2, Msh6, Msh3, Mlh1, Pms2, Mlh3, Pms1, or other mismatch repair proteins, or combinations thereof. Preferably, the agent is an agent which inhibits expression of a mismatch-repair protein, e.g., the agent is an antisense RNA. In a preferred embodiment, the agent is an antibody against a mismatch-repair protein. In a preferred embodiment, the antibody against the mismatch-repair protein is covalently or non-covalently linked to the complex.

20 In another aspect, the invention features, a composition, e.g., a complex of components, for promoting an alteration at a target DNA, e.g., a chromosome, e.g., a target DNA described herein, using a selected DNA sequence, e.g., a selected DNA sequence described herein, as a template. The composition includes: (a) a double stranded DNA sequence which includes a selected DNA sequence; (b) an agent which enhances homologous recombination, e.g., a Rad52 protein or a functional fragment thereof; and (c) an agent which inhibits non-homologous end joining, e.g., an agent which inactivates Ku. The composition can be used, for example, to alter the target DNA sequence by integration.

25 In a preferred embodiment, the agent which inhibits non-homologous end joining is: an agent which inactivates hMre11, e.g., an anti-hMre11 antibody or a hMre11-binding oligomer or polymer; an agent which inactivates hRad50, e.g., an anti-hRad50 antibody or a hRad50-binding oligomer or polymer; an agent which inactivates Nbs1, e.g., an anti-Nbs1 antibody or a hNbs1-binding oligomer or polymer; an agent which inactivates human ligase 4 (hLig4), e.g., an anti-hLig4 antibody or a hLig4-binding oligomer or polymer; an agent which inactivates hXrcc4, e.g., an anti-hXrcc4 antibody or a hXrcc4-binding oligomer or polymer;

5 an agent which inactivates a human homolog of Rap1, e.g., an antibody to a human homolog of Rap1 or an oligomer or polymer which binds a human homolog of Rap1; an agent which inactivates a human homolog of Sir2304, e.g., an antibody to a human homolog of Sir2304 or an oligomer or polymer which binds a human homolog of Sir2304; an agent which inactivates Ku, e.g., an anti-Ku antibody or a Ku-binding oligomer or polymer. Any of the
10 agents which inhibit non-homologous end joining can be administered alone or can be administered in combination with one or more of the other agents which inhibit non-homologous end joining.

In a preferred embodiment, the DNA sequence is a linear DNA sequence. In a preferred embodiment, the linear DNA sequence can have one or more single stranded overhang(s).

In a preferred embodiment, the selected DNA sequence is flanked by a targeting sequence. The targeting sequence is homologous to the target, e.g., homologous to DNA adjacent to the site where the target DNA is to be altered or to the site where the selected DNA sequence is to be integrated. Such flanking sequence can be present at one or more, 20 preferably both ends of the selected DNA sequence. If two flanking sequences are present, one should be homologous to a first region of the target and the other should be homologous to a second region of the target.

In a preferred embodiment, the DNA sequence has one or more protruding single stranded end, e.g., one or both of the protruding ends are 3' ends or 5' ends.

25 In a preferred embodiment, the agent which enhances homologous recombination is: a Rad52 protein or a functional fragment thereof; a Rad51 protein or a functional fragment thereof; a Rad54 protein or a functional fragment thereof; or a combination thereof.

In a preferred embodiment, the agent which enhances homologous recombination is adhered to, e.g., coated on, the DNA sequence. In a preferred embodiment, the Rad52 protein or functional fragment thereof is adhered to, e.g., coated on, the selected DNA 30 sequence.

In a preferred embodiment, the Rad52 protein or fragment thereof is human Rad52 (hRad52).

35 In a preferred embodiment, the anti-Ku antibody is: an anti-Ku70 antibody; an anti-Ku80 antibody. In a preferred embodiment, the anti-Ku antibody is: a humanized antibody; a human antibody; an antibody fragment, e.g., a Fab, Fab', F(ab')² or F(v) fragment.

5 In a preferred embodiment, at least one anti-Ku antibody is covalently linked to: the selected DNA sequence; the Rad52 protein or fragment thereof. In another preferred embodiment, at least one anti-Ku antibody is covalently linked to: the selected DNA sequence; the Rad52 protein or fragment thereof.

10 In a preferred embodiment, the composition includes an anti-Ku70 antibody and an anti-Ku80 antibody.

In a preferred embodiment, the selected DNA sequence differs from the target DNA by less than 10, 8, 6, 5, 4, 3, 2 or by a single nucleotide, e.g., a substitution, or a deletion, or an insertion.

15 In a preferred embodiment, the target DNA includes a mutation, e.g., the target sequence differs from wild-type sequence by about 10, 8, 6, 5, 4, 3, 2 or by a single nucleotide. Preferably, the mutation is a point mutation, e.g., a mutation due to an insertion, deletion or a substitution.

20 In a preferred embodiment, the target DNA includes a mutation and the mutation is associated with, e.g., causes, contributes to, conditions or controls, a disease or a dysfunction. Preferably, the disease or dysfunction is: cystic fibrosis; sickle cell anemia; hemophilia A; hemophilia B; von Willebrand disease type 3; xeroderma pigmentosa; thalassaemias; Lesch-Nylan syndrome; protein C resistance; a lysosomal storage disease, e.g., Gaucher disease, Fabry disease, mucopolysaccharidosis (MPS) type 1 (Hurley-Scheie syndrome), MPS type II (Hunter syndrome), MPS type IIIA (Sanfilio A syndrome), MPS type IIIB (Sanfilio B syndrome), MPS type IIIC (Sanfilio C syndrome), MPS type IIID (Sanfilio D syndrome), MPS type IVA (Morquio A syndrome), MPS type IVB (Morquio B syndrome), MPS type VI (Maroteaux-Larry syndrome), MPS type VII (Sly syndrome).

25 In a preferred embodiment, the target DNA includes a mutation and the selected DNA sequence includes a normal wild-type sequence which can correct the mutation.

30 In a preferred embodiment, the target DNA includes a mutation and the mutation is in the cystic fibrosis transmembrane regulator (CFTR) gene. Preferably, the mutation is one which alters the amino acid at codon 508 of the CFTR protein coding region, e.g., the mutation is a 3 base pair in-frame deletion which eliminates a phenylalanine at codon 508 of the CFTR protein. This deletion of phenylalanine-508 in the CFTR protein is found in a high percentage of subjects having cystic fibrosis. Thus, in a preferred embodiment, a selected

5 DNA sequence including sequence encoding phenylalanine-508 as found in the wild-type CFTR gene can be used to target and correct the mutated CFTR gene.

In a preferred embodiment, the target DNA includes a mutation and the mutation is in the human β-globin gene. Preferably, the mutation is one which alters the amino acid at the sixth codon of the β-globin gene, e.g., the mutation is an A to T substitution in the sixth codon of the β-globin gene. This mutation leads to a change from glutamic acid to valine in the β-globin protein which is found in subjects having sickle cell anemia. Thus, in a preferred embodiment, a selected DNA which encodes a wild-type amino acid residue at codon 6, e.g., a selected DNA sequence including an A as found within the sixth codon of wild-type β-globin gene, can be used to target and correct the mutated β-globin gene.

10 In a preferred embodiment, the target DNA includes a mutation and the mutation is in the Factor VIII gene. For example, a mutation can be in exon 23, 24, and/or exon 25 of the Factor VIII gene. Preferably, the mutation is one which alters the amino acid at codon 2209 of the coding region of the Factor VIII protein coding region, e.g., the mutation is a G to A substitution in exon 24 of the Factor VIII gene which leads to a change from an arginine to a glutamine at amino acid 2209 of Factor VIII. Preferably, the mutation is one which alters the amino acid at codon 2229 of the coding region of the Factor VIII protein coding region, e.g., the mutation is a G to T substitution in exon 25 of the Factor VIII gene which leads to a change from a tryptophan to a cysteine at amino acid 2229 of Factor VIII. These mutations have been associated with moderate to severe hemophilia A. Thus, in a preferred 15 embodiment, a selected DNA sequence including either DNA which encodes a wild-type amino acid at codon 2209 of the coding region of Factor VIII gene, or DNA which encodes a wild-type amino acid at codon 2229 of the coding region of the Factor VIII gene, or both, can be used to target and correct the mutated Factor VIII gene.

20 In a preferred embodiment, the target DNA includes a mutation and the mutation is in the Factor IX gene. For example, in subjects having hemophilia B, most of the mutations are point mutations in the Factor IX gene. Thus, in a preferred embodiment, the selected DNA sequence can include one or more nucleotides having at least one nucleotide from the wild-type Factor IX gene, to target and correct one or more of the point mutations in the Factor IX gene associated with hemophilia B.

25 In a preferred embodiment, the target DNA includes a mutation and the mutation is in the von Willebrand factor gene. Preferably, the mutation is a single cytosine deletion in a stretch of six cytosines at positions 2679-2684 in exon 18 of the von Willebrand gene. This

5 mutation is found in a significant percentage of subjects having von Willebrand disease type
3. Other mutations, e.g., point mutations, associated with von Willebrand disease type 3 can
also be altered as described herein. Thus, in a preferred embodiment, a selected DNA
sequence including sequences found in the wild-type von Willebrand gene, e.g., the six
cytosines at positions 2679-2684 in exon 18 of the von Willebrand gene, can be used to target
10 and correct the mutated von Willebrand gene.

In a preferred embodiment, the target DNA includes a mutation and the mutation is in
the Xeroderma pigmentosum group G (XP-G) gene. Preferably, the mutation is a deletion of
a single adenine in a stretch of three adenines at positions 19-21 of a 245 base-pair exon
found in the XP-G gene. This deletion leads to xeroderma pigmentosum. Thus, in a
15 preferred embodiment, a selected DNA including the wild-type sequence of the XP-G gene,
e.g., three adenines at positions 19-21 of the 245 base-pair exon of the XP-G gene, can be
used to target and correct the mutated XP-G gene.

20 In another preferred embodiment, the selected DNA sequence differs from the target
DNA by more than one nucleotide, e.g., it differs from the target by a sufficient number of
nucleotides such that the target, or the selected DNA sequence has an unpaired region, e.g., a
loop-out region. Preferably, an agent which inactivates a mismatch repair protein such as
Msh2, Msh6, Msh3, Mlh1, Pms2, Mlh3, Pms1, or combinations thereof, is also included in
the composition, e.g., the agent can be included in the complex.

25 In a preferred embodiment, the selected DNA sequence has a flanking sequence such
that it can integrate in a preselected relationship with a preselected element on a target DNA.
For example, if the selected DNA is a regulatory sequence and the target DNA encodes a
protein, the flanking sequence is such that it will integrate the regulatory element so that it
functions to regulate expression of the protein encoding sequence. Flanking sequences which
30 promote the selected integration can be used. The selected DNA sequence can have a
flanking sequence such that it can be integrated 5', 3' or within, a selected target sequence,
e.g., a gene or coding region in the target.

35 In a preferred embodiment, the selected DNA sequence includes a regulatory
sequence, e.g., an exogenous regulatory sequence. In a preferred embodiment, the regulatory
sequence includes one or more of: a promoter, an enhancer, an UAS, a scaffold-attachment
region or a transcription factor-binding site. In a preferred embodiment, the regulatory
sequence includes: a regulatory sequence from a metallothionein-I gene, e.g., the mouse

5 metallothionein-I gene, a regulatory sequence from an SV-40 gene, a regulatory sequence from a cytomegalovirus gene, a regulatory sequence from a collagen gene, a regulatory sequence from an actin gene, a regulatory sequence from an immunoglobulin gene, a regulatory sequence from the HMG-CoA reductase gene, a regulatory sequence from γ actin gene, a regulatory sequence from transcription activator YY1 gene, a regulatory sequence from fibronectin gene, or a regulatory sequence from the EF-1 α gene.

10 In a preferred embodiment, the selected DNA sequence includes an exon. Preferably, the exogenous exon includes: a CAP site, the nucleotide sequence ATG, and/or encoding DNA in-frame with the targeted endogenous gene.

15 In a preferred embodiment, the selected DNA sequence includes a splice-donor site.

20 In a preferred embodiment, a composition which includes a selected DNA sequence having exogenous regulatory sequence can have a flanking sequence such that it is integrated into the target such that it functions to regulate expression of an endogenous sequence. The selected DNA can be integrated into the target upstream of the coding region of an endogenous gene or coding sequence in the target, or integrated into the target upstream of the endogenous regulatory sequence of an endogenous gene or coding sequence in the target. In another preferred embodiment, the selected DNA sequence can be integrated into the target such that the endogenous regulatory sequence of the endogenous gene is inactive, e.g., is wholly or partially deleted. The selected DNA sequence can be integrated into the target downstream of the endogenous gene or coding region, or integrated within an intron of an endogenous gene.

25 In a preferred embodiment, the selected DNA sequence includes a regulatory sequence, e.g., a regulatory sequence which differs in sequence from the regulatory sequence of the FSH β gene. Preferably, the selected DNA sequence is flanked by a targeting sequence, e.g., such targeting sequence is present at one or more, preferably both ends of the selected DNA sequence. In a preferred embodiment, the targeting sequence is homologous to a region 30 5' of FSH β coding region (SEQ ID NO:1). In a preferred embodiment, the targeting sequence directs homologous recombination within the FSH β coding sequence, or upstream of the FSH β coding sequence. In a preferred embodiment, the targeting sequence includes at least 35 20, 30, 50, 100 or 1000 contiguous nucleotides from SEQ ID NO:2, which corresponds to nucleotides -7454 to -1417 of human FSH β sequence (numbering is relative to the translation start site), or SEQ ID NO:3, which corresponds to nucleotides -696 to -155 of human FSH β sequence.

5 In a preferred embodiment, the selected DNA sequence includes a regulatory sequence, e.g., a regulatory sequence which differs in sequence from the regulatory sequence of the IFN α 2 gene. Preferably, the selected DNA sequence is flanked by a targeting sequence, e.g., such targeting sequence is present at one or more, preferably both ends of the selected DNA sequence. In a preferred embodiment, the targeting sequence is homologous to 10 a region 5' of IFN α 2 coding region. In a preferred embodiment, the targeting sequence directs homologous recombination within a region upstream of the IFN α 2 coding sequence. In a preferred embodiment, the targeting sequence includes at least 20, 30, 50, 100 or 1000 contiguous nucleotides from SEQ ID NO:4, which corresponds to nucleotides -4074 to -511 of human IFN α 2 sequence (numbering is relative to the translation start site). For example, it 15 can include: at least 20, 30, 50, or 100 nucleotides from SEQ ID NO:7, which corresponds to nucleotides -4074 to -3796 of human IFN α 2 sequence; at least 20, 30, or 50 nucleotides from SEQ ID NO:8, which corresponds to nucleotides -582 to -510 of human IFN α 2 sequence; at least 20, 30, 50, 100, or 1000 nucleotides from SEQ ID NO:9, which corresponds to nucleotides -3795 to -583 of human IFN α 2 sequence.

20 In a preferred embodiment, the selected DNA sequence includes a regulatory sequence, e.g., a regulatory sequence which differs in sequence from the regulatory sequence of the GCSF gene. Preferably, the selected DNA sequence is flanked by a targeting sequence, e.g., such targeting sequence is present at one or more, preferably both ends of the selected DNA sequence. In a preferred embodiment, the targeting sequence is homologous to 25 a region 5' of GCSF coding region. In a preferred embodiment, the targeting sequence directs homologous recombination: within the GCSF coding sequence; upstream of the GCSF coding sequence. In a preferred embodiment, the targeting sequence includes at least 20, 30, 50, 100 or 1000 contiguous nucleotides from SEQ ID NO:5, which corresponds to nucleotides -6,578 to 101 of human GCSF sequence (numbering is relative to the translation 30 start site). For example, the target sequence can include 20, 30, 50, 100 or 1000 nucleotides from SEQ ID NO:6, which corresponds to nucleotides -6,578 to -364 of the human GCSF gene (numbering is relative to the translation start site).

35 In another preferred embodiment, the DNA sequence includes a coding region, e.g., the DNA sequence encodes a protein. In a preferred embodiment, the coding region encodes: a hormone, a cytokine, an antigen, an antibody, an enzyme, a clotting factor, a transport protein, a receptor, a regulatory protein, a structural protein or a transcription factor. In a

5 preferred embodiment, the coding region encodes any of the following proteins: erythropoietin, calcitonin, growth hormone, insulin, insulinotropin, insulin-like growth factors, parathyroid hormone, α 2-interferon (IFNA2), β -interferon, γ -interferon, nerve growth factors, FSH β , TGF- β , tumor necrosis factor, glucagon, bone growth factor-2, bone growth factor-7, TSH- β , interleukin 1, interleukin 2, interleukin 3, interleukin 6, interleukin 11, 10 interleukin 12, CSF-granulocyte (GCSF), CSF-macrophage, CSF-granulocyte/macrophage, immunoglobulins, catalytic antibodies, protein kinase C, glucocerebrosidase, superoxide dismutase, tissue plasminogen activator, urokinase, antithrombin III, DNase, α -galactosidase, tyrosine hydroxylase, blood clotting factor V, blood clotting factor VII, blood clotting factor VIII, blood clotting factor IX, blood clotting factor X, blood clotting factor 15 XIII, apolipoprotein E, apolipoprotein A-I, globins, low density lipoprotein receptor, IL-2 receptor, IL-2 antagonists, α -1-antitrypsin, immune response modifiers, β -glucoceramidase, α -iduronidase, α -L-iduronidase, glucosamine-N-sulfatase, α -N-acetylglucosaminidase, acetylcoenzymeA: α -glucosamine-N-acetyltransferase, N-acetylglucosamine-6-sulfatase, β -galactosidase, β -glucuronidase, N-acetylgalactosamine-6-sulfatase, and soluble CD4.

20 In a preferred embodiment, the selected DNA sequence can have a flanking sequence such that when it is integrated into the target it is under the control of an endogenous regulatory element. The selected DNA can be integrated downstream of an endogenous regulatory sequence or upstream of a coding region of an endogenous gene and downstream of the endogenous regulatory sequence of the gene. In another preferred embodiment, the 25 selected DNA can be integrated downstream of an endogenous regulatory sequence such that the coding region of the endogenous gene is inactive, e.g., is wholly or partially deleted.

In a preferred embodiment, the composition, e.g., the complex, is introduced into a cell. Preferably, the cell is a eukaryotic cell. In a preferred embodiment, the cell is of fungal, 30 plant or animal origin, e.g., vertebrate origin. In a preferred embodiment, the cell is: a mammalian cell, e.g., a primary or secondary mammalian cell, e.g., a fibroblast, a hematopoietic stem cell, a myoblast, a keratinocyte, an epithelial cell, an endothelial cell, a glial cell, a neural cell, a cell comprising a formed element of the blood, a muscle cell and precursors of these somatic cells; a transformed or immortalized cell line. Preferably, the cell 35 is a human cell. Examples of immortalized human cell line useful in the present method include, but are not limited to: a Bowes Melanoma cell (ATCC Accession No. CRL 9607), a Daudi cell (ATCC Accession No. CCL 213), a HeLa cell and a derivative of a HeLa cell

5 (ATCC Accession Nos. CCL2 CCL2.1, and CCL 2.2), a HL-60 cell (ATCC Accession No. CCL 240), a HT1080 cell (ATCC Accession No. CCL 121), a Jurkat cell (ATCC Accession No. TIB 152), a KB carcinoma cell (ATCC Accession No. CCL 17), a K-562 leukemia cell (ATCC Accession No. CCL 243), a MCF-7 breast cancer cell (ATCC Accession No. BTH 22), a MOLT-4 cell (ATCC Accession No. 1582), a Namalwa cell (ATCC Accession No. 10 CRL 1432), a Rafji cell (ATCC Accession No. CCL 86), a RPMI 8226 cell (ATCC Accession No. CCL 155), a U-937 cell (ATCC Accession No. 1593), WI-28VA13 sub line 2R4 cells (ATCC Accession No. CLL 155), a CCRF-CEM cell (ATCC Accession No. CCL 119) and a 2780AD ovarian carcinoma cell (Van Der Blick et al., Cancer Res. 48:5927-5932, 15 1988), as well as heterohybridoma cells produced by fusion of human cells and cells of another species. In another embodiment, the immortalized cell line can be cell line other than a human cell line, e.g., a CHO cell line, a COS cell line.

In a preferred embodiment, the composition further includes an agent which inhibits a mismatch-repair protein, e.g., Msh2, Msh6, Msh3, Mlh1, Pms2, Mlh3, Pms1, or other mismatch repair proteins, or combinations thereof. Preferably, the agent is an agent which inhibits expression of a mismatch-repair protein, e.g., the agent is an antisense RNA. In a preferred embodiment, the agent is an antibody against a mismatch-repair protein. In a preferred embodiment, the antibody against the mismatch-repair protein is covalently or non-covalently linked to one or more components of the composition.

25 In another aspect, the invention features, a method of providing a protein. The method includes: providing a cell made by a method described herein, and allowing the cell to express the protein.

In a preferred embodiment: the method includes: providing a cell in which the following components have been introduced at a targeted site for alteration: (a) a double stranded DNA sequence which includes a selected DNA sequence; (b) an agent which enhances homologous recombination, e.g., a Rad52 protein or a functional fragment thereof; and (c) an agent which inhibits non-homologous end joining, e.g., a Ku inactivating agent; and allowing the cell to express the protein. Expression of the protein can occur, for example, by allowing expression of a protein encoded by the DNA, or by activating expression of the protein.

30 In a preferred embodiment, components (a), (b), and (c) are provided, e.g., introduced into the cell, such that, at the site of an interaction between the selected DNA sequence and

5 the target DNA, the concentrations of the agent which enhances homologous recombination and of the agent which inhibits non-homologous end joining are sufficient that an alteration of the site, e.g., homologous recombination or gene correction, between the selected DNA sequence and the target DNA, occurs at a higher rate than would occur in the absence of the supplied agent which enhances homologous recombination and the agent which inhibits non-
10 homologous end joining. The agent which inhibits non-homologous end joining is preferably provided locally.

In a preferred embodiment, components (a), (b), and (c) can be introduced together or separately. In addition, two of the components can be introduced together and the third can be introduced separately. For example, the DNA sequence and the agent which enhances homologous recombination, e.g., Rad52, can be introduced together or the DNA sequence and the agent which inhibits non-homologous end joining, e.g., a Ku inactivating agent, can be introduced together. In another preferred embodiment, the agent which enhances homologous recombination and the agent which inhibits non-homologous end joining can be introduced together.
15

20 Two, or preferably all, of the components can be provided as a complex. In a preferred embodiment, the method includes contacting the target DNA, e.g., by introducing into the cell, a complex which includes: (a) a double stranded DNA sequence which includes the selected DNA sequence; (b) an agent which enhances homologous recombination, e.g., a Rad52 protein or functional fragment thereof; and (c) an agent which inhibits non-
25 homologous end joining, e.g., an agent which inactivates Ku.

In a preferred embodiment, one, or more, preferably all of the components, are provided by local delivery, e.g., microinjection, and are not expressed from the target genome or other nucleic acid. In a particularly preferred embodiment, the agent which inhibits non-homologous end joining, e.g., a Ku-inactivating agent such as an anti-Ku antibody, is provided by local delivery, e.g., microinjection, and is not expressed from the target genome or other nucleic acid.
30

In a preferred embodiment, the agent which inhibits non-homologous end joining is: an agent which inactivates hMre11, e.g., an anti-hMre11 antibody or a hMre11-binding oligomer or polymer; an agent which inactivates hRad50, e.g., an anti-hRad50 antibody or a hRad50-binding oligomer or polymer; an agent which inactivates Nbs1, e.g., an anti-Nbs1 antibody or a hNbs1-binding oligomer or polymer; an agent which inactivates human ligase 4 (hLig4), e.g., an anti-hLig4 antibody or a hLig4-binding oligomer or polymer; an agent which
35

5 inactivates hXrcc4, e.g., an anti-hXrcc4 antibody or a hXrcc4-binding oligomer or polymer; an agent which inactivates a human homolog of Rap1, e.g., an antibody to a human homolog of Rap1 or an oligomer or polymer which binds a human homolog of Rap1; an agent which inactivates a human homolog of Sir2304, e.g., an antibody to a human homolog of Sir2304 or an oligomer or polymer which binds a human homolog of Sir2304; an agent which
10 inactivates Ku, e.g., an anti-Ku antibody or a Ku-binding oligomer or polymer. Any of the agents which inhibit non-homologous end joining can be administered alone or can be administered in combination with one or more of the other agents which inhibit non-homologous end joining.

15 In a preferred embodiment, the DNA sequence is a linear DNA sequence. In a preferred embodiment, the linear DNA sequence can have one or more single stranded overhang(s).

20 In a preferred embodiment, the selected DNA sequence is flanked by a targeting sequence. The targeting sequence is homologous to the target, e.g., homologous to DNA adjacent to the site where the target DNA is to be altered or to the site where the selected DNA sequence is to be integrated. Such flanking sequence can be present at one or more, preferably both ends of the selected DNA sequence. If two flanking sequences are present one should be homologous with a first region of the target and the other should be homologous to a second region of the target.

25 In a preferred embodiment, the DNA sequence has one or more protruding single stranded end, e.g., one or both of the protruding ends are 3' ends or 5' ends.

In a preferred embodiment, the agent which enhances homologous recombination is: a Rad52 protein or a functional fragment thereof; a Rad51 protein or a functional fragment thereof; a Rad54 protein or a functional fragment thereof; or a combination thereof.

30 In a preferred embodiment, the agent which enhances homologous recombination is adhered to, e.g., coated on, the DNA sequence. In a preferred embodiment, the Rad52 protein or functional fragment thereof is adhered to, e.g., coated, on the selected DNA sequence.

In a preferred embodiment, the Rad52 protein or fragment thereof is human Rad52 (hRad52).

35 In a preferred embodiment, the anti-Ku antibody is: an anti-Ku70 antibody; an anti-Ku80 antibody. In a preferred embodiment, the anti-Ku antibody is: a humanized antibody; a human antibody; an antibody fragment, e.g., a Fab, Fab', F(ab')² or F(v) fragment.

5 In a preferred embodiment, at least one anti-Ku antibody is covalently linked to: the selected DNA sequence; the agent which enhances homologous recombination, e.g., the Rad52 protein or fragment thereof. In another preferred embodiment, at least one anti-Ku antibody is non-covalently linked to: the selected DNA sequence; the agent which enhances homologous recombination, e.g., the rad52 protein or fragment thereof.

10 In a preferred embodiment, the complex includes an anti-Ku70 antibody and an anti-Ku80 antibody provided, e.g., as components of a complex.

In a preferred embodiment, the cell is: a eukaryotic cell. In a preferred embodiment, the cell is of fungal, plant or animal origin, e.g., vertebrate origin. In a preferred embodiment, the cell is: a mammalian cell, e.g., a primary or secondary mammalian cell, e.g., a fibroblast, a hematopoietic stem cell, a myoblast, a keratinocyte, an epithelial cell, an endothelial cell, a glial cell, a neural cell, a cell comprising a formed element of the blood, a muscle cell and precursors of these somatic cells; a transformed or immortalized cell line. Preferably, the cell is a human cell. Examples of immortalized human cell line useful in the present method include, but are not limited to: a Bowes Melanoma cell (ATCC Accession No. CRL 9607), a Daudi cell (ATCC Accession No. CCL 213), a HeLa cell and a derivative of a HeLa cell (ATCC Accession Nos. CCL2 CCL2.1, and CCL 2.2), a HL-60 cell (ATCC Accession No. CCL 240), a HT1080 cell (ATCC Accession No. CCL 121), a Jurkat cell (ATCC Accession No. TIB 152), a KB carcinoma cell (ATCC Accession No. CCL 17), a K-562 leukemia cell (ATCC Accession No. CCL 243), a MCF-7 breast cancer cell (ATCC Accession No. BTH 22), a MOLT-4 cell (ATCC Accession No. 1582), a Namalwa cell (ATCC Accession No. CRL 1432), a Rafji cell (ATCC Accession No. CCL 86), a RPMI 8226 cell (ATCC Accession No. CCL 155), a U-937 cell (ATCC Accession No. 1593), WI-28VA13 sub line 2R4 cells (ATCC Accession No. CLL 155), a CCRF-CEM cell (ATCC Accession No. CCL 119) and a 2780AD ovarian carcinoma cell (Van Der Blick et al., Cancer Res. 48:5927-5932, 1988), as well as heterohybridoma cells produced by fusion of human cells and cells of another species. In another embodiment, the immortalized cell line can be cell line other than a human cell line, e.g., a CHO cell line, a COS cell line.

In a preferred embodiment, the components, e.g., the components of a complex, are introduced into the cell by microinjection.

35 In a preferred embodiment, the method further includes introducing an agent which inhibits a mismatch-repair protein, e.g., Msh2, Msh6, Msh3, Mlh1, Pms2, Mlh3, Pms1, or other mismatch repair proteins or combinations thereof. Preferably, the agent is an agent

5 which inhibits expression of a mismatch-repair protein, e.g., the agent is an antisense RNA. In a preferred embodiment, the agent is an antibody against a mismatch-repair protein. In a preferred embodiment, the antibody against the mismatch-repair protein is covalently or non-covalently linked to the complex.

10 In a preferred embodiment, the protein is expressed *in vitro*. In other preferred embodiments, the cell is provided in a subject, e.g., a human, and the protein is expressed in the subject. In a preferred embodiment, the protein is expressed in a subject and the cell is autologous, allogeneic or xenogeneic. Selected DNA can be introduced into a cell *in vivo*, or the cell can be removed from the subject, the selected DNA introduced *ex vivo*, and the cell returned to the subject.

15 In a preferred embodiment, the selected DNA sequence differs from the target DNA by less than 10, 8, 6, 5, 4, 3, 2, or by a single nucleotide, e.g., a substitution, or a deletion, or an insertion.

20 In a preferred embodiment, the target DNA includes a mutation, e.g., the target sequence differs from wild-type sequence by about 10, 8, 6, 5, 4, 3, 2 or by a single nucleotide. Preferably, the mutation is a point mutation, e.g., a mutation due to an insertion, deletion or a substitution.

25 In a preferred embodiment, the target DNA includes a mutation and the mutation is associated with, e.g., causes, contributes to, conditions or controls, a disease or a dysfunction. Preferably, the disease or dysfunction is: cystic fibrosis; sickle cell anemia; hemophilia A; hemophilia B; von Willebrand disease type 3; xeroderma pigmentosa; thalassaemias; Lesch-Nylan syndrome; protein C resistance; a lysosomal disease, e.g., Gaucher disease, Fabry disease, mucopolysaccharidosis (MPS) type 1 (Hurley-Scheie syndrome), MPS type II (Hunter syndrome), MPS type IIIA (Sanfilio A syndrome), MPS type IIIB (Sanfilio B syndrome), MPS type IIIC (Sanfilio C syndrome), MPS type IIID (Sanfilio D syndrome), MPS type IVA (Morquio A syndrome), MPS type IVB (Morquio B syndrome), MPS type VI (Maroteaux-Larry syndrome), MPS type VII (Sly syndrome).

30 In a preferred embodiment, the target DNA includes a mutation and the selected DNA sequence includes a normal wild-type sequence which can correct the mutation.

35 In a preferred embodiment, the target DNA includes a mutation and the mutation is in the cystic fibrosis transmembrane regulator (CFTR) gene. Preferably, the mutation is one which alters the amino acid at codon 508 of the CFTR protein-coding region, e.g., the

5 mutation is a 3 base pair in-frame deletion which eliminates a phenylalanine at codon 508 of the CFTR protein. This deletion of phenylalanine-508 in the CFTR protein is found in a high percentage of subjects having cystic fibrosis. Thus, in a preferred embodiment, a selected DNA sequence including sequence encoding phenylalanine-508 as found in the wild-type CFTR gene can be used to target and correct the mutated CFTR gene.

10 In a preferred embodiment, the target DNA includes a mutation and the mutation is in the human β-globin gene. Preferably, the mutation is one which alters the amino acid at the sixth codon of the β-globin gene, e.g., the mutation is an A to T substitution in the sixth codon of the β-globin gene. This mutation leads to a change from glutamic acid to valine in the β-globin protein which is found in subjects having sickle cell anemia. Thus, in a
15 preferred embodiment, a selected DNA which encodes a wild-type amino acid residue at codon 6, e.g., a selected DNA sequence including an A as found within the sixth codon of wild-type β-globin gene, can be used to target and correct the mutated β-globin gene.

20 In a preferred embodiment, the target DNA includes a mutation and the mutation is in the Factor VIII gene. For example, a mutation can be in exon 23, 24, and/or exon 25 of the Factor VIII gene. Preferably, the mutation is one which alters the amino acid at codon 2209 of the coding region of the Factor VIII protein coding region, e.g., the mutation is a G to A substitution in exon 24 of the Factor VIII gene which leads to a change from an arginine to a glutamine at amino acid 2209 of Factor VIII. Preferably, the mutation is one which alters the amino acid at codon 2229 of the coding region of the Factor VIII protein coding region,
25 e.g., the mutation is a G to T substitution in exon 25 of the Factor VIII gene which leads to a change from a tryptophan to a cysteine at amino acid 2229 of Factor VIII. These mutations have been associated with moderate to severe hemophilia A. Thus, in a preferred embodiment, a selected DNA sequence including either DNA which encodes a wild-type amino acid at codon 2209 of the coding region of Factor VIII gene, or DNA which encodes a wild-type amino acid at codon 2229 of the coding region of the Factor VIII gene, or both, can
30 be used to target and correct the mutated Factor VIII gene.

In a preferred embodiment, the target DNA includes a mutation and the mutation is in the Factor IX gene. For example, in subjects having hemophilia B, most of the mutations are point mutations in the Factor IX gene. Thus, in a preferred embodiment, the selected DNA sequence can include one or more nucleotides having at least one nucleotide from the wild-type Factor IX gene, to target and correct one or more of the point mutations in the Factor IX gene associated with hemophilia B.

5 In a preferred embodiment, the target DNA includes a mutation and the mutation is in
the von Willebrand factor gene. Preferably, the mutation is a single cytosine deletion in a
stretch of six cytosines at positions 2679-2684 in exon 18 of the von Willebrand gene. This
mutation is found in a significant percentage of subjects having von Willebrand disease type
3. Other mutations, e.g., point mutations, associated with von Willebrand disease type 3 can
10 also be altered as described herein. Thus, in a preferred embodiment, a selected DNA
sequence including sequences found in the wild-type von Willebrand gene, e.g., the six
cytosines at positions 2679-2684 in exon 18 of the von Willebrand gene, can be used to target
and correct the mutated von Willebrand gene.

15 In a preferred embodiment, the target DNA includes a mutation and the mutation is in
the Xeroderma pigmentosum group G (XP-G) gene. Preferably, the mutation is a deletion of
a single adenine in a stretch of adenines at positions 19-21 of a 245 base-pair exon found in
the XP-G gene. This deletion leads to xeroderma pigmentosum. Thus, in a preferred
embodiment, a selected DNA including the wild-type sequence of XP-G gene, e.g., three
adenines at positions 19-21 at the 245 base-pair exon of the XP-G gene, can be used to target
20 and correct the mutated XP-G gene.

In another preferred embodiment, the alteration includes homologous recombination
between the selected DNA sequence and the target DNA, e.g., a chromosome.

25 In preferred embodiment, the selected DNA sequence differs from the target DNA by
more than one nucleotide, e.g., it differs from the target by a sufficient number of nucleotides
such that the target, or the selected DNA sequence has an unpaired region, e.g., a loop-out
region. In such an application, Msh2, Msh6, Msh3, Mlh1, Pms2, Mlh3, Pms1, or
combinations thereof, can also be provided, e.g., as part of a complex.

30 In a preferred embodiment, the alteration includes integration of the selected sequence
into the target DNA and the selected DNA is integrated such that it is in a preselected
relationship with a preselected element on the target, e.g., if one is a regulatory element and
the other is a sequence which encodes a protein, the regulatory element functions to control
expression of the protein encoding sequence. Flanking sequences which promote the selected
integration can be used. The selected DNA sequence can be integrated 5', 3', or within, a
35 selected target sequence, e.g., a gene or coding sequence.

In a preferred embodiment, the alteration includes integration of the selected DNA
sequence and the selected DNA sequence is a regulatory sequence, e.g., an exogenous

5 regulatory sequence. In a preferred embodiment, the regulatory sequence includes one or more of: a promoter, an enhancer, an UAS, a scaffold-attachment region or a transcription factor-binding site. In a preferred embodiment, the regulatory sequence includes: a regulatory sequence from metallothionein-I gene, e.g., the mouse metallothionein gene, a regulatory sequence from an SV-40 gene, a regulatory sequence from a cytomegalovirus gene, a regulatory sequence from a collagen gene, a regulatory sequence from an actin gene, a regulatory sequence from an immunoglobulin gene, a regulatory sequence from the HMG-CoA reductase gene, a regulatory sequence from γ actin gene, a regulatory sequence from transcription activator YY1 gene, a regulatory sequence from fibronectin gene, or a regulatory sequence from the EF-1 α gene.

10 15 In a preferred embodiment, the selected DNA sequence includes an exon. Preferably, the exogenous exon includes: a CAP site, the nucleotide sequence ATG, and/or encoding DNA in-frame with the targeted endogenous gene.

In a preferred embodiment, the selected DNA sequence includes a splice-donor site.

20 25 In a preferred embodiment, the selected DNA sequence includes an exogenous regulatory sequence which when integrated into the target functions to regulate expression of an endogenous gene. The selected DNA can be integrated upstream of the coding region of an endogenous gene in the target or upstream of the endogenous regulatory sequence of an endogenous gene or coding region in the target. In another preferred embodiment, the selected DNA can be integrated downstream of an endogenous gene or coding region or within an intron or endogenous gene. In another preferred embodiment, the endogenous regulatory sequence of the endogenous gene is inactive, e.g., is wholly or partially deleted.

In a preferred embodiment, the selected DNA sequence is upstream of the endogenous gene and is linked to the second exon of the endogenous gene.

30 35 In a preferred embodiment, the endogenous gene encodes: a hormone, a cytokine, an antigen, an antibody, an enzyme, a clotting factor, a transport protein, a receptor, a regulatory protein, a structural protein or a transcription factor. In a preferred embodiment, the endogenous gene encodes any of the following proteins: erythropoietin, calcitonin, growth hormone, insulin, insulinotropin, insulin-like growth factors, parathyroid hormone, α 2-interferon (IFNA2), β -interferon, γ -interferon, nerve growth factors, FSH β , TGF- β , tumor necrosis factor, glucagon, bone growth factor-2, bone growth factor-7, TSH- β , interleukin 1, interleukin 2, interleukin 3, interleukin 6, interleukin 11, interleukin 12, CSF-granulocyte (GCSF), CSF-macrophage, CSF-granulocyte/macrophage, immunoglobulins, catalytic

5 antibodies, protein kinase C, glucocerebrosidase, superoxide dismutase, tissue plasminogen activator, urokinase, antithrombin III, DNase, α -galactosidase, tyrosine hydroxylase, blood clotting factor V, blood clotting factor VII, blood clotting factor VIII, blood clotting factor IX, blood clotting factor X, blood clotting factor XIII, apolipoprotein E, apolipoprotein A-I, globins, low density lipoprotein receptor, IL-2 receptor, IL-2 antagonists, α -1-antitrypsin, 10 immune response modifiers, β -glucoceramidase, α -iduronidase, α -L-iduronidase, glucosamine-N-sulfatase, α -N-acetylglucosaminidase, acetylcoenzymeA: α -glucosamine-N-acetyltransferase, N-acetylglucosamine-6-sulfatase, β -galactosidase, β -glucuronidase, N-acetylgalactosamine-6-sulfatase, and soluble CD4.

In a preferred embodiment, the endogenous gene encodes follicle stimulating hormone β (FSH β) and the selected DNA sequence includes a regulatory sequence, e.g., a regulatory sequence which differs in sequence from the regulatory sequence of the FSH β gene. Preferably, the selected DNA sequence is flanked by a targeting sequence, e.g., such targeting sequence is present at one or more, preferably both ends of the selected DNA sequence. In a preferred embodiment, the targeting sequence is homologous to a region 5' of 15 FSH β coding region (SEQ ID NO:1). In a preferred embodiment, the targeting sequence directs homologous recombination within the FSH β coding sequence or upstream of the FSH β coding sequence. In a preferred embodiment, the targeting sequence includes at least 20, 30, 50, 100 or 1000 contiguous nucleotides from SEQ ID NO:2, which corresponds to 20 nucleotides -7454 to -1417 of human FSH β sequence (numbering is relative to the translation start site), or SEQ ID NO:3, which corresponds to nucleotides -696 to -155 of 25 human FSH β sequence.

In a preferred embodiment, the endogenous gene encodes interferon α 2 (IFNa2) and the selected DNA sequence includes a regulatory sequence, e.g., a regulatory sequence which differs in sequence from the regulatory sequence of the IFNa2 gene. Preferably, the selected 30 DNA sequence is flanked by a targeting sequence, e.g., such targeting sequence is present at one or more, preferably both ends of the selected DNA sequence. In a preferred embodiment, the targeting sequence is homologous to a region 5' of IFNa2 coding region. In a preferred embodiment, the targeting sequence directs homologous recombination within a region upstream of the IFNa2 coding sequence. In a preferred embodiment, the targeting sequence includes at least 20, 30, 50, 100 or 1000 contiguous nucleotides from SEQ ID NO:4, which corresponds to 35 nucleotides -4074 to -511 of human IFNa2 sequence (numbering is relative to the translation start site). For example, it can include: at least 20, 30, 50, or 100

5 nucleotides from SEQ ID NO:7, which corresponds to nucleotides -4074 to -3796 of human IFNa2 sequence; at least 20, 30, or 50 nucleotides from SEQ ID NO:8, which corresponds to nucleotides -582 to -510 of human IFNa2 sequence; at least 20, 30, 50, 100, or 1000 nucleotides from SEQ ID NO:9, which corresponds to nucleotides -3795 to -583 of human IFNa2 sequence.

10 In a preferred embodiment, the endogenous gene encodes granulocyte colony stimulating factor (GCSF) and the selected DNA sequence includes a regulatory sequence, e.g., a regulatory sequence which differs in sequence from the regulatory sequence of the GCSF gene. Preferably, the selected DNA sequence is flanked by a targeting sequence, e.g., such targeting sequence is present at one or more, preferably both ends of the selected DNA sequence. In a preferred embodiment, the targeting sequence is homologous to a region 5' of 15 GCSF coding region. In a preferred embodiment, the targeting sequence directs homologous recombination within the GCSF coding sequence or upstream of the GCSF coding sequence. In a preferred embodiment, the targeting sequence includes at least 20, 30, 50, 100 or 1000 contiguous nucleotides from SEQ ID NO:5, which corresponds to nucleotides -6,578 to 101 20 of human GCSF sequence (numbering is relative to the translation start site). For example, the target sequence can include 20, 30, 50, 100 or 1000 nucleotides from SEQ ID NO:6, which corresponds to nucleotides -6,578 to -364 of the human GCSF gene (numbering is relative to the translation start site).

25 In another preferred embodiment, the DNA sequence includes a coding region, e.g., the DNA sequence encodes a protein. In a preferred embodiment, the coding region encodes: a hormone, a cytokine, an antigen, an antibody, an enzyme, a clotting factor, a transport protein, a receptor, a regulatory protein, a structural protein or a transcription factor. In a preferred embodiment, the coding region encodes any of the following proteins: 30 erythropoietin, calcitonin, growth hormone, insulin, insulinotropin, insulin-like growth factors, parathyroid hormone, β -interferon, γ -interferon, nerve growth factors, FSH β , TGF- β , tumor necrosis factor, glucagon, bone growth factor-2, bone growth factor-7, TSH- β , interleukin 1, interleukin 2, interleukin 3, interleukin 6, interleukin 11, interleukin 12, CSF-granulocyte, CSF-macrophage, CSF-granulocyte/macrophage, immunoglobulins, catalytic 35 antibodies, protein kinase C, glucocerebrosidase, superoxide dismutase, tissue plasminogen activator, urokinase, antithrombin III, DNase, α -galactosidase, tyrosine hydroxylase, blood clotting factor V, blood clotting factor VII, blood clotting factor VIII, blood clotting factor

5 IX, blood clotting factor X, blood clotting factor XIII, apolipoprotein E, apolipoprotein A-I, globins, low density lipoprotein receptor, IL-2 receptor, IL-2 antagonists, α -1-antitrypsin, immune response modifiers, β -glucoceramidase, α -iduronidase, α -L-iduronidase, glucosamine-N-sulfatase, α -N-acetylglucosaminidase, acetylcoenzymeA: α -glucosamine-N-acetyltransferase, N-acetylglucosamine-6-sulfatase, β -galactosidase, β -glucuronidase, N-acetylgalactosamine-6-sulfatase, and soluble CD4.

10 In a preferred embodiment, the selected DNA sequence can be integrated into the target downstream of an endogenous regulatory sequence or upstream of a coding region of an endogenous gene and downstream of the endogenous regulatory sequence of the gene. In another preferred embodiment, the selected DNA sequence can be integrated downstream of 15 an endogenous regulatory sequence such that the coding region of the endogenous gene is inactive, e.g., is deleted.

20 In another aspect, the invention features, a cell made by any of the methods described herein.

25 In another aspect, the invention features a method of altering expression of a protein coding sequence of a gene in a cell, by any of the methods described herein.

30 In a preferred embodiment, the method includes introducing a complex described herein having a DNA sequence which includes a regulatory sequence into the cell; maintaining the cell under conditions which permit alteration of a targeted genomic sequence to produce a homologously recombinant cell; and maintaining the homologously recombinant cell under conditions which permit expression of the protein coding sequence of the gene under control of the regulatory sequence.

35 maintaining the homologously recombinant cell under conditions which permit expression of the protein coding sequence of the gene under control of the regulatory sequence, thereby altering expression of the protein coding sequence of the gene.

 The term "homologous" as used herein, refers to a targeting sequence that is identical to or sufficiently similar to a target site, e.g., a chromosomal DNA target site, so that the targeting sequence and the target site can undergo homologous recombination. A small percentage of base pair mismatches is acceptable, as long as homologous recombination can occur at a useful frequency.

5 As used herein, the term "wild-type" refers to a sequence which is not associated with, e.g., causes, contributes to, conditions or controls, a disease or dysfunction.

As used herein, a "complex" refers to a stable association in which the components are coupled by covalent or non-covalent bonds.

10 Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

15 *Detailed Description of the Invention*

Agents Which Enhance Homologous Recombination

Agents which enhance homologous recombination can be provided with a selected 20 DNA sequence in order to promote homologous recombination between the selected DNA sequence and the target DNA, e.g., chromosomal DNA. Agents which enhance homologous recombination have one or more of the following functions: 1) increase homologous recognition between the selected DNA sequence and the selected site for integration; 2) increase homologous pairing between the selected DNA sequence and the selected site for integration; 25 3) increase efficiency of strand invasion and strand exchange between the recombining DNA sequences; 4) increase efficiency of processing of intermediate structures into mature products of recombination.

An agent which enhances homologous recombination can be introduced to a cell in a mixture which includes the double stranded DNA sequence, it can be introduced immediately 30 prior to or after administration of the DNA sequence or it can be adhered, e.g., coated, on the DNA sequence. The entire DNA sequence can be coated with an agent which enhances homologous recombination, e.g., Rad52, e.g., hRad52, or a fragment thereof, or one or more 35 of the ends of the DNA sequence can be coated, e.g., one or more of a protruding single stranded end of the DNA sequence can be coated. Preferably, the agent which enhances homologous recombination coats at least a portion of a protruding single stranded 3' end or 5' end of the DNA sequence.

5 Examples of agents which enhance homologous recombination include: Rad52 or a functional fragment thereof; Rad51 or a functional fragment thereof; Rad54 or a functional fragment thereof; or a combination or two or more of these proteins or fragments of these proteins. The agent which enhances homologous recombination can also be expressed intercellularly, e.g., a nucleic acid sequence encoding any of the above-described agents can
10 be introduced into a cell.

A determination of whether a Rad51 fragment is functional can be made by known techniques. For example, the functionality of a Rad51 fragment can be determined based on its ability to mediate homologous pairing and strand exchange in an *in vitro* assay known in the art, e.g., as described in Baumann et al. (1996) *Cell* 87:757-766. Briefly, hRad51 is first
15 preincubated with circular ssDNA and then ³²P-labeled linear duplex DNA is added. The formation of joint molecules and the amount of strand exchange can be determined by electrophoresis. In addition, the functionality of a Rad51 fragment can be determined based on its ability to bind nicked duplex DNA in the presence of ATP to form helical nucleoprotein filament which can be visualized by electron microscopy as described in
20 Benson et al. (1994) *EMBO J.* 13:5764-5771. The functionality of Rad51 can also be determined based on its ability to alleviate defects in DNA repair and homologous recombination in cells lacking functional Rad51 protein. Thus, it can be determined if a Rad51 fragment is functional if it confers a positive effect in the above-mentioned assays as compared to its absence. Moreover, the extent of the positive effect conferred by a Rad51
25 fragment can be compared to the extent of positive effect conferred by full-length Rad51.

The functionality of a Rad54 fragment can be determined based on its ability to hydrolyze ATP in the presence of dsDNA in an assay known in the art, e.g., as described in Swagemakers et al. (1998) *J. Biol. Chem.* 273:28292-28297. In addition, the functionality of a Rad54 fragment can be determined based on its ability to alleviate defects in DNA repair and homologous recombination in cells lacking functional Rad54 protein.
30

Rad52 and Functional Fragments Thereof

Rad52 provided with a DNA sequence at a selected site in a target DNA, e.g., a
35 selected site in chromosomal DNA, can provide a higher rate of alteration of the site, e.g., homologous recombination, than would occur in its absence. While not wishing to be bound

5 by theory, it is believed that Rad52 can provide one or more of the following functions: 1) protect the entire DNA sequence from nuclease degradation; 2) protect a protruding single stranded end of the DNA sequence, e.g., a 3' tail, from nuclease degradation; 3) increase homologous recognition between the DNA sequence and the selected site for integration; and
10 4) increase homologous pairing between the DNA sequence and the selected site for integration.

Rad52 can be obtained in several ways including isolation of Rad52 or expression of a sequence encoding by genetic engineering methods. For example, Van Dyke et al. (1999) *Nature* 398:728, describe production and purification of hRad52 from Sf9 cells. The nucleotide sequences of Rad52 of various species are known. See, e.g., Shen et al. (1995) *Genomics* 25(1):199-206 (murine and human Rad52); Muris et al. (1994) *Mutat. Res.* 315(3):295-305 (murine and human Rad52); Park et al. (1995) *J. Biol. Chem.* 270(26):15467-15470 (human Rad52).

20 Fragments of Rad52 can be produced in several ways, e.g., by expression of the sequence encoding Rad52 or a portion thereof or by gene activation (the preferred method), by proteolytic digestion, or by chemical synthesis. Internal or terminal fragments of Rad52 can be generated by removing one or more nucleotides from one end (for a terminal fragment) or both ends (for an internal fragment) of a nucleic acid which encodes Rad52. Expression of the mutagenized DNA produces Rad52 polypeptide fragments. Digestion with "end-nibbling" endonucleases or with various restriction enzymes can thus generate DNA's which encode an array of Rad52 fragments. DNA's which encode fragments of a Rad52 protein can also be generated by random shearing, restriction digestion or a combination of the above-discussed methods.

25 Rad52 fragments can also be chemically synthesized using techniques known in the art such as conventional Merrifield solid phase f-Moc or t-Boc chemistry. For example, Rad52 peptides may be arbitrarily divided into fragments of desired length with no overlap of the fragments, or divided into overlapping fragments of a desired length.

30 A determination of whether a Rad52 fragment is functional can be made by known techniques. For example, to determine whether a Rad52 fragment can protect against nucleic acid degradation, an end-labeled linearized double stranded DNA sequence, e.g., a ³²P-labeled linearized double stranded DNA sequence, can be incubated with a Rad52 fragment prior to introduction of a nuclease, e.g., an exonuclease or endonuclease. The amount of released label, e.g., ³²P, can then be determined. The amount of released label serves as an

5 indicator of the ability of the Rad52 fragment to protect against nuclease degradation. In addition, the functionality of a Rad52 fragment can be determined based on its ability to stimulate the formation of joint molecules. The functionality of a Rad52 fragment can be analyzed *in vitro* by stimulation of hRad51-driven joint molecule formation as described in Benson et al. (1998) *Nature* 391:401-404. Briefly, hRad51 is first preincubated with circular ssDNA and then ³²P-labeled linear duplex DNA is added. The formation of joint molecules can be determined by electrophoresis. The addition of Rad52 stimulates the formation of joint molecules as compared to joint molecule formation in the absence of Rad52. Thus, it can be determined if a Rad52 fragment is functional if it stimulates joint molecule formation as compared to joint molecule formation in its absence. Moreover, the extent of stimulation by a Rad52 fragment can be compared to the extent of full-length Rad52 stimulation. In addition, the functionality of a Rad52 fragment can be determined based on its ability to increase resistance to ionizing radiation and to increase rates of homologous recombination when overexpressed in cultured monkey cells as described in Park (1995) *J. Biol. Chem.* 270:15467-15470.

20

Agents Which Inhibit Non-Homologous End Joining

An agents which inhibits non-homologous end joining can be used to provide a DNA sequence at a selected site in target DNA at a higher rate than would occur in its absence. 25 Non-homologous end joining can lead to imprecise fusion between double stranded ends, e.g., the rejoined ends can have insertions or deletions. An agent which inhibits non-homologous end joining can be any agent which inhibits expression of and/or an activity of a molecule involved in a non-homologous end joining pathway. For example, a complex of Mre11, Rad50 and Nbs1 is involved in non-homologous end joining. Thus, for example, by 30 inhibiting formation of this complex, e.g., by binding any of these proteins or inhibiting expression of any of these proteins, non-homologous end joining can be inhibited. In addition, other proteins involved in non-homologous end joining include Ku proteins, e.g., Ku70 or Ku80, Ligase 4 (Lig4) and Xrcc4.

35

5 Ku Inactivating Agents

Providing a Ku inactivating agent with a DNA sequence at a selected site in a target DNA, e.g., a selected site in chromosomal DNA, can provide a higher rate of alteration of the site, e.g., homologous recombination, than would occur in its absence. Ku is a heterodimer of approximately 70 kDa and 80 kDa that binds to DNA discontinuities and plays a role in double-strand break repair by non-homologous end joining. "Ku80" can also be referred to as "Ku86".

10 A Ku inactivating agent can inhibit Ku expression or a Ku activity. Preferably, a Ku inactivating agent interacts, e.g., binds, Ku or a nucleotide sequence encoding Ku, to inhibit Ku expression or a Ku activity. Preferably, Ku-dependent non-homologous end joining is inhibited. A Ku inhibiting agent can inhibit Ku70, Ku80 or both.

15 Agents which can be used to inactivate Ku include anti-Ku antibodies and Ku-binding molecules, e.g., randomly generated peptides which bind to Ku, Ku binding oligomers and polymers, and antisense Ku nucleic acid molecules. Preferably, the agent which inactivates Ku is an agent which can be administered locally such as anti-Ku antibodies and Ku-binding molecules, e.g., randomly-generated peptides which bind to Ku, and Ku binding oligomers or polymers.

20 Preferably, the Ku inactivating agent interacts with, e.g., binds to, Ku. Agents which interact with the Ku protein can inactivate Ku locally at the site of alteration.

25 For example, a Ku inactivating agent is introduced into a cell in close proximity to the DNA sequence and the targeted DNA to thereby inhibit Ku locally at the site of homologous recombination. A Ku inactivating agent can be introduced to a cell in a mixture which includes the double stranded DNA sequence, it can be introduced immediately prior to or after administration of the DNA sequence or it can be covalently linked to the DNA sequence or proteins associated with the DNA sequence, e.g., Rad52 or a fragment thereof. Cells can 30 also be preincubated with a Ku inactivating agent such as an anti-Ku antibody or an antisense Ku nucleic acid molecule.

Anti-Ku Antibodies

35 An anti-Ku antibody or fragment thereof can be used to bind Ku, and thereby reduce a Ku activity. Anti-Ku antibodies can be administered such that they interact with Ku locally

5 at the site of alteration but do not inhibit Ku expression generally in the cell. Anti-Ku antibodies include anti-Ku70 and anti-Ku80 antibodies.

10 A Ku protein, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that bind Ku using standard techniques for polyclonal and monoclonal antibody preparation. The full-length Ku protein can be used or, alternatively, antigenic peptide fragments of Ku can be used as immunogens.

15 Typically, Ku or a Ku peptide is used to prepare antibodies by immunizing a suitable subject, (e.g., rabbit, goat, mouse or other mammal) with the immunogen. An appropriate immunogenic preparation can contain, for example, a Ku protein obtained by expression of the sequence encoding Ku or by gene activation, or a chemically synthesized Ku peptide. See, e.g., U.S. Patent No. 5,460,959; and co-pending U.S. applications USSN 08/334,797; USSN 08/231,439; USSN 08/334,455; and USSN 08/928,881 which are hereby expressly incorporated by reference in their entirety. The nucleotide and amino acid sequences of Ku are known and described, for example, in Takiguchi et al. (1996) *Genomics* 35(1):129-135. The preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or similar immunostimulatory agent. Immunization of a suitable subject with an immunogenic Ku preparation induces a polyclonal anti-Ku antibody response.

20 Anti-Ku antibodies or fragments thereof can be used as a Ku inactivating agent. Examples of anti-Ku antibody fragments include F(v), Fab, Fab' and F(ab')₂ fragments which can be generated by treating the antibody with an enzyme such as pepsin. The term "monoclonal antibody" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope of Ku. A monoclonal antibody composition thus typically displays a single binding affinity for a particular Ku protein with which it immunoreacts.

25 Additionally, anti-Ku antibodies produced by genetic engineering methods, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, can be used. Such chimeric and humanized monoclonal antibodies can be produced by genetic engineering using standard DNA techniques known in the art, for example using methods described in Robinson et al. International Application No. PCT/US86/02269; Akira, et al. European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Morrison et al. European Patent Application 173,494; Neuberger et al. PCT International Publication No.

5 WO 86/01533; Cabilly et al. U.S. Patent No. 4,816,567; Cabilly et al. European Patent Application 125,023; Better et al., *Science* 240:1041-1043, 1988; Liu et al., *PNAS* 84:3439-3443, 1987; Liu et al., *J. Immunol.* 139:3521-3526, 1987; Sun et al. *PNAS* 84:214-218, 1987; Nishimura et al., *Canc. Res.* 47:999-1005, 1987; Wood et al., *Nature* 314:446-449, 1985; and Shaw et al., *J. Natl. Cancer Inst.* 80:1553-1559, 1988); Morrison, S. L., *Science* 229:1202-1207, 1985; Oi et al., *BioTechniques* 4:214, 1986; Winter U.S. Patent 5,225,539; Jones et al., *Nature* 321:552-525, 1986; Verhoeven et al., *Science* 239:1534, 1988; and Beidler et al., *J. Immunol.* 141:4053-4060, 1988.

In addition, a human monoclonal antibody directed against Ku can be made using standard techniques. For example, human monoclonal antibodies can be generated in transgenic mice or in immune deficient mice engrafted with antibody-producing human cells. Methods of generating such mice are described, for example, in Wood et al. PCT publication WO 91/00906, Kucherlapati et al. PCT publication WO 91/10741; Lonberg et al. PCT publication WO 92/03918; Kay et al. PCT publication WO 92/03917; Kay et al. PCT publication WO 93/12227; Kay et al. PCT publication 94/25585; Rajewsky et al. PCT publication WO 94/04667; Ditullio et al. PCT publication WO 95/17085; Lonberg, N. et al. (1994) *Nature* 368:856-859; Green, L.L. et al. (1994) *Nature Genet.* 7:13-21; Morrison, S.L. et al. (1994) *Proc. Natl. Acad. Sci. USA* 81:6851-6855; Bruggeman et al. (1993) *Year Immunol.* 7:33-40; Choi et al. (1993) *Nature Genet.* 4:117-123; Tuailon et al. (1993) *PNAS* 90:3720-3724; Bruggeman et al. (1991) *Eur J Immunol.* 21:1323-1326); Duchosal et al. PCT publication WO 93/05796; U.S. Patent Number 5,411,749; McCune et al. (1988) *Science* 241:1632-1639), Kamel-Reid et al. (1988) *Science* 242:1706; Spanopoulou (1994) *Genes & Development* 8:1030-1042; Shinkai et al. (1992) *Cell* 68:855-868). A human antibody-transgenic mouse or an immune deficient mouse engrafted with human antibody-producing cells or tissue can be immunized with Ku or an antigenic Ku peptide and splenocytes from these immunized mice can then be used to create hybridomas. Methods of hybridoma production are well known.

Human monoclonal antibodies against Ku can also be prepared by constructing a combinatorial immunoglobulin library, such as a Fab phage display library or a scFv phage display library, using immunoglobulin light chain and heavy chain cDNAs prepared from mRNA derived from lymphocytes of a subject. See, e.g., McCafferty et al. PCT publication WO 92/01047; Marks et al. (1991) *J. Mol. Biol.* 222:581-597; and Griffiths et al. (1993) *EMBO J* 12:725-734. In addition, a combinatorial library of antibody variable regions can

5 be generated by mutating a known human antibody. For example, a variable region of a
human antibody known to bind Ku, can be mutated, by for example using randomly altered
mutagenized oligonucleotides, to generate a library of mutated variable regions which can
then be screened to bind to Ku. Methods of inducing random mutagenesis within the CDR
regions of immunoglobulin heavy and/or light chains, methods of crossing randomized heavy
10 and light chains to form pairings and screening methods can be found in, for example, Barbas
et al. PCT publication WO 96/07754; Barbas et al. (1992) *Proc. Nat'l Acad. Sci. USA*
89:4457-4461.

The immunoglobulin library can be expressed by a population of display packages,
preferably derived from filamentous phage, to form an antibody display library. Examples of
15 methods and reagents particularly amenable for use in generating antibody display library can
be found in, for example, Ladner et al. U.S. Patent No. 5,223,409; Kang et al. PCT
publication WO 92/18619; Dower et al. PCT publication WO 91/17271; Winter et al. PCT
publication WO 92/20791; Markland et al. PCT publication WO 92/15679; Breitling et al.
20 PCT publication WO 93/01288; McCafferty et al. PCT publication WO 92/01047; Garrard et
al. PCT publication WO 92/09690; Ladner et al. PCT publication WO 90/02809; Fuchs et al.
(1991) *Bio/Technology* 9:1370-1372; Hay et al. (1992) *Hum Antibod Hybridomas* 3:81-85;
Huse et al. (1989) *Science* 246:1275-1281; Griffiths et al. (1993) *supra*; Hawkins et al. (1992)
J Mol Biol 226:889-896; Clackson et al. (1991) *Nature* 352:624-628; Gram et al. (1992)
25 *PNAS* 89:3576-3580; Garrad et al. (1991) *Bio/Technology* 9:1373-1377; Hoogenboom et al.
displayed on the surface of a display package (e.g., filamentous phage), the antibody library
is screened to identify and isolate packages that express an antibody that binds Ku. In a
preferred embodiment, the primary screening of the library involves panning with an
immobilized Ku and display packages expressing antibodies that bind immobilized Ku are
30 selected.

Monoclonal antibodies to Ku are also commercially available from, for example,
Neomarkers (Fremont, CA).

5 Molecules which bind Ku such as Ku-binding peptides, e.g., randomly generated peptides, and Ku-binding oligomers or polymers can be used as Ku inactivating agents. Such molecules can bind to the Ku protein and thereby inhibit at least one activity of Ku such as non-homologous end-joining.

10 Examples of Ku-binding oligomers are set forth in WO 99/33971, the contents of which is incorporated herein by reference. Such oligomers can be composed of nucleotides, nucleotide analogs, or a combination. Preferably, the oligomers are composed of ribonucleotides. These Ku oligomers can be used to bind Ku or to identify proteins that interact with Ku. Methods of identifying Ku binding peptides using these oligomers are described in WO99/33971.

15 In addition, randomly generated peptides can be screened for the ability to bind Ku. For example, various techniques are known in the art for screening generated mutant gene products. Techniques for screening large gene libraries often include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the genes under conditions in which detection of a desired activity, e.g., binding to Ku, facilitates relatively easy isolation of the vector encoding the gene whose product was detected. Each of the techniques described below is amenable to high throughput analysis for screening large numbers of sequences created, e.g., by random mutagenesis techniques.

25 Display Libraries

In another approach to screening for Ku binding peptides, the candidate peptides are displayed on the surface of a cell or viral particle, and the ability of particular cells or viral particles to bind a Ku protein via the displayed product is detected in a "panning assay". For example, the gene library can be cloned into the gene for a surface membrane protein of a bacterial cell, and the resulting fusion protein detected by panning (Ladner et al., WO 30 88/06630; Fuchs et al. (1991) *Bio/Technology* 9:1370-1371; and Goward et al. (1992) *TIBS* 18:136-140). In a similar fashion, a detectably labeled ligand can be used to score for potentially functional peptide homologs. Fluorescently labeled ligands can be used to detect homolog which retain ligand-binding activity. The use of fluorescently labeled ligands, allows cells to be visually inspected and separated under a fluorescence microscope, or, where the morphology of the cell permits, to be separated by a fluorescence-activated cell sorter.

5 A gene library can be expressed as a fusion protein on the surface of a viral particle. For instance, in the filamentous phage system, foreign peptide sequences can be expressed on the surface of infectious phage, thereby conferring two significant benefits. First, since these phage can be applied to affinity matrices at concentrations well over 10^{13} phage per milliliter, a large number of phage can be screened at one time. Second, since each infectious phage
10 displays a gene product on its surface, if a particular phage is recovered from an affinity matrix in low yield, the phage can be amplified by another round of infection. The group of almost identical *E. coli* filamentous phages M13, fd., and f1 are most often used in phage display libraries. Either of the phage gIII or gVIII coat proteins can be used to generate fusion proteins without disrupting the ultimate packaging of the viral particle. Foreign epitopes can be expressed at the NH₂-terminal end of pIII and phage bearing such epitopes
15 recovered from a large excess of phage lacking this epitope (Ladner et al. PCT publication WO 90/02909; Garrard et al., PCT publication WO 92/09690; Marks et al. (1992) *J. Biol. Chem.* 267:16007-16010; Griffiths et al. (1993) *EMBO J* 12:725-734; Clackson et al. (1991) *Nature* 352:624-628; and Barbas et al. (1992) *PNAS* 89:4457-4461).

20 A common approach uses the maltose receptor of *E. coli* (the outer membrane protein, LamB) as a peptide fusion partner (Charbit et al. (1986) *EMBO* 5, 3029-3037). Oligonucleotides have been inserted into plasmids encoding the LamB gene to produce peptides fused into one of the extracellular loops of the protein. These peptides are available for binding to ligands, e.g., to antibodies, and can elicit an immune response when the cells
25 are administered to animals. Other cell surface proteins, e.g., OmpA (Schorr et al. (1991) *Vaccines* 91, pp. 387-392), PhoE (Agterberg, et al. (1990) *Gene* 88, 37-45), and PAL (Fuchs et al. (1991) *Bio/Tech* 9, 1369-1372), as well as large bacterial surface structures have served as vehicles for peptide display. Peptides can be fused to pilin, a protein which polymerizes to form the pilus-a conduit for interbacterial exchange of genetic information (Thiry et al.
30 (1989) *Appl. Environ. Microbiol.* 55, 984-993). Because of its role in interacting with other cells, the pilus provides a useful support for the presentation of peptides to the extracellular environment. Another large surface structure used for peptide display is the bacterial motive organ, the flagellum. Fusion of peptides to the subunit protein flagellin offers a dense array of many peptide copies on the host cells (Kuwajima et al. (1988) *Bio/Tech.* 6, 1080-1083).
35 Surface proteins of other bacterial species have also served as peptide fusion partners. Examples include the *Staphylococcus* protein A and the outer membrane protease IgA of

5 *Neisseria* (Hansson et al. (1992) *J. Bacteriol.* 174, 4239-4245 and Klauser et al. (1990)
EMBO J. 9, 1991-1999).

In the filamentous phage systems and the LamB system described above, the physical link between the peptide and its encoding DNA occurs by the containment of the DNA within a particle (cell or phage) that carries the peptide on its surface. Capturing the peptide captures the particle and the DNA within. An alternative scheme uses the DNA-binding protein LacI to form a link between peptide and DNA (Cull et al. (1992) *PNAS USA* 89:1865-1869). This system uses a plasmid containing the LacI gene with an oligonucleotide cloning site at its 3'-end. Under the controlled induction by arabinose, a LacI-peptide fusion protein is produced. This fusion retains the natural ability of LacI to bind to a short DNA sequence known as LacO operator (LacO). By installing two copies of LacO on the expression plasmid, the LacI-peptide fusion binds tightly to the plasmid that encoded it. Because the plasmids in each cell contain only a single oligonucleotide sequence and each cell expresses only a single peptide sequence, the peptides become specifically and stably associated with the DNA sequence that directed its synthesis. The cells of the library are gently lysed and the peptide-DNA complexes are exposed to a matrix of immobilized receptor to recover the complexes containing active peptides. The associated plasmid DNA is then reintroduced into cells for amplification and DNA sequencing to determine the identity of the peptide ligands.
As a demonstration of the practical utility of the method, a large random library of dodecapeptides was made and selected on a monoclonal antibody raised against the opioid peptide dynorphin B. A cohort of peptides was recovered, all related by a consensus sequence corresponding to a six-residue portion of dynorphin B. (Cull et al. (1992) *Proc. Natl. Acad. Sci. U.S.A.* 89:1869)

This scheme, sometimes referred to as peptides-on-plasmids, differs in two important ways from the phage display methods. First, the peptides are attached to the C-terminus of the fusion protein, resulting in the display of the library members as peptides having free carboxy termini. Both of the filamentous phage coat proteins, pIII and pVIII, are anchored to the phage through their C-termini, and the guest peptides are placed into the outward-extending N-terminal domains. In some designs, the phage-displayed peptides are presented right at the amino terminus of the fusion protein. (Cwirla, et al. (1990) *Proc. Natl. Acad. Sci. U.S.A.* 87, 6378-6382) A second difference is the set of biological biases affecting the population of peptides actually present in the libraries. The LacI fusion molecules are confined to the cytoplasm of the host cells. The phage coat fusions are exposed briefly to the

5 cytoplasm during translation but are rapidly secreted through the inner membrane into the periplasmic compartment, remaining anchored in the membrane by their C-terminal hydrophobic domains, with the N-termini, containing the peptides, protruding into the periplasm while awaiting assembly into phage particles. The peptides in the LacI and phage libraries may differ significantly as a result of their exposure to different proteolytic activities. The phage coat proteins require transport across the inner membrane and signal peptidase processing as a prelude to incorporation into phage. Certain peptides exert a deleterious effect on these processes and are underrepresented in the libraries (Gallop et al. 10 (1994) *J. Med. Chem.* 37(9):1233-1251). These particular biases are not a factor in the LacI display system.

15 The number of small peptides available in recombinant random libraries is enormous. Libraries of 10^7 - 10^9 independent clones are routinely prepared. Libraries as large as 10^{11} recombinants have been created, but this size approaches the practical limit for clone libraries. This limitation in library size occurs at the step of transforming the DNA containing randomized segments into the host bacterial cells. To circumvent this limitation, 20 an *in vitro* system based on the display of nascent peptides in polysome complexes has recently been developed. This display library method has the potential of producing libraries 3-6 orders of magnitude larger than the currently available phage/phagemid or plasmid libraries. Furthermore, the construction of the libraries, expression of the peptides, and screening, is done in an entirely cell-free format.

25 In one application of this method (Gallop et al. (1994) *J. Med. Chem.* 37(9):1233-1251), a molecular DNA library encoding 10^{12} decapeptides was constructed and the library expressed in an *E. coli* S30 *in vitro* coupled transcription/translation system. Conditions were chosen to stall the ribosomes on the mRNA, causing the accumulation of a substantial proportion of the RNA in polysomes and yielding complexes containing nascent peptides still 30 linked to their encoding RNA. The polysomes are sufficiently robust to be affinity purified on immobilized receptors in much the same way as the more conventional recombinant peptide display libraries are screened. RNA from the bound complexes is recovered, converted to cDNA, and amplified by PCR to produce a template for the next round of synthesis and screening. The polysome display method can be coupled to the phage display 35 system. Following several rounds of screening, cDNA from the enriched pool of polysomes was cloned into a phagemid vector. This vector serves as both a peptide expression vector, displaying peptides fused to the coat proteins, and as a DNA sequencing vector for peptide

5 identification. By expressing the polysome-derived peptides on phage, one can either continue the affinity selection procedure in this format or assay the peptides on individual clones for binding activity in a phage ELISA, or for binding specificity in a completion phage ELISA (Barret, et al. (1992) *Anal. Biochem* 204,357-364). To identify the sequences of the active peptides one sequences the DNA produced by the phagemid host.

10

Antisense Ku Nucleic Acid Sequences

Nucleic acid molecules which are antisense to a nucleotide encoding Ku can be used as an inactivating agent which inhibits Ku expression. An "antisense" nucleic acid includes a nucleotide sequence which is complementary to a "sense" nucleic acid encoding Ku, e.g., 15 complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can form hydrogen bonds with a sense nucleic acid. The antisense nucleic acid can be complementary to an entire Ku coding strand, or to only a portion thereof. For example, an antisense nucleic acid molecule which antisense to the "coding region" of the coding strand of a nucleotide sequence 20 encoding Ku can be used.

Given the coding strand sequences encoding Ku disclosed in, for example, Takiguchi et al. (1996) Genomics 35(1):129-135 and Genbank Accession Number L35932, antisense nucleic acids can be designed according to the rules of Watson and Crick base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of Ku 25 mRNA, but more preferably is an oligonucleotide which is antisense to only a portion of the coding or noncoding region of Ku mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of Ku mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 30 nucleotides in length. An antisense nucleic acid can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase 35 the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-

5 (carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-
carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-
isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-
methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-
methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-
10mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-
isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-
thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-
15 oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-
N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense
nucleic acid can be produced biologically using an expression vector into which a nucleic
acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted
nucleic acid will be of an antisense orientation to a target nucleic acid of interest).

Exogenous DNA Sequences

20 The DNA sequence to be provided, e.g., introduced, into the cell can alter a target
sequence in a cell. For example, a selected DNA sequence can be introduced which differs
from the target DNA by less than 10, 8, 5, 4, 3, 2, or by a single nucleotide, e.g., by a
substitution, a deletion or an insertion. The selected DNA sequence can also differ from the
target sequence by more than one nucleotide, e.g., differs from the target sequence by a
25 number of nucleotides such that the selected DNA sequence has an unpaired region, e.g., a
loop out region. These alterations can modify target sequence expression. Modified
sequence expression includes: activating a sequence, e.g., a coding DNA sequence, e.g., a
coding sequence normally found in a cell, which is normally silent (unexpressed) in the cell;
increasing expression of a sequence, e.g., a coding DNA sequence, e.g., a coding sequence
30 normally found in a cell, which is expressed at lower than normal levels in the cell;
expressing a sequence, e.g., a coding DNA sequence, e.g., a coding sequence normally found
in a cell, which is normally expressed in a defective form in the cell; changing the pattern of
regulation or induction of a sequence, e.g., a coding DNA sequence, e.g., a coding sequence
35 normally found in a cell, such that it is different than the cell's normal pattern; reducing
expression of a sequence, e.g., a coding DNA sequence, e.g., a coding sequence normally
found in a cell, from normal expression levels in the cell.

5 A selected DNA sequence can be introduced which differs from the target DNA by less than 10, 8, 5, 4, 3, 2, or by a single nucleotide, e.g., by a substitution, a deletion or an insertion. For example, the targeted sequence can differ from the wild-type sequence by less than 10, 8, 5, 4, 3, 2, or by a single nucleotide. Preferably, the targeted sequence differs from the wild-type sequence by a point mutation, e.g., a mutation arising from an insertion, 10 deletion or substitution. Preferably, the mutation in the target sequence, e.g., a gene, is associated with, e.g., controls, a disease or a dysfunction. Examples of genes in which a mutation, e.g., a point mutation, has been associated with a disease or dysfunction include, but are not limited to, cystic fibrosis transmembrane regulator (CFTR) gene, β -globin gene, Factor VIII gene, Factor IX gene, von Willebrand factor gene, xeroderma pigmentosum 15 group G (XP-G) gene. The selected DNA sequence for altering the target sequence can include a normal wild-type sequence which can correct the mutation. There are several genetic disorders and genes which can be altered according to the methods described herein.

In another aspect, the selected DNA sequence can also differ from the target sequence by more than one nucleotide, e.g., differs from the target sequence by a number of 20 nucleotides such that the selected DNA sequence has an unpaired region, e.g., a loop out region. For example, the selected DNA sequence can be homologously recombined with a preselected element of the target, e.g., if one is a regulatory element and the other is a sequence which encodes a protein, the regulatory element controls expression of the protein encoding sequence. The selected DNA sequence can be a regulatory sequence, e.g., an 25 exogenous regulatory sequence. Regulatory sequences include a promoter, an enhancer, an UAS, a scaffold-attachment region and a transcription binding site. In addition, the selected DNA sequence can also include an exon, an intron, a CAP site, a nucleotide sequence ATG, a marker, e.g., a selection marker, a splice-donor site and/or encoding DNA in frame with the target sequence. The selected DNA sequence can also include a coding region, e.g., DNA 30 sequence encoding a protein.

The coding sequence can be endogenous, e.g., the selected DNA sequence is a regulatory sequence, or the selected DNA sequence can include the coding region, i.e., the coding region is exogenous. The coding region can encode various proteins. Examples of such proteins include: erythropoietin, calcitonin, growth hormone, insulin, insulinotropin, 35 insulin-like growth factors, parathyroid hormone, α 2-interferon (IFNA2), β -interferon, γ -interferon, nerve growth factors, FSH β , TGF- β , tumor necrosis factor, glucagon, bone growth factor-2, bone growth factor-7, TSH- β , interleukin 1, interleukin 2, interleukin 3, interleukin

5 6, interleukin 11, interleukin 12, CSF-granulocyte (GCSF), CSF-macrophage, CSF-
granulocyte/macrophage, immunoglobulins, catalytic antibodies, protein kinase C,
glucocerebrosidase, superoxide dismutase, tissue plasminogen activator, urokinase,
antithrombin III, DNase, α -galactosidase, tyrosine hydroxylase, blood clotting factor V,
blood clotting factor VII, blood clotting factor VIII, blood clotting factor IX, blood clotting
10 factor X, blood clotting factor XIII, apolipoprotein E, apolipoprotein A-I, globins, low
density lipoprotein receptor, IL-2 receptor, IL-2 antagonists, α -1-antitrypsin, immune
response modifiers, β -glucoceramidase, α -iduronidase, α -L-iduronidase, glucosamine-N-
sulfatase, α -N-acetylglucosaminidase, acetylcoenzymeA: α -glucosamine-N-acetyltransferase,
N-acetylglucosamine-6-sulfatase, β -galactosidase, β -glucuronidase, N-acetylgalactosamine-
15 6-sulfatase, and soluble CD4. Sequences encoding these proteins are known.

The term *exogenous* refers to a sequence which is introduced into a cell by the methods described herein. The exogenous sequence can have a sequence identical or different from an endogenous sequence present in the cell.

Preferably, the DNA sequence is a linear sequence.

20

Targeting Sequence or Sequences

Targeting sequence or sequences are DNA sequences which permit homologous recombination into the genome of a cell containing the targeted sequence, e.g., the targeted gene. The term "targeting sequence" and "flanking sequence" are used interchangeably herein. Targeting sequences are, generally, DNA sequences which are homologous to (i.e., identical or sufficiently similar to cellular DNA such that the targeting sequence and cellular DNA can undergo homologous recombination) DNA sequences normally present in the genome of a cells as obtained. For example, the targeting sequence can be sufficiently homologous to: coding or noncoding DNA, a sequence lying upstream of the transcriptional start site, within, or downstream of the transcriptional stop site of a gene of interest, or sequences present in the genome through a previous modification. The targeting sequence or sequences used are selected with reference to the site into which the selected DNA sequence is to be inserted or the site into which the targeted sequence is to be altered.

One or more targeting sequences can be employed. Preferably, the selected DNA sequence is flanked by two targeting sequences. A targeting sequence can be within a gene or coding sequence (such as, the sequences of an exon and/or intron), immediately adjacent to a coding sequence of a gene (e.g., with less than 10, 5, 4, 3, 2, 1 or no additional nucleotides

5 between the targeting sequence and the coding region of the gene), upstream of a coding sequence of a gene (such as the sequences of the upstream non-coding region or endogenous promoter sequences), or upstream of and at a distance from the coding sequence of a gene (such as, sequences upstream of the endogenous promoter). The targeting sequence or sequences can include those regions of the targeted sequence presently known or sequenced and/or regions further upstream which are structurally uncharacterized but can be mapped 10 using restriction enzymes and determined by one skilled in the art.

A targeting sequence can be used to insert a DNA sequence which includes a regulatory sequence immediately adjacent to, upstream, or at a substantial distance from the coding sequence of an endogenous gene. Alternatively or additionally, sequences which 15 affect the structure or stability of the RNA or protein produced can be replaced, removed, added, or otherwise modified by targeting. For example, RNA stability elements, splice sites, and/or leader sequences of RNA molecules can be modified to improve or alter the function, stability, and/or translatability of an RNA molecule. Protein sequences may also be altered, such as signal sequences, propeptide sequences, active sites, and/or structural sequences for 20 enhancing or modifying transport, secretion, or functional properties of a protein. A protein sequence can also be altered, e.g., corrected, by targeting a site in the gene encoding the protein which includes a mutation, e.g., a point mutation.

In one aspect, the targeting sequence can be homologous to a portion of human follicle stimulating hormone β (FSHβ). FSH is a gonadotrophin which plays an essential role 25 in the maintenance and development of oocytes and spermatozoa in normal reproductive physiology. FSH includes two subunits, α and β, the latter being responsible for FSH's biological specificity. The target site to which a given targeting sequence is homologous can reside within an exon and/or intron of the FSHβ gene, upstream of and immediately adjacent to the FSHβ-coding region, or upstream of and at a distance from the FSHβ-coding region. 30 For example, the first of the two targeting sequences (or the entire targeting sequence, if there is only one targeting sequence in the construct) can be derived from the genomic regions upstream of the FSHβ-coding sequences. For example, this targeting sequence can include a portion of SEQ ID NO:1, e.g., at least 20, 30, 50, 100, or 1000 consecutive nucleotides from the sequence corresponding to positions -7,454 to -1,417 (SEQ ID NO:2) or to positions -696 35 to -155 (SEQ ID NO:3). The second of the two targeting sequences can target a genomic region upstream of the coding sequence (e.g., also contain a portion of SEQ ID NO:2 or 3), or target an exon or intron of the gene. Sequences which can be used to target FSHβ are further

5 described in U.S. Serial Number 09/305,639, the contents of which is incorporated herein in its entirety.

The targeting sequence can be homologous to a portion of human interferon- α 2 (IFN α 2). Interferon- α constitutes a complex gene family with 14 genes clustered on the short arm of chromosome 9. None of these genes, including IFN α 2 gene, have introns. Interferon- α is produced by macrophages, T cells and B cells as well as many other cell types. 10 Interferon- α has considerable anti-viral effects, and has been shown to be efficacious in treating infections by papilloma virus, hepatitis B and C viruses, vaccinia, herpes simplex virus, herpes zoster varicellosus virus and rhinovirus.

The target site to which a given targeting sequence is homologous can reside within 15 the coding region of the IFN α 2 gene, upstream of and immediately adjacent to the coding region, or upstream and at a distance from the coding region. For example, the first of the two targeting sequences (or the entire targeting sequence, if there is only one targeting sequence in the construct) can be derived from the genomic regions upstream of the IFN α 2 coding sequences. For example, this targeting sequence can include a portion (e.g., at least 20 20, 50, 100 or 1000 consecutive nucleotides) of SEQ ID NO:4, which corresponds to nucleotides -4074 to -511 of the IFN α 2 gene. The second of the two targeting sequences may target a genomic region upstream of the coding sequence itself. By way of example, the 25 second targeting sequence may contain at its 3' end, an exogenous coding region identical to the first few codons of the IFN α 2 coding sequence. Upon homologous recombination, the exogenous coding region recombines with the targeted part of the endogenous IFN α 2 coding sequence. Sequences which can be used to target IFN α 2 are further described in U.S. Serial 30 Number 09/305,638, the contents of which is incorporated herein in its entirety.

In another aspect, the targeting sequence can be homologous to a portion of human granulocyte colony-stimulating factor (GCSF). GCSF is a cytokine that stimulates the proliferation and differentiation of hematopoietic progenitor cells committed to the neutrophil/granulocyte lineage. GCSF is routinely used in the prevention of chemotherapy-induced neutropenia and in association with bone marrow transplantation. Chronic idiopathic and congenital neutropenic disorders also show improvement after GCSF injection. The target site to which a given targeting sequence is homologous can reside within an exon 35 and/or intron of the GCSF gene, upstream of and immediately adjacent to the GCSF coding region, or upstream of and at a distance from the GCSF coding region.

5 For example, the first of the two targeting sequences in the construct (or
the entire targeting sequence, if there is only one targeting sequence in the construct) can be
homologous to the genomic regions upstream of the GCSF-coding sequences. For example,
this targeting sequence can contain a portion of SEQ ID NO:5, which corresponds to
nucleotides -6,578 to 101 of human GCSF gene (e.g., at least 20, 50, 100, or 1000
10 consecutive nucleotides from the sequence corresponding to positions -6,578 to -364 (SEQ
ID NO:6)). The second of the two targeting sequences in the construct may target a genomic
region upstream of the coding sequence (e.g., also contain a portion of SEQ ID NO:6), or
target an exon or intron of the gene. Sequences which can be used to target GCSF are further
described in U.S. Serial Number 09/305,384, the contents of which is incorporated herein in
15 its entirety.

Regulatory Sequence

A DNA sequence can include a regulatory sequence. The regulatory sequence can
include one or more promoters (such as a constitutive or inducible promoter), enhancers, an
20 UAS, scaffold-attachment regions or matrix attachment sites, negative regulatory elements,
transcription factor binding sites, or combinations of these sequences.

The regulatory sequence can contain an inducible promoter such that cells as
produced or as introduced into an individual can be induced to express a product, e.g., the cell
does not express the product but can be induced to express it. The regulatory sequence can
25 contain an inducible promoter such that the product is expressed upon introduction of the
regulatory sequence. The regulatory sequence can be a cellular or viral sequence. Such
regulatory sequences include, but are not limited to, those that regulate the expression of
SV40 early or late genes, adenovirus major late genes, the mouse metallothionein-I gene, the
elongation factor-1 α gene, cytomegalovirus genes, collagen genes, actin genes,
30 immunoglobulin genes, γ actin gene, transcription activator YY1 gene, fibronectin gene, or
the HMG-CoA reductase gene. The regulatory sequence can further contain a transcription
factor binding site, such as a TATA Box, CCAAT Box, AP1, Sp1 or NF- κ B binding site.

Additional DNA Sequence Elements

35 The DNA sequence can further include one or more exons. An exon is a DNA
sequence which is copied into RNA and is present in a mature mRNA molecule. An exons

5 can contain DNA which encodes one or more amino acids and/or partially encodes an amino acid (i.e., one or two bases of a codon). Alternatively, an exon contains DNA which corresponds to a non-coding region, e.g., a 5' non-coding region. Where the exogenous exon or exons encode one or more amino acids and/or a portion of an amino acid, the DNA sequence can be designed such that, upon transcription and splicing, the reading frame is in-frame with the second exon or coding region of a targeted gene. As used herein, in-frame means that the encoding sequences of a first exon and a second exon, when fused, join together nucleotides in a manner that does not change the appropriate reading frame of the portion of the mRNA derived from the second exon.

10 15 If the first exon of the targeted gene contains the sequence ATG to initiate translation, the exogenous exon preferably contains an ATG. In addition, an exogenous exon containing an ATG can further include one or more nucleotides such that the resulting coding region of the mRNA including the second and subsequent exons of the targeted gene is in-frame. Examples of such targeted genes in which the first exon contains an ATG include the genes encoding human erythropoietin, human growth hormone, human colony stimulating factor-granulocyte/macrophage (hGM-CSF), and human colony stimulating factor-granulocyte (hG-CSF).

20 25 A splice-donor site is a sequence which directs the splicing of one exon to another exon. Typically, a first exon lies 5' of a second exon, and a splice-donor site overlapping and flanking the first exon on its 3' side recognizes a splice-acceptor site flanking the second exon on the 5' side of the second exon. A splice-donor site can have a characteristic consensus sequence represented as: (A/C)AG GURAGU (where R denotes a purine nucleotide) with the GU in the fourth and fifth positions, being required (Jackson 1991) *Nucleic Acids Res.* 19: 3715-3798). The first three bases of the splice-donor consensus site are the last three bases of the exon. Splice-donor sites can be functionally defined by their ability to effect the appropriate reaction within the mRNA splicing pathway.

30 An unpaired splice-donor site is a splice-donor site which is present in a targeted sequence and is not accompanied in the DNA sequence by a splice-acceptor site positioned 3' to the unpaired splice-donor site. The unpaired splice-donor site can result in splicing to an endogenous splice-acceptor site.

35 A splice-acceptor site in a sequence which, like a splice-donor site, directs the splicing of one exon to another exon. Acting in conjunction with a splice-donor site, the splicing apparatus uses a splice-acceptor site to effect the removal of an intron. Splice-

5 acceptor sites can have a characteristic sequence represented as: YYYYYYYYYYYNYAG, where Y denotes any pyrimidine and N denotes any nucleotide (Jackson (1991) *Nucleic Acids Res.* 19:3715-3798).

10 An intron is defined as a sequence of one or more nucleotides lying between two exons and which is removed, by splicing, from a precursor RNA molecule in the formation of an mRNA molecule.

15 The regulatory sequence can be linked to an ATG start codon, for initiating translation. Optionally, a CAP site (a specific mRNA initiation site which is associated with and utilized by the regulatory region) can be linked to the regulatory sequence and the ATG start codon. Alternatively, the CAP site associated with and utilized by the regulatory sequence is not included in the target sequence, and the transcriptional apparatus provides a new CAP site. A CAP site can usually be found approximately 25 nucleotides 3' of the TATA box. A splice-donor site can be placed immediately adjacent to an ATG, e.g., where the presence of one or more nucleotides is not required for the exogenous exon to be in-frame with the second exon of the targeted gene. DNA encoding one or more amino acids or portions of an amino acid in-frame with the coding sequence of the targeted gene, can be placed immediately adjacent to the ATG on its 3' side. As such, the splice-donor site can be placed immediately adjacent to the encoding DNA on its 3' side.

20 An encoding portion of a DNA sequence (e.g., in exon 1 of the DNA sequence) can encode one or more amino acids, and/or a portion of an amino acid, which are the same as those of the endogenous protein. For example, the encoding DNA sequence can correspond to the first exon of the gene of interest. The encoding DNA can alternatively encode one or more amino acids or a portion of an amino acid different from the first exon of the protein of interest, for example, where the amino acids of the first exon of the protein of interest are not critical to the activity or activities of the protein. For example, when fusions to an endogenous human erythropoietin (EPO) gene are constructed, sequences encoding the first exon of human growth hormone (hGH) can be employed. In this example, fusion of hGH exon 1 to EPO exon 2 results in the formation of a hybrid signal peptide which is functional. However, any exon of human or non-human origin in which the encoded amino acids do not prevent the function of the hybrid signal peptide can be used.

30 Where the desired product is a fusion protein of the endogenous protein and encoding sequences in the DNA sequence, the exogenous encoding DNA incorporated into the cells can include DNA which encodes one or more exons or a sequence of cDNA corresponding to

5 a translation or transcription product which is to be fused to the product of the endogenous targeted gene. Thus, targeting can be used to prepare chimeric or multifunctional proteins which combine structural, enzymatic, or ligand or receptor binding properties from two or more proteins into one polypeptide. For example, the exogenous DNA sequence can encode, e.g., an anchor to the membrane for the targeted protein or a signal peptide to provide or 10 improve cellular secretion, leader sequences, enzymatic regions, transmembrane domain regions, co-factor binding regions or other functional regions. Examples of proteins which are not normally secreted, but which could be fused to a signal protein to provide secretion include dopa-decarboxylase, transcriptional regulatory proteins and tyrosine hydroxylase.

15 The DNA sequence can be obtained from sources in which it occurs in nature or can be produced, using genetic engineering techniques or synthetic processes.

Target Sequence

20 The DNA sequence, when transfected into cells, such as primary, secondary or immortalized cells, can control the expression of a desired product for example, the active or, functional portion of the protein or RNA. The DNA sequence can also encode a desired product. The product can be, for example, a hormone, a cytokine, an antigen, an antibody, an enzyme, a clotting factor, a transport protein, a receptor, a regulatory protein, a structural 25 protein, a transcription factor, an anti-sense RNA, or a ribozyme. Additionally, the product can be a protein or a nucleic acid which does not occur in nature (i.e., a fusion protein or nucleic acid).

Such products include erythropoietin, calcitonin, growth hormone, insulin, insulinotropin, insulin-like growth factors, parathyroid hormone, interferon β , and interferon γ , nerve growth factors, FSH β , TGF- β , tumor necrosis factor, glucagon, bone growth factor-30 2, bone growth factor-7, TSH- β , interleukin 1, interleukin 2, interleukin 3, interleukin 6, interleukin 11, interleukin 12, CSF-granulocyte, CSF-macrophage, CSF-granulocyte/macrophage, immunoglobulins, catalytic antibodies, protein kinase C, glucocerebrosidase, superoxide dismutase, tissue plasminogen activator, urokinase, antithrombin III, DNase, α -galactosidase, tyrosine hydroxylase, blood clotting factors V, 35 blood clotting factor VII, blood clotting factor VIII, blood clotting factor IX, blood clotting factor X, blood clotting factor XIII, apolipoprotein E or apolipoprotein A-I, globins, low density lipoprotein receptor, IL-2 receptor, IL-2 antagonists, alpha-1 anti-trypsin, immune

5 response modifiers, β -glucoceromidase, α -iduronidase, α L-iduronidase, glucosamine-N-sulfatase, α -N-acetylglucosaminidase, acetylcoenzymeA: α -glucosamide-N-acetyltransferase, N-acetylglucosamine-6-sulfatase, β -galactosidase, β -glucuronidase, N-acetylgalactosamine-6-sulfatase, and soluble CD4.

10 Selectable Markers and Amplification

The identification of the targeting event can be facilitated by the use of one or more selectable marker genes. These markers can be included in the DNA sequence or can be present on a different construct. Selectable markers can be divided into two categories: positively selectable and negatively selectable (in other words, markers for either positive selection or negative selection). In positive selection, cells expressing the positively selectable marker are capable of surviving treatment with a selective agent (such as neo, xanthine-guanine phosphoribosyl transferase (gpt), dhfr, adenine deaminase (ada), puromycin (pac), hygromycin (hyg), CAD which encodes carbamyl phosphate synthase, aspartate transcarbamylase, and dihydro-orotate glutamine synthetase (GS), multidrug resistance 1 (mdrl) and histidine D (hisD), allowing for the selection of cells in which the targeting construct integrated into the host cell genome. In negative selection, cells expressing the negatively selectable marker are destroyed in the presence of the selective agent. The identification of the targeting event can be facilitated by the use of one or more marker genes exhibiting the property of negative selection, such that the negatively selectable marker is linked to the exogenous DNA sequence, but configured such that the negatively selectable marker flanks the targeting sequence, and such that a correct homologous recombination event with sequences in the host cell genome does not result in the stable integration of the negatively selectable marker (Mansour et al. (1988) *Nature* 336:348-352). Markers useful for this purpose include the Herpes Simplex Virus thymidine kinase (TK) gene, the bacterial gpt gene, diphtheria toxin and antisense RNA or ribozyme for mRNA that codes for a gene essential for cell survival.

A variety of selectable markers can be incorporated into primary, secondary or immortalized cells. For example, a selectable marker which confers a selectable phenotype such as drug resistance, nutritional auxotrophy, resistance to a cytotoxic agent or expression of a surface protein, can be used. Selectable marker genes which can be used include neo, gpt, dhfr, ada, pac, hyg, CAD, GS, mdrl and hisD. The selectable phenotype conferred makes it possible to identify and isolate recipient cells.

5 Genes encoding selectable markers (e.g., ada, GS, dhfr and the multifunctional CAD gene) have the added characteristic that they enable the selection of cells containing increased copies of the selectable marker and flanking the genomic sequence. This feature provides a mechanism for significantly increasing the copy number of an adjacent or linked gene for which increased copies is desirable. Mutated versions of these sequences showing improved
10 selection properties and other sequences leading to increased copies can also be used.

The order and number of components in the DNA sequence can vary. For example, the order can be: a first targeting sequence--selectable marker—regulatory sequence--an exon--a splice-donor site--a second targeting sequence or, in the alternative, a first targeting sequence--regulatory sequence--an exon--a splice-donor site--DNA encoding a selectable marker--a second targeting sequence. Cells that stably integrate the construct will survive treatment with the selective agent; a subset of the stably transfected cells will be homologously recombinant cells. The homologously recombinant cells can be identified by a variety of techniques, including PCR, Southern hybridization and phenotypic screening. The order of the construct can be: a first targeting sequence--selectable marker—regulatory sequence--an exon--a splice-donor site--an intron--a splice-acceptor site--a second targeting sequence.
15
20

Alternatively, the order of components in the DNA sequence can be, for example: a first targeting sequence —selectable marker 1--regulatory sequence--an exon--a splice-donor site--a second targeting sequence--selectable marker 2, or, alternatively, a first targeting sequence--regulatory sequence--an exon--a splice-donor site--selectable marker 1--a second targeting sequence--selectable marker 2. In this arrangement, selectable marker 2 can display the property of negative selection. That is, the gene product of selectable marker 2 can be selected against by growth in an appropriate media formulation containing an agent (typically a drug or metabolite analog) which kills cells expressing selectable marker 2. Recombination between the targeting sequences flanking selectable marker 1 with homologous sequences in the host cell genome results in the targeted integration of selectable marker 1, while selectable marker 2 is not integrated. Such recombination events generate cells which are stably transfected with selectable marker 1 but not stably transfected with selectable marker 2, and such cells can be selected for by growth in the media containing the selective agent which selects for selectable marker 1 and the selective agent which selects against selectable marker 2.
25
30
35

5 The DNA sequence also can include a positively selectable marker that allows for the selection of cells containing increased copies of that marker. The increased copies of such a marker result in the co-amplification of flanking DNA sequences. For example, the order of components can be: a first targeting sequence--a positively selectable marker which increases the number of copies--a second selectable marker (optional)--regulatory sequence--an exon--
10 a splice-donor site--a second targeting DNA sequence. The activated gene can be further increased by the inclusion of a selectable marker gene which has the property that cells containing increased copies of the selectable marker gene can be selected for by culturing the cells in the presence of the appropriate selectable agent. The activated endogenous gene will be increases in tandem with the selectable marker gene. Cells containing many copies of the
15 activated endogenous gene may produce very high levels of the desired protein and are useful for *in vitro* protein production and gene therapy.

The selectable and other marker genes do not have to lie immediately adjacent to each other.

20 DNA Sequence/Homologous Recombination Enhancing Agent/Non-Homologous End Joining Inhibiting Agent Complexes

Homologous recombination between a double stranded DNA sequence and a selected target DNA, e.g., chromosomal DNA in a cell, can be promoted by providing an agent which enhances homologous recombination, e.g., a Rad52 protein, and an agent which inhibits non-homologous end joining, e.g., a Ku inactivating agent (e.g., a anti-Ku antibody), in sufficiently close proximity to the DNA sequence and the targeted site. "Sufficiently close proximity" as used herein refers to introduction of a homologous recombination enhancing agent or an agent which inhibits non-homologous end joining or both such that the concentration of the homologous recombination enhancing agent and/or agent which inhibits non-homologous end joining is sufficient to provide a higher rate of an alteration at a targeted site, e.g., homologous recombination between a DNA sequence and a target sequence.
25 Several methods can be used to provide the introduction of the DNA sequence, homologous recombination enhancing agent, and an agent which inhibits non-homologous end joining within close proximity of each other. By administering these compounds in close proximity of each other and the target DNA, the activity of compounds such as Rad52 and Ku inactivating molecules, e.g., an anti-Ku antibody, are localized at the site of homologous
30 35

5 recombination. For example, local inhibition of Ku activity may be preferable over whole cell inhibition of Ku activities.

The close proximity of the DNA sequence, a homologous recombination enhancing agent, and an agent which inhibits non-homologous end joining can be maintained by introducing these elements as part of a complex. For example, DNA-protein complexes can 10 be used. The core of a DNA-protein complex can be composed of the double stranded DNA sequence which is to be introduced into the selected site in the target DNA. A homologous recombination enhancing agent, e.g., a Rad52 protein or fragment thereof, can be adhered, e.g., coated, on the DNA sequence, e.g., on the entire sequence or just the ends of the DNA sequence, e.g., on at least a portion of a single stranded protruding end of the DNA sequence. 15 The DNA-protein complex can further include an agent which inhibits non-homologous end joining, e.g., a Ku inactivating agent such as an anti-Ku antibody, which is covalently linked to either the DNA sequence or to the homologous recombination enhancing agent. The agent which inhibits non-homologous end joining can also be non-covalently linked to the DNA sequence or to the homologous recombination enhancing agent.

20 The compounds can also be maintained in close proximity to one another by providing the DNA sequence, the homologous recombination enhancing agent and the agent which inhibits non-homologous end joining in a liposome or vesicle. For example, liposomal suspensions can also be used as pharmaceutically acceptable carriers of these elements. Liposomal suspensions can be prepared according to methods known to those skilled in the 25 art, for example, as described in U.S. Patent No. 4,522,811.

The DNA sequence, the homologous recombination enhancing agent and the agent which inhibits non-homologous end joining can also be part of a mixed solution which can be microinjected into a cell or each of these compounds can be introduced in quick succession to the others such that all three of these compounds are present in the cell at the same time. 30 Other methods of introducing one or more of these compounds include receptor-mediated delivery, electroporation and calcium phosphate precipitation.

Cells

Primary and secondary cells to be transfected can be obtained from a variety of tissues 35 and include cell types which can be maintained and propagated in culture. For example, primary and secondary cells which can be transfected include fibroblasts, keratinocytes, epithelial cells (e.g., mammary epithelial cells, intestinal epithelial cells), endothelial cells,

5 glial cells, neural cells, formed elements of the blood (e.g., lymphocytes, bone marrow cells), muscle cells and precursors of these somatic cell types. Primary cells are preferably obtained from the individual to whom the transfected primary or secondary cells are administered (i.e., an autologous cell). However, primary cells may be obtained from a donor (other than the recipient) of the same species (i.e., an allogeneic cell) or another species (i.e., a xenogeneic cell) (e.g., mouse, rat, rabbit, cat, dog, pig, cow, bird, sheep, goat, horse).

10 Primary or secondary cells of vertebrate, particularly mammalian, origin can be transfected with an exogenous DNA sequence, e.g., an exogenous DNA sequence encoding a therapeutic protein, and produce an encoded therapeutic protein stably and reproducibly, both *in vitro* and *in vivo*, over extended periods of time. In addition, the transfected primary and
15 secondary cells can express the encoded product *in vivo* at physiologically relevant levels, cells can be recovered after implantation and, upon reculturing, to grow and display their preimplantation properties.

20 Alternatively, primary or secondary cells of vertebrate, particularly mammalian, origin can be transfected with an exogenous DNA sequence which includes a regulatory sequence. Examples of such regulatory sequences include one or more of: a promoter, an enhancer, an UAS, a scaffold attachment region or a transcription binding site. The targeting event can result in the insertion of the regulatory sequence of the DNA sequence, placing a targeted endogenous gene under their control (for example, by insertion of either a promoter or an enhancer, or both, upstream of the endogenous gene or regulatory region). Optionally,
25 the targeting event can simultaneously result in the deletion of an endogenous regulatory sequence, such as the deletion of a tissue-specific negative regulatory sequence, of a gene. The targeting event can replace an existing regulatory sequence; for example, a tissue-specific enhancer can be replaced by an enhancer that has broader or different cell-type specificity than the naturally-occurring elements, or displays a pattern of regulation or
30 induction that is different from the corresponding nontransfected cell. In this regard, the naturally occurring sequences are deleted and new sequences are added. Alternatively, the endogenous regulatory sequences are not removed or replaced but are disrupted or disabled by the targeting event, such as by targeting the exogenous sequences within the endogenous regulatory elements. Introduction of a regulatory sequence by homologous recombination
35 can result in primary or secondary cells expressing a therapeutic protein which it does not normally express. In addition, targeted introduction of a regulatory sequence can be used for cells which make or contain the therapeutic protein but in lower quantities than normal (in

5 quantities less than the physiologically normal lower level) or in defective form, and for cells which make the therapeutic protein at physiologically normal levels, but are to be augmented or enhanced in their content or production.

10 The transfected primary or secondary cells may also include a DNA sequence encoding a selectable marker which confers a selectable phenotype upon them, facilitating their identification and isolation. Methods for producing transfected primary, secondary cells which stably express the DNA sequence, clonal cell strains and heterogenous cell strains of such transfected cells, methods of producing the clonal and heterogenous cell strains, and methods of treating or preventing an abnormal or undesirable condition through the use of populations of transfected primary or secondary cells are part of the invention.

15

Transfection of Primary or Secondary Cells, Homologous Recombination and Production of Clonal or Heterogenous Cell Strains

20 Vertebrate tissue can be obtained by standard methods such as punch biopsy or other surgical methods of obtaining a tissue source of the primary cell type of interest. For example, punch biopsy is used to obtain skin as a source of fibroblasts or keratinocytes. A mixture of primary cells is obtained from the tissue, using known methods, such as enzymatic digestion or explanting. If enzymatic digestion is used, enzymes such as collagenase, hyaluronidase, dispase, pronase, trypsin, elastase and chymotrypsin can be used.

25 The resulting primary cell mixture can be transfected directly or it can be cultured first, removed from the culture plate and resuspended before transfection is carried out. Primary cells or secondary cells are combined with the DNA sequence to be introduced into their genomes which optionally includes DNA encoding a selectable marker, and treated in order to accomplish transfection. In addition, the primary or secondary cells are combined with a Rad52 protein or fragment thereof and a Ku-inactivating molecule, e.g., an anti-Ku antibody, either alone or as part of a complex.

30 Transfected primary or secondary cells, can be made by electroporation. Electroporation is carried out at appropriate voltage and capacitance (and corresponding time constant) to result in entry of the DNA construct(s) into the primary or secondary cells. Electroporation can be carried out over a wide range of voltages (e.g., 50 to 2000 volts) and corresponding capacitance. Total DNA of approximately 0.1 to 500 µg is generally used.

35 Preferably, primary or secondary cells are transfected using microinjection. Alternatively, known methods such as calcium phosphate precipitation, modified calcium

5 phosphate precipitation and polybrene precipitation, liposome fusion and receptor-mediated gene delivery can be used to transfect cells. A stably, transfected cell is isolated and cultured and subcultivated, under culturing conditions and for sufficient time, to propagate the stably transfected secondary cells and produce a clonal cell strain of transfected secondary cells. Alternatively, more than one transfected cell is cultured and subcultivated, resulting in
10 production of a heterogenous cell strain.

After transfection, the cell is maintained under conditions which permit homologous recombination, as is known in the art (Capecchi (1989) *Science* 244:1288-1292.

Homologously recombinant primary or secondary cells can undergo a sufficient number of doublings to produce either a clonal cell strain or a heterogenous cell strain of sufficient size to provide the therapeutic protein to an individual in effective amounts. In
15 general, for example, 0.1 cm² of skin is biopsied and assumed to contain 100,000 cells; one cell is used to produce a clonal cell strain and undergoes approximately 27 doublings to produce 100 million homologously recombinant secondary cells. If a heterogenous cell strain is to be produced from an original homologously recombinant population of approximately
20 100,000 cells, only 10 doublings are needed to produce 100 million cells.

The number of required cells in a homologously recombinant clonal or heterogenous cell strain is variable and depends on a variety of factors, including but not limited to, the use of the homologously recombinant cells, the functional level of the exogenous DNA sequence in the cells, the functional level of altered DNA sequence in the cell, the site of implantation of the homologously recombinant cells (for example, the number of cells that can be used is limited by the anatomical site of implantation), and the age, surface area, and clinical
25 condition of the patient. To put these factors in perspective, to deliver therapeutic levels of human growth hormone in an otherwise healthy 10 kg patient with isolated growth hormone deficiency, approximately one to five hundred million homologously recombinant fibroblasts would be necessary (the volume of these cells is about that of the very tip of the patient's
30 thumb).

Several methods can be used to determine the efficacy of the methods described herein to enhance homologous recombination in a cell. For example, an experimental system can be designed to detect a non-conservative substitution in a cell, e.g., a human cell. The substitution can be a C to T substitution at the CGA codon of exon 3 of the HPRT gene,
35 which is part of an *Xba*I site. This mutation creates a TGA termination signal which results in a HPRT-negative phenotype scored as resistant to 6-thioguanine (6-TG). This mutation is

5 also accompanied by a loss of the corresponding *Xba*I site. Briefly, a DNA sequence which includes the C to T substitution can be introduced by microinjection into a human fibroblast cell as part of a complex which includes an agent which enhances homologous recombination and an agent which inactivates Ku. The cells are cultured and allowed to propagate prior to introducing the cells onto media which includes 6-TG. 6-TG resistant clones can then be
10 scored to determine the presence of the mutated DNA sequence. The presence of a homologous recombination event can be detected by Southern blot analysis of *Xba*I digested genomic DNA using an HPRT-specific probe. The results can also be compared to control cells in which the mutated DNA sequence is introduced in the absence of an agent which enhances homologous recombination and an agent which inactivates Ku.

15

Implantation of Clonal Cell Strain or Heterogenous Cell Strain of Homologously Recombinant Secondary Cells

20 The homologously recombinant cells produced as described above can be introduced into an individual to whom the therapeutic protein is to be delivered, using known methods. The clonal cell strain or heterogenous cell strain is then introduced into an individual, using known methods, using various routes of administration and at various sites (e.g., renal subcapsular, subcutaneous, central nervous system (including intrathecal), intravascular,
25 intrahepatic, intrasplanchic, intraperitoneal (including intraomental), or intramuscular implantation). Once implanted in the individual, the homologously recombinant cells produce the therapeutic product encoded by the exogenous synthetic DNA or the homologously recombinant cells express a therapeutic protein encoded by an endogenous DNA sequence under the control of an exogenous regulatory sequence. For example, an
30 individual who has been diagnosed with Hemophilia B, a bleeding disorder that is caused by a deficiency in Factor IX, a protein normally found in the blood, is a candidate for a gene therapy cure. The patient has a small skin biopsy performed; this is a simple procedure which can be performed on an out-patient basis. The piece of skin, approximately the size of a matchhead, is taken, for example, from under the arm and requires about one minute to remove. The sample is processed, resulting in isolation of the patient's cells (in this case, fibroblasts) and genetically engineered to produce the missing Factor IX. Based on the age,
35 weight, and clinical condition of the patient, the required number of cells are grown in large-

5 scale culture. The entire process should require 4-6 weeks and, at the end of that time, the appropriate number of genetically-engineered cells are introduced into the individual, once again as an outpatient (e.g., by injecting them back under the patient's skin). The patient is now capable of producing his or her own Factor IX and is no longer a hemophiliac.

10 A similar approach can be used to treat other conditions or diseases. For example, short stature can be treated by administering human growth hormone to an individual by implanting primary or secondary cells which express human growth hormone.

15 As this example suggests, the cells used will generally be patient-specific genetically-engineered cells. It is possible, however, to obtain cells from another individual of the same species or from a different species. Use of such cells might require administration of an immunosuppressant, alteration of histocompatibility antigens, or use of a barrier device to prevent rejection of the implanted cells.

For many diseases, this will be a one-time treatment and, for others, multiple gene therapy treatments will be required.

20 Transfected primary or secondary cells can be administered alone or in conjunction with a barrier or agent for inhibiting immune response against the cell in a recipient subject. For example, an immunosuppressive agent can be administered to a subject inhibit or interfere with normal response in the subject. Preferably, the immunosuppressive agent is an immunosuppressive drug which inhibits T cell/or B cell activity in a subject. Examples of such immunosuppressive drugs commercially available (e.g., cyclosporin A is commercially 25 available from Sandoz Corp. East Hanover, NJ).

An immunosuppressive agent e.g., drug, can be administered to a subject at a dosage sufficient to achieve the desired therapeutic effect (e.g., inhibition of rejection of the cells). Dosage ranges for immunosuppressive drugs are known in the art. See, e.g., Freed et al. (1992) *N. Engl. J. Med.* 327:1549; Spencer et al. (1992) *N. Engl. J. Med.* 327:1541' Widner et al. (1992) *n. Engl. J. Med.* 327:1556). Dosage values may vary according to factors such 30 as the disease state, age, sex, and weight of the individual.

35 Another agent with can be used to inhibit T cell activity in a subject is an antibody, or fragment of derivative thereof. Antibodies capable of depleting or sequestering T cells *in vivo* are known in the art. Polyclonal antisera can be used, for example, anti-lymphocyte serum. Alternatively, one or more monoclonal antibodies can be used. Preferred T cell depleting antibodies include monoclonal antibodies which bind to CD2, CD3, CD4, CD8, CD40, CD40, ligand on the cell surface. Such antibodies are known in the art and are

5 commercially available, for example, from American Type Culture Collection. A preferred antibody for binding CD3 on human T cells is OKT3 (ATCC CRL 8001).

10 An antibody which depletes, sequesters or inhibits T cells within a recipient subject can be administered in a dose for an appropriate time to inhibit rejection of cells upon transplantation. Antibodies are preferably administered intravenously in a pharmaceutically acceptable carrier of diluent (e.g., saline solution).

15 Another way of interfering with or inhibiting an immune response to the cells in a recipient subject is to use an immunobarrier. An "immunobarrier" as used herein, refers to a device which serves as a barrier between the administered cell and cells involved in immune response in a subject. For example, the cells can be administered in an implantable device.

20 An implantable device can include the cells contained within a semi-permeable barrier, i.e., one which lets nutrients and the product diffuse in and out of the barrier but which prevents entry or larger immune system components, e.g., antibodies or complement. An implantable device typically includes a matrix, e.g., a hydrogel, or core in which cells are disposed.

25 Optionally, a semi permeable coating can enclose the gel. If disposed within the gel core, the administered cells should be sequestered from the cells of the immune system and should be cloaked from the cells and cytotoxic antibodies of the host. Preferably, a permselective coating such as PLL or PLO is used. The coating often has a porosity which prevents components of the recipient's immune system from entering and destroying the cells within the implantable device.

30 Many methods for encapsulating cells are known in the art. For example, encapsulation using a water soluble gum to obtain a semi-permeable water insoluble gel to encapsulate cells for production and other methods of encapsulation are disclosed in U.S. Patent No: 4,352,883. Other implantable devices which can be used are disclosed in U.S. Patent No.: 5,084,350, U.S. Patent No. 5,427,935, WO 95/19743 published July 27, 1995, U.S. Patent No.: 5,545,423, U.S. Patent Number 4,409,331, U.S. Patent Number 4,663,286, and European Patent No. 301,777.

Uses of Homologously Recombinant Primary and Secondary Cells and Cell Strains

35 Homologously recombinant primary or secondary cells or cell strains have wide applicability as a vehicle or delivery system for therapeutic proteins, such as enzymes, hormones, cytokines, antigens, antibodies, clotting factors, anti-sense RNA, regulatory proteins, transcription proteins, receptors, structural proteins, novel (non-optimized) proteins

5 and nucleic acid products, and engineered DNA. For example, homologously recombinant primary or secondary cells can be used to supply a therapeutic protein, including, but not limited to, erythropoietin, calcitonin, growth hormone, insulin, insulinotropin, insulin-like growth factors, parathyroid hormone, α 2-interferon (IFNA2), β -interferon, γ -interferon, nerve growth factors, FSH β , TGF- β , tumor necrosis factor, glucagon, bone growth factor-2, bone 10 growth factor-7, TSH- β , interleukin 1, interleukin 2, interleukin 3, interleukin 6, interleukin 11, interleukin 12, CSF-granulocyte (GCSF), CSF-macrophage, CSF- granulocyte/macrophage, immunoglobulins, catalytic antibodies, protein kinase C, glucocerebrosidase, superoxide dismutase, tissue plasminogen activator, urokinase, antithrombin III, DNase, α -galactosidase, tyrosine hydroxylase, blood clotting factor V, 15 blood clotting factor VII, blood clotting factor VIII, blood clotting factor IX, blood clotting factor X, blood clotting factor XIII, apolipoprotein E, apolipoprotein A-I, globins, low density lipoprotein receptor, IL-2 receptor, IL-2 antagonists, α -1-antitrypsin, immune response modifiers, β -glucoceramidase, α -iduronidase, α -L-iduronidase, glucosamine-N-sulfatase, α -N-acetylglucosaminidase, acetylcoenzymeA: α -glucosamine-N-acetyltransferase, 20 N-acetylglucosamine-6-sulfatase, β -galactosidase, β -glucuronidase, N-acetylgalactosamine-6-sulfatase, and soluble CD4.

All patents and references cited herein are incorporated in their entirety by reference. Other embodiments are within the following claims.

5

What is claimed:

1. A complex for promoting alteration of a target sequence in a cell, comprising:
a double stranded DNA sequence, a homologous recombination-enhancing agent, and an
agent which inhibits non-homologous end joining.

10 2. The complex of claim 1, wherein the homologous recombination-enhancing
agent is selected from the group consisting of: a Rad52 protein or functional fragment
thereof, a Rad51 protein or functional fragment thereof, a Rad54 protein or functional
fragment thereof, and combinations thereof.

15 3. The complex of claim 1, wherein the homologous recombination-enhancing
agent is Rad52 protein or functional fragment thereof.

20 4. The complex of claim 1, wherein the agent which inhibits non-homologous
end joining is selected from the group consisting of an agent which inactivates hMre11, an
agent which inactivates hRad50, an agent which inactivates Nbs1, an agent which inactivates
hLig4, an agent which inactivates hXrcc4, and an agent which inactivates Ku.

25 5. The complex of claim 1, wherein the agent which inhibits non-homologous
end joining is a Ku inactivating agent.

30 6. The complex of claim 5, wherein the Ku-inactivating agent is selected from
the group consisting of: an anti-Ku antibody, a Ku-binding oligomer, and a Ku-binding
polypeptide.

7. The complex of claim 5, wherein the Ku-inactivating agent is an anti-Ku-
antibody.

35 8. The complex of claim 1, wherein the DNA sequence comprises a linear DNA
sequence.

5 9. The complex of claim 1, wherein the DNA sequence is flanked by at least one targeting sequence.

10 10. The complex of claim 1, wherein the DNA sequence comprises an exogenous regulatory sequence.

15 11. The complex of claim 10, wherein the regulatory sequence is a promoter, an enhancer, an upstream activating sequence, a scaffold-attachment region or a transcription factor-binding site.

20 12. The complex of claim 11, wherein the regulatory sequence is a promoter and an enhancer.

25 13. The complex of claim 11, wherein the regulatory sequence is a promoter and an upstream activating sequence.

30 14. The complex of claim 3, wherein the Rad52 protein or functional fragment thereof is coated on the DNA sequence.

35 15. The complex of claim 3, wherein the Rad52 protein or fragment thereof is human Rad52.

40 16. The complex of claim 7, wherein the anti-Ku antibody is an anti-Ku70 antibody.

45 17. The complex of claim 7, wherein the anti-Ku antibody is an anti-Ku80 antibody.

50 18. The complex of claim 7, wherein at least one anti-Ku antibody is covalently linked to the DNA sequence.

55 19. The complex of claim 7, wherein at least one anti-Ku antibody is covalently linked to the agent for enhancing homologous recombination.

5

20. The complex of claim 7, wherein the complex comprises an anti-Ku70 antibody and an anti-Ku80 antibody.

10 21. The complex of claim 9, wherein the DNA sequence comprises a regulatory sequence and the targeting sequence is derived from a sequence 5' of the protein coding region of the FSH β gene.

15 22. The complex of claim 9, wherein the DNA sequence comprises a regulatory sequence and the targeting sequence is derived from a sequence 5' of the protein coding region of the IFN α gene.

20 23. The complex of claim 9, wherein the DNA sequence comprises a regulatory sequence and the targeting sequence is derived from a sequence 5' of the protein coding region of the GCSF gene.

24. The complex of claim 1, further comprising an agent which inhibits a mismatch repair protein.

25 25. A method of promoting an alteration at a selected site in a target DNA of a cell, comprising:

introducing into the cell a double stranded DNA sequence, an agent which enhances homologous recombination, and an agent which inhibits non-homologous end joining, to thereby promote alteration of the chromosomal DNA, to thereby promote alteration at a selected site in the chromosomal DNA.

30 26. The method of claim 25, wherein the DNA sequence comprises a linear DNA sequence.

35 27. The method of claim 25, wherein the DNA sequence is flanked by at least one targeting sequence.

5 28. The method of claim 25, wherein the DNA sequence comprises an exogenous
regulatory sequence.

10 29. The method of claim 28, wherein the regulatory sequence selected from the
group consisting of: a promoter, an enhancer, an upstream activating sequence, a scaffold-
attachment region and a transcription factor-binding site.

15 30. The method of claim 28, wherein the regulatory sequence is a promoter and an
enhancer.

15 31. The method of claim 28, wherein the regulatory sequence is a promoter and an
upstream activating sequence.

20 32. The method of claim 25, wherein the agent which enhances homologous
recombination is selected from the group consisting of: a Rad52 protein or functional
fragment thereof, a Rad51 protein or functional fragment thereof, a Rad54 protein or
functional fragment thereof, and combinations thereof.

25 33. The method of claim 25, wherein the agent which enhances homologous
recombination is a Rad52 protein or functional fragment thereof.

34. The method of claim 33, wherein the Rad52 protein or functional fragment
thereof is coated on the DNA sequence.

30 35. The method of claim 33, wherein the Rad52 protein or fragment thereof is
human Rad52.

35 36. The method of claim 25, wherein the agent which inhibits non-homologous
end joining is selected from the group consisting of an agent which inactivates hMre11, an
agent which inactivates hRad50, an agent which inactivates Nbs1, an agent which inactivates
hLig4, an agent which inactivates hXrcc4, and an agent which inactivates Ku.

5 37. The method of claim 25, wherein the agent which inhibits non-homologous end joining is a Ku inactivating agent.

10 38. The method of claim 37, wherein the agent which inactivates Ku is an anti-Ku antibody, a Ku-binding oligomer, and a Ku-binding polypeptide.

15 39. The method of claim 37, wherein the agent which inactivates Ku is a Ku antisense molecule.

20 40. The method of claim 37, wherein the agent which inactivates Ku is an anti-Ku antibody.

25 41. The method of claim 40, wherein the anti-Ku antibody is an anti-Ku70 antibody.

30 42. The method of claim 40, wherein the anti-Ku antibody is an anti-Ku80 antibody.

35 43. The method of claim 40, wherein at least one anti-Ku antibody is covalently linked to the DNA sequence.

40 44. The method of claim 40, wherein at least one anti-Ku antibody is covalently linked to the Rad52 protein or fragment thereof.

45. The method of claim 25, wherein the cell is of fungal, plant or animal origin.

50 46. The method of claim 45, wherein the cell is of vertebrate origin.

55 47. The method of claim 46, wherein the cell is a primary or secondary mammalian cell.

60 48. The method of claim 46, wherein the cell is a primary or secondary human cell.

5

49. The method of claim 46, wherein the cell is an immortalized mammalian cell.

50. The method of claim 46, wherein the cell is an immortalized human cell.

10 51. The method of claim 25, wherein the DNA sequence, the agent which enhances homologous recombination and the agent which inhibits non-homologous end joining are introduced into the cell as a complex.

15 52. The method of claim 25, further comprising introducing an agent which inhibits a mismatch-repair protein.

53. The method of claim 52, wherein the mismatch-repair protein is selected from the group consisting of: Msh2, Msh6, Msh3, Mlh1 and PMS2.

20 54. The method of claim 52, wherein the agent is an agent which inhibits expression of a mismatch-repair protein.

55. The method of claim 54, wherein the agent is an anti-mismatch-repair protein antibody.

25 56. The method of claim 54, wherein at least one anti-mismatch-repair protein antibody is covalently linked to the DNA sequence.

57. The method of claim 55, wherein at least one anti-mismatch-repair protein antibody is covalently linked to the Rad52 protein or fragment thereof.

30 58. The method of claim 27, wherein the DNA sequence comprises a regulatory sequence and the targeting sequence is derived from the region 5' of the FSH β coding region.

35 59. The method of claim 27, wherein the DNA sequence comprises a regulatory sequence and the targeting sequence is derived from the region 5' of the IFN α coding region.

5 60. The method of claim 27, wherein the DNA sequence comprises a regulatory sequence and the targeting sequence is derived from the region 5' of the GCSF coding region.

10 61. The method of claim 25, wherein the target DNA comprises a mutation having less than 10 base pairs which differ from wild-type sequence.

15 62. The method of claim 61, wherein the mutation is a point mutation.

20 63. The method of claim 62, wherein the DNA sequence comprises a wild-type sequence which can correct the mutation.

25 64. The method of claim 63, wherein the target DNA is a cystic fibrosis transmembrane regulator (CFTR) gene.

30 65. The method of claim 64, wherein the mutation changes an amino acid encoded by codon 508 of the coding region of the CFTR gene.

35 66. The method of claim 63, wherein the target DNA is a β-globin gene.

40 67. The method of claim 66, wherein the mutation changes an amino acid encoded by codon 6 of the coding region of the β-globin gene.

45 68. The method of claim 63, wherein the target DNA is a Factor VIII gene.

50 69. The method of claim 68, wherein the mutation changes an amino acid encoded by codon 2209 of the coding region of the Factor VIII gene.

55 70. The method of claim 68, wherein the mutation changes an amino acid encoded by codon 2229 of the coding region of the Factor VIII gene.

60 71. The method of claim 63, wherein the target DNA is a Factor IX gene.

5 72. The method of claim 63, wherein the target DNA is a von Willebrand factor gene.

10 73. The method of claim 63, wherein the target DNA is a xeroderma pigmentosum group G gene.

15 74. A homologously recombinant cell made by the method of claim 25.

20 75. A method of altering expression of a protein coding sequence of a gene in a cell, the method comprising:

introducing the complex of claim 1 into the cell, wherein the DNA sequence comprises a regulatory sequence;

maintaining the cell under conditions which permit alteration of a targeted genomic sequence to produce a homologously recombinant cell; and

25 maintaining the homologously recombinant cell under conditions which permit expression of the protein coding sequence of the gene under control of the regulatory sequence, thereby altering expression of the protein coding sequence of the gene.

1/11

SEQUENCE LISTING

<110> Evguenii Ivanov

<120> METHODS OF IMPROVING HOMOLOGOUS RECOMBINATION

<130> 10278/016001

<160> 9

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 7622

<212> DNA

<213> Homo sapiens

<400> 1

ggatccgaga acatagaagg agcaggtaat ttatcaaggc atgaacacgg	gtgcttaatt	60
tcctattttg aggccaggca tggtggtca cacctgtaat cccaacactt	taggaagcca	120
agggtgggtgg attgcgttag tctaggattt tgagaccagc ctggccaaaca	tggcgaaatc	180
ctgtctctac taaaaatact aaaattaacc agtcatggtg gtgggtgtgcc	tttagtccc	240
gctactctgg tggctgaggc acaagaatca cttgaacctq ggaggcagag	gttgcagtga	300
gctgagactg tgccacttca ctccagcctg ggtgacagag taagattctg	tctcaaaaaa	360
tatgtatata tacacacata taatagatac ataaacatat atacatatat	aatatataaa	420
tatatatatt atatataata tataaacata tataaatata tatatatata	tatatatata	480
tatataaaacc aaacataaaag gaataatttt gggggaaaat cttcataaat	gaaagaacaa	540
cataggctgt tgagtatatg cacagaaatt caagagatct tccagcaatt	gaagacattg	600
gtttaccaga attcacaaaaa gaagtcagct gtgcatttaa agtagaatgt	gatgagtgtt	660
accactgagg taggaactgg gaactaagga agcgtaaagac agaaagtgt	gaactgagag	720
ttgggcattt gaggctgtgt aaggcagggt aagtgaatgt ctcctagaag	ctacctttaa	780
atggagttt gaagtactt taggatgtc ttaggtgaaa agaagaggag	aaacatgtat	840
caggcagagg gactagaacc ttattacctt caaagaagaa gcaaaaagaa	tacatgtgac	900
tttgaggtgg tgggaggtgc tttaagccaa tataaggtaa tttgacatag	gacttcccta	960
aataatgttc ggtcatttgt taaatattga gtgatatac actgtattaa	agccccaaagag	1020
ttgcttttat atagaaagaa gaaaaaagcc caagagagtt ttatttctag	aggaaatatt	1080
ttctagaaat aaaggaaggt gtatcagcca gtttctagtc aggaaaacag	aaatcacacc	1140
tgatatgcaa aatagaggaa aatcaggaa ttcattaatc cagagattt	gttgctcaag	1200
tattagattt ctgaaaaagcc agacaggaa tatgaggcaa tcagagataa	gtattagtga	1260
caagctccat ttatgtgcag gattggaggg acataggtgg ggttcccaga	agccagaagg	1320
tgagaccacc tagcagaagc tcaaaccaca gctgggttt ctcacaaaaa	gctgggacca	1380
ccaggaggag ctgtccaatg ggatctggag ccagggagat catgcagtca	ctaccaggaa	1440
gggaaggcaga atgtaaaagg tagagagaaa tactccaact gcttcottgc	attcactttc	1500
caatctccat tcacaaaagc aaaaacctgc taatacagca gagtggaaa	agcagcctgc	1560
caaggtcctt tctcccacaa aacagagcac aaaaccaagc aaaaacaagg	aatgcatttg	1620
atagcaaaca ggctatggac caacccaaca taaaagaaaat gatgagtgt	ttcttttttc	1680
atttggttca agaaaagtat ttcaactt attatgtAAC agaaaattcta	tttattttgg	1740
ggaattcaaa ggtgaataaa aaagaactct aaatttttat caatasataa	tttcaaaaac	1800
ctcaatgaga gtaatggcat taactagca atatgtaat gagatgagct	agccataaga	1860
ggcttagaat tgagagaaag gcttggggc ctcttgacag gccaaattca	gagctgtttg	1920
tgggaatctc tgacctaact gcaggtggaa atataaatat gggcatttag	aatagtggcc	1980
caaactttgg atgatttctg tcttgggtc tctccaatta atgggattga	tgagaactgt	2040
agaccactga ggtcaccatg gctcaatgaa tagtcccctg gctttggagt	caaactgacc	2100
tgaatatgaa ccccagctt gctacttaca gttgcattt atcctcagtt	ttctcatctt	2160
tcaaagaaga acagtaactt cttaaaaagg ttattgtagg ctgggtgcag	tggctcacgc	2220
ctgtaatcgc agcactttgg gaggcggagg ctgtggatc acttgaggcc	aggagttgga	2280
aactagcctg gccaacatgg tggaaactctg tctctacaaa aagaaattta	aaaaattttg	2340
ctgggtgtgg tggcacacac ctggaatttc agtacacctgg gaggccgagg	catgagcatc	2400
acttgagtct ggaaaggcaga gggttgcagt gagccaagat tgtaccactg	tactcaagcc	2460
tgggtgacac agttagacact tgcataaaaaa aaaaaaaaaat tattgtgtt	ttgtaaatat	2520
tgtatatgaa cttctattta acatgtttag taaaatgcct gtgtaaatgt	ccaatgtgt	2580

cttctagctc	actgcacaga	caaaactgat	tcactgaaat	catggattg	cagcaaagaa	2640
caaactaat	taatgttagt	caaacgggag	gactggagtt	attattcaaa	tcagtctccc	2700
tgaaaactca	gaggctaggg	tttatggat	aatttggtg	gcagggact	agggaatggg	2760
tgctgctgat	tgggtggga	atgaaaatagt	aagattgtgg	aaaactgtcc	tccttcattg	2820
agtctgcttc	cgggtgttag	ccacacgacc	agttgagtc	tgaagcatgc	gtccaagtgg	2880
agtcaagttt	ttgccagaat	gcaaaaagcct	gaaaaatgtc	tcaaataatgc	aactgttaggc	2940
tccacaataa	tgatattatc	tataggagca	attggggaaag	taacaaatct	tgtgacactct	3000
ggacacataa	ctcctgaact	agtaagggt	tataaaaacc	atgcctat	cttatacgaa	3060
ttcaggtccc	ccataatcc	taatctcaca	gcatttcatt	tgttagaaaa	ggccattttc	3120
agtcctgag	caaggagggg	gttagttta	ggataggact	attatccttg	cttcgttaaaa	3180
ctataaaacta	aattcctccc	atggtagct	tggctcacac	ctaagaatga	gtgagaacag	3240
ccagcctgtg	aggctagagg	caagatggag	tcagccatgc	tagatttac	tcactgtcat	3300
aacctttgca	aaggcagtt	cacctgggac	ataggaggt	ctcaatgaaa	aagaagctat	3360
taatattaaa	attttaaaaa	tgaatttaag	gaactaatac	tatgtacata	ttagtcatta	3420
aaacaaagtg	gttcatttac	attcacacaa	ataaatctt	tgattataca	tagtaatat	3480
gaaaaacttt	gtttcttc	ataatacaag	gtattagcaa	tagatatagt	aatgttagca	3540
ttcccttgg	aaaaatgaaa	agatttataa	ttttccaaga	atcattagta	tttttattt	3600
atatacataa	tataaaattt	attcattcta	taacttggaa	atatgcttgc	ttaccaatta	3660
ctgacagatt	tcaaaatatt	tctatactca	caatattcat	ttacataat	attgatttgg	3720
tacttacaat	gtgtactgct	atgctaagtt	ttgtcttgt	caaacatatt	ttataaaaatc	3780
ataatcctag	atgaatccaa	cttttggtaa	cccacgtgcc	tgaaccctg	ctgttaacag	3840
gcaaagtgtg	gttagtacag	atctataacct	accacctcc	tctaccacc	agcatctgca	3900
cccaccaccc	ctccccaccc	accattatct	ataccaacca	cccctccaa	cctaccagca	3960
tctgacccca	ccacaccgccc	cacccaccac	catgtacact	cactacacct	tccagccatc	4020
accatctgca	cccatcactc	ctccccatcc	acaagcatct	gcacccacca	cattttcccta	4080
cctaccagca	tcttactca	ccacctctcc	acccaccagc	atctgacccc	acaaccctc	4140
ctcaccaccc	agagtctgca	tccatcacac	ttgcccactc	gctagcatct	gcaccatcaa	4200
gctctgcctt	cttgcttaat	acgggatgag	ctctccatgg	ttctgcctaa	agacaatgct	4260
tccactcctc	ttctataacc	catttcctt	tacctcttca	agtacacttc	agaacttctc	4320
tctccttctg	ataccaactt	tttccacttt	actcaatcat	tcctatcacc	atacaaacgt	4380
gtttatttct	cccatcttaa	agttaaaaat	caaaagaaaa	ttgtctgcgg	ccaggcacgg	4440
tggctcacgc	ctgtatccc	aacactttgg	gaggccaagg	agggttggat	gacttaaggt	4500
taggagttca	agaccagct	ggccaacatg	gtgaaaccca	tctctactaa	aaatacaaaa	4560
attagccagg	catggtgcc	catgcctgta	gtctcaggt	cttgggaggc	tgaggccaga	4620
gaatggcttg	aaccggggag	gcagagggt	cagttagcc	agatttgcc	cttgcactcc	4680
agcctgggtg	acagagttag	actccatctc	aaaaataaaa	aataaaaaata	aaacaaaaga	4740
aagttatttt	tacccaacat	ccacattaac	caaataccca	tttcttatt	gatcttgcgt	4800
aaaaaaagct	cttggaaaaaa	ttgtctat	tcactatgac	ttatctcctc	caaatacactt	4860
aaacacatac	caatcaggtt	tttggtttca	tcattccaaa	gtactttta	cagccaagga	4920
cagtagcgaa	cttacatcg	catatgcatt	gtgaagtct	tgatcctcat	cttacttaac	4980
ctgtcagcag	tatctgacac	agggtcact	ggctcctccc	tgagatgctc	tcttttattt	5040
gcttgggga	caccatattc	tcccccattcc	taacttcc	aatggccctc	ctcagtcctcc	5100
tttggaaaga	ggaaaaagaa	acttattat	cteetggatg	tagtacaaac	aactcaagct	5160
caacatgtgc	atactgaact	ccatttcctt	ttcccact	tgcacattt	cagccatccc	5220
cttcagctg	atagcaagtt	tatccttcca	gotactcaa	ccagaatctt	tagaccatc	5280
cttgaccctt	ttcctcctt	cacactcaac	atctatccat	cagaaaattt	tgttggttct	5340
acttcaaaaa	tgcatacaga	gtcagagcat	gtctcattac	ctccaaatgc	taccatacta	5400
gtctgaacaa	acatcatttc	tcacctgggt	tattgaacaa	acatcatttc	tcacctgggt	5460
tattgatagc	atcctaacgg	gtcttcctgt	ttcttggttc	ccctatatta	gcaacacagc	5520
agtcagagga	gtccttttag	aactcaatca	gatcatgtca	cgtcactcct	ctactaaaa	5580
tccttcaatg	ggtcccatta	cacaagagt	acaaaccaga	gcccttacac	ttgtctacaa	5640
gttccaacat	ttgactcctg	ttatctct	gacatcat	tctaata	ctgctgttgt	5700
ccttttgc	cagtcacact	gtttgattag	taaatattt	ttaaacaag	caatcctagt	5760
ctccaaagag	atcatagttt	attggagggaa	acaagagct	ataaaatggtt	acacacagaa	5820
ggttagtgatt	atggttctcc	ctcacctccc	atcctaaact	ttgacaggt	aaactcccct	5880
ggatgttgaa	ggttgaggaa	tttggccaggg	ttcagggtgg	tttggagga	ggcaggggagg	5940
aagcaaggac	atttcaggca	ggaagaacat	tacatgcaaa	gatctaaaga	tatgaatcag	6000
caacatattt	atgaaattac	aagtaaaagta	gaaagttctt	gctaaaacat	caaaaaataaa	6060
agatttgtga	ttagggggcc	agaatgtggg	agggaaaagag	agatacagtt	cacacttta	6120
gacaggagcc	agatcatgaa	atgtttctc	tttggttgtt	tcttcctca	cagctttga	6180
tatgctcttg	gagcaattta	ttaaccat	tttttaatgc	atctcctgaa	cagagtcaaa	6240
gcaatacttg	gaaaggactc	tgaatttct	gatttaaaga	tacaaaagaa	aatctggag	6300

3/11

tcacaattaa	tttgagaagg	taaaggagtg	ggtgtgctac	tgtatcaaat	ttaatttcta	6360
caaaaatcatc	atctctagta	acattatttt	ttctaatcta	ctgcgtttag	actactttag	6420
taaagcttga	tctccctgtc	tatctaaaca	ctgattcaact	tacagcaagc	ttcaggctag	6480
cattggcat	attaataccc	aacaatcca	caaggtgtta	gttgcacatg	atttgtata	6540
aaaggtaac	tgagattca	ttcagtctac	agctctgcc	aggcaaggca	gccgaccaca	6600
ggtgagtctt	ggcatctacc	gtttcaagt	gtgacagcta	cttttgaat	tacagatttgc	6660
tcaggacatg	gaggacaaaa	ctagagcttc	tcactactgt	tgtgtaggaa	atttatgctt	6720
gtcaacctgg	ctttaaaaat	atggtaata	taacgtatc	actgttagca	agtaactgac	6780
tttataagacc	aatatgcctc	tcttctgaaa	tggcttatt	ttaaacaat	gtgagcaaaa	6840
gaaaatattt	atgagattct	aaaaatgaag	acataatttt	gtatgtataga	attttcttgg	6900
ccaggaatgg	tggctcatgc	ttgtatccc	agcactttgg	gaggccaagg	tcagaggatt	6960
gcttggcct	ggaagggtga	agatgcagtg	attcatgatt	ataccactgc	actccagcct	7020
gggcaacaga	gcaagaccct	gtctcaagaa	aagaaaagaa	ttttatTTT	cttttcagac	7080
aaaaatagac	ttttaaaaataa	taatggaga	acaaatatga	tgatcacaat	tatcagagta	7140
attactttat	gacagtcatgc	aataagattc	taatctttaa	atattcctct	gcttaaatca	7200
tttatatttga	gttttgcatt	ataatataatt	cccaccctga	ccccaaaatt	gaagaaggac	7260
aaggaaaaat	gttgcattcaa	gaaacaaaaga	tgttaagtaaa	aaggcataag	gaaggaaaaaa	7320
aaacttttga	agcaaaaatgt	gattgaggag	gatgagcaga	ccaattattt	ttgggtttgt	7380
cagcttacat	aatgatttac	gttctttgtt	ttctcagttt	ctagtggct	tcattgtttg	7440
cttcccagac	caggatgaag	acactccagt	ttttcttctt	tttctgttgc	tggaaagcaa	7500
tctgctgcaa	tagctgtgag	ctgaccaaca	tcaccattgc	aatagagaaa	gaagaatgtc	7560
gtttctgcat	aagcatcaac	accacttgg	gtgctggcta	ctgctacacc	aggtaggtta	7620
cc						7622

<210> 2

<211> 6038

<212> DNA

<213> Homo sapiens

<400> 2

ggatccgaga	acatagaagg	agcaggtaat	ttatcaaggc	atgaacacgg	gtgcttaatt	60
tcctatTTT	aggccaggca	tgtggctca	cacctgttaat	cccaacactt	taggaagcca	120
agggggtgg	attgctttag	tctaggattt	tgagaccagc	ctggccaaaca	tggcggaaatc	180
ctgtctctac	taaaaatact	aaaattaacc	agtcatggtg	gtgggtgtcc	tttagtcccc	240
gctactctgg	tggctgaggc	acaagaatca	cttgaacctg	ggaggcagag	tttgcagtga	300
gctgagactg	tgccacttca	ctccagccctg	ggtgacagag	taagattctg	tctcaaaaaaa	360
tatgtatata	tacacacata	taatagatac	ataaaacatat	atacatatat	aatatataaa	420
tatatatatt	atataataata	tataaacata	tataaatata	tatatatata	tatatatata	480
tatataaaacc	aaacataaaag	gaataatttt	gggggaaaat	tttcataaaat	gaaagaacaa	540
cataggctgt	tgagtatatg	cacagaaatt	caagagatct	tccagcaatt	gaagacattg	600
gtttaccaga	attcacaaaa	gaagtcagct	gtgcatttaa	agttagatgt	gttagtgtt	660
accactgagg	taggaactgg	gaactaagga	agcgtaagac	agaaagtgt	gaactqagag	720
ttggcattt	gaggctgtt	aaggcagggt	aagtgaatgt	ctcctagaag	ctacctttaa	780
atggagtttt	gaagtacttg	taggatagc	ttaggtgaaa	agaagaggag	aaacatgtat	840
caggcagagg	gactagaacc	ttattaccc	caaagaagaa	gcaaaaaagaa	tacatgtgac	900
tttgagggtgg	tgggaggtgc	tttaagccaa	tataggtgaa	tttgacatag	gactcccta	960
aataatgttc	ggtcattttgt	taaatattga	gtgatataatc	actgtattaa	agcccaagag	1020
ttgcTTT	atagaaagaa	gaaaaaagcc	caagagatgt	ttatttctag	aggaaatatt	1080
ttctagaaat	aaaggaaggt	gtatcagcca	gtttctagtc	aggaaaacag	aaatcacacc	1140
tgatatgcaa	aatagaggaa	aatcaggaa	ttcattaatc	cagagatttgc	gttgctcaag	1200
tattagattt	ctgaaaagcc	agacaggaa	tatgaggcaa	tcagagataaa	gtattagtga	1260
caagctccat	ttatgtgcag	gattggaggg	acataggtgg	gttcccccaga	agccagaagg	1320
tgagaccacc	tagcagaagc	tcaaaccaca	gctgggttt	cctcacaaaaa	gctgggacca	1380
ccaggaggag	ctgtccaaatg	ggatctggag	ccagggagat	catgcagtca	ctaccaggaa	1440
gggasgcaga	atgtaaaagg	tagagagaaa	tactccaact	gcttccttgc	attcactttc	1500
caatctccat	tcacaaaggc	aaaaacctgc	taatacagca	gagtggaaa	agcagcctgc	1560
caaggctt	tctcccacaa	aacagagcac	aaaaccaagc	aaaaacaagg	aatgcatttg	1620
atagcaaaca	ggctatggac	caacccaaaca	taaaagaaaat	gatgagtgt	ttcttttttc	1680
atttggttca	agaaaagtat	ttcagtaact	attatgtaac	agaaattcta	tttattttgg	1740
ggaattcaaa	ggtgaataaa	aaagaactct	aaattttat	caataaaaata	tttcaaaaac	1800
ctcaatgaga	gtaatggcat	taactagcaa	atatgcta	gagatgagct	agccataaga	1860
ggcttagaat	tgagagaaaag	gtctggggc	ctcttgacag	gccaaattca	gagctgtttg	1920

tgggaatctc	tgacctaact	gcaggtggaa	atataaatat	ggcatttag	aatagtggcc	1980
caaactttgg	atgatttctg	tcttgggtc	tctccaatta	atgggattga	tgagaactgt	2040
agaccactga	ggtcaccatg	gctcaatgaa	tagtcccctg	gctttggagt	caaactgacc	2100
tgaatatgaa	ccccagctt	gctacttaca	ggttgcattt	atcctcagtt	ttctcatctt	2160
tcaaagaaga	acagtaactt	cttaaaagg	ttattgtagg	ctgggtgcag	tggctcacgc	2220
ctgtaatcgc	agcactttgg	gaggcggagg	ctagtggatc	acttgaggcc	aggagttgga	2280
aactagcctg	gccaaacatgg	tgaaactctg	tctctacaaa	aagaaattta	aaaaattttg	2340
ctgggtgtgg	tggcacacac	ctggaattcc	agctacctgg	gaggccgagg	catgagcattc	2400
acttgagtct	ggaaagcaga	gggttgcagt	gagccaagat	tgtaccactg	tactcaagcc	2460
tgggtgacac	agttagacct	tgtctaaaaaa	aaaaaaaggt	tattgttta	ttgtaaatat	2520
tgtatatgaa	cttctattta	acatgttttag	ttaaatgcct	gtgtattgt	ccaatgtgct	2580
cttctagctc	actgcacaga	caaaactgat	tcactgaaat	catggaattg	cagcaaagaa	2640
caaatactaat	taatgttagt	caaacgggag	gactggagtt	attattcaaa	tcagtctccc	2700
tgaaaactca	gaggctaggg	tttatggat	aatttggtgg	gcaggggact	aggaaatggg	2760
tgctgctgat	tggttgggaa	atgaaaatagt	aagattgtgg	aaaactgtcc	tccttcattt	2820
agtctgcttc	cgggtgtagg	ccacacgacc	agttgagtc	tgaagcatgc	gtccaaagtgg	2880
agtcagtttgc	ttgccagaat	gaaaaagcct	gaaaaatgtc	tcaaataatgc	aactgttaggc	2940
tccacaataa	tgatattatc	tataggagca	attggggaaag	taacaaatct	tgtgacactct	3000
ggacacataa	ctcctgaact	agtaagggat	tataaaaacc	atgcctatata	tttatcagaa	3060
ttcagggtccc	cccataatcc	taatctcaca	gcatttcatt	tgtttagaaa	ggccattttc	3120
agtccttgag	caaggagggg	gttagttta	ggataggact	attatccttgc	cttcgttaaa	3180
ctataaaacta	aattcctccc	atggtttagct	tggctcacac	ctaagaatga	gtgagaacag	3240
ccagcctgtg	aggctagagg	caagatggag	tcagccatgc	tagatttac	tcactgtcat	3300
aacctttgca	aaggcagttt	cacctgggac	ataggaggt	ctcaatgaaa	aagaagctat	3360
taatattaaa	attttaaaaaa	tgaatttaag	gaactaatac	tatgtacata	ttagtcatta	3420
aaacaaagtgc	gttcatttac	attcacacaa	ataaaatcttgc	tgattataca	tagtaataat	3480
gaaaaacttt	gtttcttgc	ataatacaag	gtattagcaa	tagatatagt	aatgttagca	3540
ttcccttggaa	aaaaatgaaa	agatttataa	ttttccaaaga	atcattagta	tttttatttt	3600
atatacataa	tataaaattt	attcattcta	taacttggaa	atatgcttgc	ttaccaatta	3660
ctgacagatt	tcaaaatatt	tctatactca	caatattcat	ttacataaaat	attgatttgg	3720
tacttacaat	gtgtactgct	atgctaagtt	ttgtctttgt	caaacatatt	ttataaaaatc	3780
ataatcctag	atgaatccaa	cttttggtaa	cccacgtgcc	tgaaccctg	ctgttaacag	3840
gcaaagtgtg	gttaggtacag	atctatact	accaccttcc	tctaccacc	agcatctgca	3900
cccaccaccc	ctccccaccc	accattatct	ataccaacca	cccctcccaa	cctaccagca	3960
tctgcaccca	ccacaccggc	cacccaccac	catgtacact	cactacacct	tccagccatc	4020
accatctgca	cccatcactc	ctccccatcc	acaagcatct	gcacccacca	cattcccta	4080
cctaccagca	tcttcaactca	ccacctctcc	acccaccagc	atctgcaccc	acaaccctc	4140
ctcaccaccc	agagtctgca	tccatcacac	ttgcccactc	gctagcatct	gcaccatcaa	4200
gctctgcctt	cttgccataat	acgggatgag	ctctccatgg	ttctgcctaa	agacaatgct	4260
tccactcctc	ttctataacc	catttcctt	tacctcttca	agtacacttc	agaacttctc	4320
tctccttctg	ataccaactt	tttccactt	actcaatcat	tcctatcacc	atacaaacgt	4380
gtttattttct	cccatcttaa	agttaaaaaaat	caaaagaaaa	ttgtctgcgg	ccaggcacgg	4440
tggctcacgc	ctgtaatccc	aacactttgg	gaggccaagg	agggttggat	gacttaaggt	4500
taggagttca	agaccagcct	ggccaacatg	gtgaaaccca	tctctactaa	aaataaaaaaa	4560
attagccagg	catggtggca	catgcctgta	gtctcaggt	tttgggaggc	tgaggccaga	4620
gaatggcttgc	aacccgggag	gcagaggttgc	cagttagccg	agattgtgcc	ttgcactcc	4680
agcctgggtg	acagagttag	actccatctc	aaaaataaaa	aataaaaaata	aaacaaaaga	4740
aagtattttt	tacccaacat	ccacattaac	caaataccca	tttcttatt	gatctttgt	4800
aaaaaaaaagct	cttggaaaaaa	ttgtcttat	tcactatgac	ttatctcctc	caaatactt	4860
aaacacatac	caatcagggt	tttgtttca	tcattccaaa	gtactttta	cagccaaagga	4920
cagttagcgaa	ctttacatcg	catatgcatt	gtgaagtct	tgatcctcat	cttacttaac	4980
ctgtcagcag	tatctgacac	aggtgtact	ggctcctccc	tgagatgctc	tctttatttg	5040
gctttggggaa	caccatattc	tccccattcc	tacttcttc	aatggccctc	ctcagtcctc	5100
tttggaaaga	ggaaaaaagaa	acttcattat	ctcctggatg	tagtacaaac	aactcaagct	5160
caacatgtgc	atactgaact	ccatttcctt	ttcccaaact	tcgacattta	cagccatccc	5220
ctttcagctg	atagcaagtt	tatccttcca	gtactcaaa	ccagaatctt	tagaccatc	5280
cttgaccctt	ttcctcctt	cacactcaac	atctatccat	cagaaaattt	tgttggttct	5340
actttcaaaa	tgcatacaga	gtcagagcat	gtctcattac	ctccaaatagc	taccatacta	5400
gtctgaacaa	acatcatttc	tcacctgggt	tattgaacaa	acatcatttc	tcacctgggt	5460
tattgatagc	atcctaacgg	gtcttcctgt	ttcttggttc	ccctatatta	gcaacacacgc	5520
agtcagagga	gtccttttag	aactcaatca	gatcatgtca	gtcactcct	ctactaaaa	5580
tccttcaatg	ggtcccat	cacaaagagt	acaaaccaga	gcccttacac	tggtctacaa	5640

5/11

gttccaacat ttgactcctg ttatctctct gacatcatat tctaataattta ctgctgttgt	5700
cctttgctc cagtcacact gtttgattag taaatattta ttaaacaaag caatccatgt	5760
ctccaaagag atcatagttt atggaggaa acaagagcct ataaatggtt acacacagaa	5820
ggttagtattt atgggtctcc ctcacccccc atcctaaact ttgacaggtg aaactccct	5880
ggatgtgaa ggttgaggaa ttgcaggggg ttcaggggtgg tggtggagga ggcaggagg	5940
aagcaaggac attcaggca ggaagaacat tacatgcaaa gatctaaaga tatgaatcag	6000
caacatattt atgaaattac aagtaaaagta gaaagttc	6038

<210> 3
<211> 542
<212> DNA
<213> Homo sapiens

<400> 3

tcactgttag caagtaactg actttataga ccaatatgcc tctcttctga aatggcttta	60
ttttaaacaat atgtgagcaa aagaaaatat ttatgagatt ctaaaaatga agacataatt	120
ttgttagtata gaattttctt ggccaggaat ggtggctcat gcttgttaatc ccagcacttt	180
gggaggccaa ggtcagagga ttgcttgagc ctggaaagggtt gaagatgcag tgattcatga	240
ttataccact gcactccagc ctgggcaaca gagcaagacc ctgtctcaag aaaagaaaaag	300
aattttatcc ttcttttcag acaaaaaatag actttaaaat aataatggaa gaacaaatat	360
gatgatcaca attatcagag taattacattt atgacagtca gcaataagat tctaatacttt	420
aaatattcct ctgcttaaat cattatattt gagtttgat ctataatata ttcccaccct	480
gacccaaaaaa ttgaagaagg acaaggaaaaa atgttgttcc aagaaacaaa gatgtaagta	540
aa	542

<210> 4
<211> 3213
<212> DNA
<213> Homo sapiens

<400> 4

actaacataa agctgaaggt gaataaaaaaa atcagggtta gccaaacaaa ttttcatgg	60
caaataccac ataaaaagta aatatactta agtccccagc aaaatctgaa ttgaacgtag	120
acaaaatgtt catttctcag tgtttgacag acttaacagt ttgagccat aaaaatgtac	180
tgactagata aactactaaa agttgttaat ttttgcataat tatatttctg aaaagaaaagt	240
ttatctatta tagaaatcc tggccatt taagaacttt gagcatttttta attgtttaat	300
aatatagttt aattgcatac tgaaaataat caataataca atttatttgg ttttattttaa	360
aaaactgatt ctctctgctc tctctatata tagactgatt ttataactat gttgcctaaa	420
gatcaccaaa ttgtttgaag cctagggttc tgagggtatgg aaaatgtgt cacaactatt	480
tacagttcac acacacattc tggggattta atacatcctt tacaagtgc gggaaaggtgg	540
aagattgatg atttggggga attagagcta ccacacccca gaggggtggta tggtatgtt	600
tctgttgtga gctgtgtgaa tcagagagtt tgatttagac atatattttag aaagaggaaa	660
gatgaaccaa tcaaaaataa taactataat gactttcaa gatatagaca atacagttaa	720
gatataaatg gaaacaaaaa aagttaaaag tggggagatg aagtctgatt ttttggttt	780
tttttttt tgctttttt tttgtttatg taatcagtgt taccagtttta aaataatggg	840
ttataagaca ctatatgcaat gcctcatggt aacctccat ctaaaacata caacaaatac	900
acacaaaataa aaaaggagaa attaaaacac accaccagag aaaatcacct acattaaaag	960
aaagacaaat aggaagaaaa taagaaagag aaggccatca aataatcaga aaatgaataa	1020
caaaatgaca ggaataagtc ctcataaata ataacattga atgtaaatgg actaagctct	1080
ccaatgaaaag acaggagtg gctgaatgta ttttaaaaaa aatattacac cgagctgtgc	1140
gtggtgtctc acacctataa tcccagcatt ttgggagact gagccgggtg gatcacttga	1200
gccaggagt tcgagaccag cctggccaaat atggcaaaac cctgtctcta ctaaaaatac	1260
aaaaaaattag ctgaacatgg tggcacatgc ctgtgggtcc agctactaga gaggtcgagg	1320
cagaagaatt gctgaactt gggagggtgaa ggttgcagtg agctaagatt gatggagcca	1380
ctgcacccca gcctaggta cagaataaga ctctgcctca aaaaaaaaaa gcaaaacaaa	1440
acaaaacaaa aaacccttag acccaatgat tcattgccta caagaagtat gcttcacctt	1500
taaagacaca tatagactga aggtaaaagg atggaaaaat attctatgcc tatgaaaaca	1560
acaaaaaaga agcagaagct acatttatat cagacaaaat agactgcaag acaaaaaacta	1620
tgaaaaagaga gaaagaaggt cattatatac tgataaaagg gtccatttag caagagcatt	1680
taacaattct aaatataat tcacccaaata ctggagttact caggtatata aagcaaatat	1740
tattagagcc aaagagagag atagacagac ccccatacaa taataactgg agacttcaac	1800
accccaactt cagcattgga cagatcatcc agacagaaaaa ttaacaaaca tcaaaatttca	1860

6/11

tctgcaccat	aggtaaaatg	gacctagtag	atattacag	aacatttgat	ccaacagctg	1920
tagaatacac	attcttctcc	tcagcacatg	gataatttc	aaggatatac	caaatgttag	1980
gtcacaaaac	aaatcttaaa	atttagaaaa	aaagtgaat	aatatcaaac	gttttctctc	2040
accacagact	aagaaaaaaa	gaagtccaa	ataaaataca	tctgagataa	aaaaggagac	2100
gagacaacca	ataccacaaa	aaattaaagg	atcattagaa	gatactatga	aactataatgc	2160
taataaaattg	gaaaacctga	acaaaataga	taattcctag	aaacatacaa	catactggc	2220
tgttcaggtt	ttgtatTTT	tcatagtacc	atgaagaaat	acaagaattg	tttctagaac	2280
cattcttgc	tttcttcatg	gttttgtat	ttcttcatgg	aaccatgaag	aaatacaaaa	2340
tgtgaacagg	ccaataacaa	gtaatgagac	agaagccata	ctaaaaagta	tcccagaaaa	2400
gaactcagga	tctgatggct	tcactgatga	attttccaa	atatttaaaa	aactaataacc	2460
aatccaactc	aaattattaa	aaaaatagag	gtggacagaa	tctttccaaa	tgtattctat	2520
gaggccagtg	tttttctga	ttgaatctcc	cattatattt	taatcacata	taaaaccaga	2580
gaaagacaca	ttaaaaagaa	agaaaactgt	aggccatat	ctctgatgaa	cattgatgca	2640
gaaatcctca	acaacaaatt	agcaaactga	attcaagaac	acattaaaaac	aatcattcat	2700
catgaccaag	tggaatttgt	cctagagatt	caagtgttgt	taggtatgt	cagatcaatg	2760
ggtttaatgt	tgtccaatga	acataatgtc	ctccagctcc	atccatgttc	ttgcaaatga	2820
caggatctca	ttcttttta	tggctaagta	gtactccatt	gtgtataagt	gccatatttt	2880
ctttatccat	tcatctgtt	gacacctaag	ttgcttccaa	atcttagcta	ttgtgaatag	2940
tgcgtcaata	aacatggag	tgtaaatatt	ttgttgacat	actgatttca	tttcctttgg	3000
ataaataaccc	agtagtggga	ttgctggatc	atatggggga	aaatggagat	ggctaacggg	3060
ctcaaaaata	tagttagaaa	aaatgaatat	gatttagtat	tcgatagcac	aataggatga	3120
ctactgttaa	tgataattta	ttatataatta	taaaataact	aaaatagtat	aaatggatg	3180
tatgttagcag	agagaaatga	taaatgtttg	aag			3213

<210> 5

<211> 6679

<212> DNA

<213> Homo sapiens

<400> 5

gtcgacctgc	aggtaaacgg	atcaattttag	gacagtagtt	caagaccagc	ctgggcagca	60
tagggagact	gtctctacga	aaaatcaaaa	aattatggcc	gggcatggtg	gtcacgtct	120
gtaatccctg	aactttggga	catcaaggca	agtggatcac	ttgaggtcag	gagttcgaga	180
ctagcctggc	caacatggtg	aaaccctatc	tccactaaaa	aatacaaaaa	ttagccaggc	240
atggtggcag	gcacctgtaa	tcccggctac	tcaggaggt	gaggcaggag	aatcacattg	300
acccaggagg	cggagggtgc	agttagctga	gatcacacca	ctgcactcca	gcctgggtga	360
cagagcaaga	ctctatctca	aaaaaaaataa	aaaaataaaa	aaattagcca	ggcatggtag	420
tgcacacetc	tagtctcagc	tactcaggag	gctgaggtgg	gaggatca	tgaacctggg	480
gcagtcaagg	ctacagttag	ccaagatcat	gccactacac	tccagcctgg	gcaacagaga	540
gagaccctgt	ctctaaaaaa	ataataataa	taaagaaaaa	aacagctctg	tttatgtctc	600
ctggccata	catactacta	tgtatatagt	ttgcaaactc	aaagatccag	atagtcaatt	660
tttttaggctt	gtgggcccgt	tggctctgt	cacaatca	ctgccccgtc	tttctagcac	720
aaaagcagct	ataaaacaata	catacatgaa	tttttata	acatcgagat	ttgaatttca	780
tatgattttt	acatTTTata	aaataatctt	tttaaaaatt	ttccccta	catttaaaag	840
tgtaaaagcc	ggccagcgc	ccatcgtaac	gcctgttaatt	ccagcacattt	gggaggctga	900
ggtggcaga	tcacttgaga	tcaacagttc	gagaccagcc	tggccaaacat	agcaaaaaccc	960
catttctact	aaaaataaaa	aaattagctg	ggcatagttg	tgcacacctg	tgatcccagc	1020
tacttggag	gctgaggcag	gagaatcgct	tgaacctggg	aagcggaggt	tgcagtgagc	1080
caacatcatg	ccactgcact	ccagcctgg	tgacagagt	agacttcgtc	tcaacgaaaa	1140
aaaaaaagtgt	aaaagccatt	cctaattcag	tgtacatcag	tgtacatact	caggtctcg	1200
tacttctgct	ctgaggcata	cctgagaagt	agagttgtt	ggtcacagga	catacacatt	1260
tccacattaa	ctagacacta	ccaagttgcc	atccaaggag	gtttttttt	tacaatctac	1320
actcccccca	gcaacaaatg	agagttactc	cagatcctt	acaaagatgc	tctaagccca	1380
gtaccagatg	aaaacaggaa	gtgggagggg	aagctgccag	ccccttctaa	ccatgaagaa	1440
atacctggta	gagccttctg	gatgctggaa	ggatgaataa	cgggggtctc	tggagcctgc	1500
cccctgtcag	atcactgtga	cttctgagcc	tccagtccag	tctcagcccc	atgtgtcatg	1560
gccagtgata	atgagccctc	actctctgtt	tggctttat	tctccccatg	ttgggctgaa	1620
gtctggattg	agccgttatt	caagatgtac	agctttcttg	acaggaaagt	agtgtcacag	1680
aaacagcagg	ggcttgccaa	gatgatctaa	ctgcaaatcc	tacctggctc	agccaccagc	1740
tagttctgtg	atcttgaaca	agtttttca	cttctctgag	gccatccctt	ggctacaaca	1800
caccagttgg	ttgacaggat	gaaatgacga	agtcccttac	acctgtatc	ccagcacttt	1860
gggaggccaa	ggcggtgga	tggcttgagc	ctgagaggtg	acagcatgcc	ggcagtcctc	1920

7/11

acagccctcg	ttcgctctcg	gcccctcctc	tgcctggct	cccacttcgg	tggcacttga	1980
ggagcccttc	agcccaccgc	tgcaactgtgg	gagccccctt	ctgggctggc	caaggccaga	2040
gccggctccc	tcagcttgc	gggaggtgtg	gagggagagg	ctcaagcagg	aaccggggct	2100
gcccacggcg	cttgccgggc	agctggagtt	ccgggtgggc	gtgggcttgg	cgggccccgc	2160
actcggagca	gcgggcccagc	cctgccaggc	cccgggcaat	gagaggctta	gcaccggggc	2220
cagcggctgc	ggagggtgta	ctgggtgccc	cagcagtgcc	agcccggccgg	cgctgtgctc	2280
gctcgatttc	tcactgggccc	ttagcagcct	tcccgggggg	cagggctcgg	gacctgcagc	2340
cgcgcattgcc	tgagcctccc	ctccatgggc	tcctgtgcgg	cccgagcctc	cccgacgagc	2400
accacccccc	gctccacacgc	gcccagttccc	atcgaccacg	caagggtgt	gaagtgcggg	2460
cgcacggcac	cgggactggc	aggcagctac	ccctgcagcc	ctgggtgcgg	atccactggg	2520
tgaagccagc	tgggctcctg	agtctgggtg	agacttggag	aacctttatg	tctagtcag	2580
ggatcgtaaa	tacaccaatc	agcaccctgt	gtctagctca	gggtctgtga	atgcaccaat	2640
ccacactctg	tatctagcta	ctctgatggg	gccttgagaa	acctttatgt	ctagctcagg	2700
gattgtaaaat	acaccaatcg	gcactctgt	tctagctcaa	ggtttgtaaa	cacaccaatc	2760
agcaccctgt	gtctagctca	gggtatgtga	atgcaccaat	cgacagtctg	tatctggcta	2820
ctttcatggg	catccgtgt	aagagaccac	caaacaggct	ttgtgtgagc	aataaaagctt	2880
ctatcacctg	ggtgtcaggtg	ggctgagtc	gaaaagagag	tcagcgaagg	gagataaggg	2940
tggggccgtt	ttataggatt	tggtaggt	aaggaaaaatt	acagtcaaag	ggggtttgtt	3000
ctctggcggg	caggagtggg	gggtcgcaag	gtgctcagtg	ggggtgcttt	ttgagccagg	3060
atgagccagg	aaaaggactt	tcacaaggta	atgtcatcaa	ttaaggcaag	gaccggccat	3120
ttacacctct	tttgtgggtg	aatgtcatca	gttaagttgg	ggcagggcat	attcacttct	3180
tttgtgattc	ttagttact	tcaggccatc	tggcgatata	tgtgcaagtt	acaggggatg	3240
cgtatggctt	gcttggggtc	agaggctgt	cagctactct	ggtggggct	tggagaatgt	3300
tttgtcgcac	actctgtatc	tagttatct	agtggggacg	tggagaacct	ttgtgtctag	3360
ctcaggatt	gtaaacgcac	caatcagcgc	cctgtcaaaa	cagaccactc	ggctctacca	3420
atcagcagga	tgtgggtggg	gccagataag	agaataaaaag	caggctgccc	gagccagcag	3480
tggcaacgcg	cacaggtccc	tatccacaat	atggcagctt	tgttctttt	ctgtttgcga	3540
taaatcttgc	tactgctcgc	tttttgggtc	cacactgctt	ttatgagctg	taacactcac	3600
cacgaaggtc	tgcagcttca	ctcctgaagc	cactaagacc	acgagccac	cgggaggaat	3660
gaacaactcc	ggccgcgtg	ccttaagagc	tataacactc	accgcgaagg	tctgcagctt	3720
cactcctcag	ccagcgagac	cacgaaccca	ccagaaggaa	gaaactgcga	acacatctga	3780
acatcagaag	gaacaaactc	cagatgcacc	accttaagag	ctgtAACACT	cactgcgagg	3840
gtccgcggct	tccttcttga	agtcagttag	accaagact	caccagttc	ggacacacaagc	3900
ccaggagtt	gagatcagcc	tggcaacat	gatgaaatgc	cctctctgca	aaaaaaaaaaa	3960
aaattacaaa	aattggcgga	gcatgggtgt	ccgtgcctgt	ggtcccagct	acgcgggagg	4020
ctaaagtggg	aggatcgctt	gaggctggga	ggtgaagact	gcagttagct	gtgattgtac	4080
cacagccctc	taggctgggg	gacagactga	gaccctgttt	cccctccgca	aaaaaaattga	4140
caaaagtgt	ataagaggtg	cctgatatgg	ctaggcgcag	tggctcatgc	ctgtaatccc	4200
agcaactttgg	gaagccgagg	cgggcgggtc	acctaaggct	aggagtgtga	gaccagcctg	4260
gccaacatgg	agaaaagccca	tctttctaa	aaataaaaaa	ttagccggct	gtgggggcag	4320
tggtgagca	tgctgttaat	cccagctact	caggaggctg	aggcaggaga	atcacttgaa	4380
cccaggagc	ggcggttgca	gtgagccgag	atcgtgccat	tgcactccac	ccactccagc	4440
ctggcaaca	agagccaaac	tctgtcttaa	aaaaaaaaaa	aaaaagtgcc	tgacatataaa	4500
gaggtgtgca	atgcaatagt	tgccaggcaa	catgtttaag	aatgtggagc	tcctgccttc	4560
catggcctg	ttaaaaaccc	accctcaagg	ccaggtgcag	tggctcatgc	ctataatccc	4620
agcaactttgg	gaggccgagg	cggttggtac	acctgaggtc	aggagttcga	gaccagcctg	4680
accaccaaca	tggtaaaatc	ccacctctac	taaaaataca	aaatttagatg	agcatggtgg	4740
tgcattgcctg	taatcccacc	tacttggag	gctgaggcag	aaaaatact	agaaccaggg	4800
aggcggaggt	tgtatgtgagc	cgagatcg	ccattgcact	ccagcctgag	caatgagcga	4860
aactccatct	aaaaaaaaca	acaacaaaaaa	cccactctct	actcccagg	agctgggtac	4920
agagctgggc	cacatcagt	caaggtctg	agccacagag	ctaaggcgg	gctgcaggac	4980
cgcggaccag	ataacagtgt	gtgagatcg	tgtgtgagat	cagacgtccc	tgccatttgt	5040
gaccaccagg	ggccccccaa	gcaccagaga	tggcccccac	cagtcaccac	atccacttct	5100
catccagaga	tgtctgtttc	ttggcagcgt	ggggtaaatt	aggacagaag	tgacatgtct	5160
tgggtgtgt	cagtcagact	gccccaggca	ggccttgtgg	cctgtagaaa	acgttcaggc	5220
ctaggccggg	cacggtggt	cacgcctgt	atcccagcac	tttgggaggc	cgaggcgggt	5280
ggatcacgag	gtcaggagat	cgtgaccatc	ctggcttaaca	cggtgaaaacc	ccgtctctac	5340
taaaaataca	aaaaattggc	cgggcatgt	ggcgggcacc	tgttagttca	gctactcgcc	5400
aggctgaggc	aggagaatgg	cgtgaacccg	agaggcagag	tttgcagtga	gccgagatcg	5460
cgcactgca	ctccagcctg	ggcgacagag	caagactcca	tctggaaaag	aaaaagaaaa	5520
cgttcaggc	ttagccagag	gcccaggctg	taattctgtc	acttaccatg	acttgggca	5580
aggcacttcc	ttccctgccc	cagttcacgg	ggttggaaatc	gactccaagg	tcccttccag	5640

8/11

cattaacgct	gcattggttct	aagatgagaa	gatggggcag	tttcccctct	ctcacccca	5700
cccgtgtcca	cttcagggtg	aatgaccagg	gaagtacgt	gtcccaatcc	cgcaggttcca	5760
aaggcccttgg	ggaccctact	gtcagggtcg	tgcacgagga	ggtgaaggtc	aggtgagcca	5820
atcgccctcg	agggtcttgc	ctcattcggg	acagacatcc	gtttccctct	ggctctaccg	5880
ggattcttagg	ggcttagcc	aatgagtca	tggggggcgg	gggggtttct	gggggagttc	5940
ccagctaatac	aacttgggac	aggacagcct	ggaactttcg	atggtgccct	tccaaagtgtg	6000
gggtgggcac	agcagccaaag	acccaatgtc	cttatctcag	gtaggggctc	aggaggctc	6060
ccagacaggc	agcctccgga	gagttgggg	gttaggaatgg	gagcaaccag	gcttcctttt	6120
ttctctctta	gaatttgggg	gcttggggga	caggctttag	aatcccaaag	gagaggggca	6180
aaggacactc	ccccacaagt	ctgccagagc	gagagaggg	gaccccgact	cagctgcccac	6240
ttccccacag	gcctctgcgg	cttccaggcg	tctatcagcg	gctcagccct	tgttcagctg	6300
ttctgttcaa	acactctggg	gccattcagg	cctgggtggg	gcagcgggag	gaagggagtt	6360
tgagggggc	aaggcgacgt	caaaggagga	tcagagattc	cacaatttca	caaaaacttc	6420
gcaaacagct	ttttgttcca	accccccctgc	attgtcttgg	acaccaaatt	tgcataaaatc	6480
ctgggaagtt	attactaagc	cttagtcgtg	gccccaggt	atttcctccc	aggcctccat	6540
gggttatgt	ataaaagggcc	ccctagagct	ggggcccaaa	acagcccgga	gcctgcagcc	6600
cagccccacc	cagacccatg	gctggacctg	ccacccagag	ccccatgaag	ctgatgggtg	6660
agtgtcttgg	cccaggatg					6679

<210> 6

<211> 6235

<212> DNA

<213> Homo sapiens

<400> 6

gatcaattga	ggacagtagt	tcaagaccag	cctgggcagc	atagggagac	tgtctctacg	60
aaaaatcaaa	aaattatggc	cgggcattgt	ggctcacgtc	tgtaatccct	gaactttggg	120
acatcaaggc	aagtggatca	cttggggatca	ggagttcgag	actagctgg	ccaacatgg	180
gaaaccctat	ctccactaaa	aaatacaaaa	attagccagg	catgggtggca	ggcacctgt	240
atcccggtca	ctcaggaggc	tgaggcagga	gaatcacttg	aacccaggag	ggggagggtt	300
cagttagctg	agatcacacc	actgcactcc	agcctgggtg	acagagcaag	actctatctc	360
aaaaaaaaata	aaaaaataaa	aaaattagcc	aggcatggta	gtgcacacct	ctagtcctag	420
ctactcagga	ggctgggtg	ggaggatcac	ttgaacctgg	ggcagtcag	gctacagtga	480
gccaagatca	tgccactaca	ctccagcctg	ggcaacagag	agagaccctg	tctctaaaaa	540
aataataata	ataaaagaaaa	aaacagctct	gtttatgtct	cctgggtccat	acataactact	600
atgtatata	tttgcaaaact	caaagatcca	gatagtcaat	tttttaggt	tgtggccgt	660
atggtctctg	tcacaatcac	tctggccctgt	ctttctagca	caaaagcagc	tataaacaat	720
acatacatga	attttttata	gacatcgaga	tttgaatttc	atatgatttt	tacattttat	780
aaaataatct	tttaaaaat	tttcccctaa	ccatttaaaa	gtgtaaaagc	cggccagcgc	840
gccatcgta	cgcctgtat	tccagcactt	ttggaggctg	aggtgggcag	atcaccttgc	900
atcaacagtt	cgagaccagc	ctggccaaaca	tagcaaaacc	ccatttctac	taaaaataaa	960
aaaattagct	gggcatagtg	gtgcacacct	gtgatcccag	ctacttggga	ggctgaggca	1020
ggagaatcgc	ttgaacctgg	gaagcggagg	ttgcagttag	ccaacatcat	gccactgcac	1080
tccaggctgg	gtgacagagt	gagacttcgt	ctcaacgaaa	aaaaaaagtg	taaaagccat	1140
tcctaattca	gtgtacatca	gtgtacatac	tcaggtctgc	gtactcctgc	tctgaggcat	1200
acctgagaag	taggttgct	tggtcacagg	acatacacat	ttccacattt	actagacact	1260
accaagttgc	catccaagga	gtttttttt	ttacaatcta	cactcccccc	agcaacaaat	1320
gagagttact	ccagatcctt	tacaaagatg	ctctaagccc	agtaccagat	gaaaacagga	1380
agtgggaggg	gaagctgcca	gcccttcta	accatgaaga	aataaccttgt	agagccttct	1440
ggatgctgga	aggatgaata	acgggggtct	ctggaggctg	ccccctgtca	gatcaactgt	1500
acttctgagc	ctccagtcca	gtctcagccc	catgtgtcat	ggccagtgtat	aatgagccct	1560
cactctctgt	ttggtcttta	ttctcccat	gtggggctga	agtctggatt	gagccgttat	1620
tcaagatgt	cagtttttt	gacagggaaag	tagtgtcaca	gaaacagcag	gggcttggca	1680
agatgatcta	actgcaaatac	ctacctggct	cagccaccag	ctagttctgt	gatcttgaac	1740
aagtttttca	acttctctga	ggccatccct	tggctacaac	acaccagttg	gttgacagga	1800
tgaaatgacg	aagtccctta	cacctgtat	cccagcactt	tgggaggcca	aggcgggtgg	1860
atggctttag	cctgagaggt	gacagcatgc	cgccagtcct	cacagccctc	gttcgctctc	1920
ggcgcttcct	ctgcctgggc	tcccacttcg	gtggcacttg	aggagccctt	cagccaccg	1980
ctgcactgtg	ggagccctt	tctgggctgg	ccaaggccag	agccggctcc	ctcagcttgc	2040
aggaggtgt	ggagggagag	gctcaagcag	gaaccggggc	tgccgcacggc	gttcgctggc	2100
cagctggagt	tccgggtggg	cgtggcttg	gcgggccccg	cactcggagc	agcgggcccag	2160
ccctgcccagg	ccccggggcaa	tgagaggctt	agcaccgggg	ccagcggctg	cgaggagggt	2220

10/11

caggacagcc	tggaactttc	gatgggcct	atccaagtgt	gggggtgggca	cagcagccaa	6000
gaccataatgt	ccttatctca	ggtagggct	caggaggct	cccagacagg	cagcctccgg	6060
agagtttggg	ggtaggaatg	ggagcaacca	ggcttctttt	tttctctctt	agaatttggg	6120
ggcttggggg	acaggcttga	gaatccccaa	ggagaggggc	aaaggacact	cccccacaaag	6180
tctgccagag	cgagagaggg	agaccccgac	tcagctgcca	tttccccaca	ggcct	6235

<210> 7
<211> 278
<212> DNA
<213> Homo sapiens

<400> 7	aagctttat	aggtaaat	tttccactta	gtactgctt	tgtaatgttg	tctttttatt	60
	ttcatttata	tcaagatgtt	ttctaatttc	tcttgacttc	cttcttaat	tcttacactca	120
	tgttagacata	cattttggc	cctatgcatt	ggatgcaaa	accagactaa	tttactttgt	180
	acaaaaagaa	aatgagaaa	gaaatatatt	tgttcttg	agcactata	ggaaataactt	240
	tatattccat	ttgtttcatc	atattcatat	atcccttt			278

<210> 8
<211> 73
<212> DNA
<213> Homo sapiens

<400> 8	cattggatac	tccatcacct	gctgtgat	tatgaatgtc	tgcctatata	aatattcact	60
	attccataaac	aca					73

<210> 9
<211> 3033
<212> DNA
<213> Homo sapiens

<400> 9	actaacataa	agctgaaggt	gaataaaaaa	atcagggta	gccaaacaaa	ttttcatggt	60
	caaataccac	ataaaaagta	aatatactta	agttcccagc	aaaatctgaa	ttgaacgttag	120
	acaaaaatgt	catttctcag	tgttgacag	acttaacagt	ttgagccaa	aaaaatgtac	180
	tgactagata	aactactaa	agttgttaat	tttgcaatg	tatatttctg	aaaagaaaagt	240
	ttatctatta	tagaaattcc	tgtgcccatt	taagaacttt	gagcatttt	attgtttaat	300
	aatatagtt	aattgcata	tgaaaaata	caataataca	atttatttgg	tttattttaaa	360
	aaaactgatt	cttctgttc	tctctatata	tagactgatt	ttataactat	tttgccctaaa	420
	gatcaccaaa	ttgttgaag	cctaggttc	tgagggatgg	aaaatgtgt	cacaactatt	480
	tacagttcac	acacacattc	tgggattta	atacattcctt	tacaagtgc	ggaaagggtgg	540
	aagattgatg	atttggggaa	attagagct	ccacacccca	gaggggtggta	tggtagtttg	600
	tctgttgtga	gctgtgtgaa	tcagagat	tgatttagac	atataatttt	aaagaggaaa	660
	gatgaaccaa	tcaaaaataa	taactataat	gactttca	gatatagaca	atacattttaa	720
	gatataaaatg	gaaacaaaaa	aagttaaaag	tggggagatg	aagtctgtt	ttttggtttt	780
	tttttttttt	tgctttttt	tttgttttag	taatcagtgt	taccagttt	aaataatggg	840
	ttataagaca	ctatatgca	gcctcatgtt	aacctccaa	ctaaaacata	caacaaatac	900
	acacaaaata	aaaaggagaa	attaacac	accaccagag	aaaatcacct	acattaaaag	960
	aaagacaaat	aggaagaaaa	taagaaagag	aaggccatca	aataatcaga	aatgaataaa	1020
	caaataatgaca	ggaataagt	ctcataataa	ataacattga	atgtaaatgg	actaagctct	1080
	ccaatgaaag	acagggagt	gctgaatgt	ttttaaaaaa	aatatttacac	cgagctgtgc	1140
	gtggtgtctc	acacctataa	tcccagcatt	ttgggagact	gagccgggtg	gatcacttga	1200
	gcccaggagt	tcgagaccag	cctggccaa	atggcaaaac	cctgtctcta	ctaaaaatac	1260
	aaaaaaattag	ctgaacatgg	tggcacatgc	ctgtgggtcc	agctactaga	gaggctgagg	1320
	cagaagaatt	gcttgaactt	gggaggttgg	ggttgcagt	agctaagatt	gatggagcca	1380
	ctgcacccca	gccttaggt	cagaataaga	ctctgcctca	aaaaaaaaaa	gcaaaacaaa	1440
	acaaaacaaa	aaacccttag	acccaatgt	tcattgccta	caagaagtat	gcttcacctt	1500
	taaagacaca	tataactgt	agttaaaggg	atggaaaaat	attctatgcc	tatgaaaaca	1560
	aacaaaaaga	agcagaagct	acatttat	cagacaaaat	agactgcaag	acaaaaacta	1620
	tgaaaagaga	gaaagaaggt	cattatata	tgataaaaggg	gtccatttag	caagagcatt	1680
	taacaattct	aaatataat	tcacccaa	ctggagact	caggtatata	aagcaaaat	1740

9/11

actgggtgcc	ccagcagtgc	cagcccgcg	gchgctgtct	cgctcgat	ttcaactggc	2280
cttagcagcc	ttccccgcgg	gcagggctcg	ggacctgcag	cccgccatgc	ctgagcctcc	2340
cctccatggg	ctcctgtgcg	gcccggcct	cccgacgag	caccacccc	tgctccacag	2400
cgcggcgtcc	catcgaccac	gcaagggctg	agaagtgcgg	gchgcacggca	ccgggactgg	2460
caggcagcta	cccctgcagc	cctgggtcg	aatccactgg	gtgaagccag	ctgggctcct	2520
gagtcgttgt	gagacttgg	gaacctttat	gtctagctca	gggatcgtaa	atacaccaat	2580
cagcaccctg	tgtctagctc	agggtctgt	aatgcaccaa	tccacactct	gtatcttagct	2640
actctgtatgg	ggccttggag	aacctttatg	tctagctcag	ggattgtaaa	tacaccaatc	2700
ggcactctgt	atctagctca	agggtgtaa	acacaccaat	cagcacccctg	tgtctagctc	2760
agggtatgt	aatgcaccaa	tcgacagct	gtatctggct	actttcatgg	gcatccgtgt	2820
gaagagacca	ccaaacaggc	tttgggtgag	caataaagct	tctatcacct	gggtgcaggt	2880
gggctgagtc	cgaaaagaga	gtcagcgaag	ggagataagg	gtggggccgt	tttataaggat	2940
ttgggttaggt	aaaggaaaaat	tacagtcaaa	gggggtttgt	tctctggcgg	gcaggagtgg	3000
ggggtcgcaa	ggtgtcagt	gggggtgttt	tttggagccag	gatgagccag	aaaaaggact	3060
ttcacaaggt	aatgtcatca	attaaggcaa	ggacccgcca	tttacacctc	ttttgtggtg	3120
gaatgtcatc	agtttaagtt	gggcaggggca	tattcacttc	ttttgtgatt	tttcagttac	3180
ttcaggccat	ctggggcgtat	atgtgcagt	tacagggat	gcgatggctt	ggcttgggct	3240
cagaggcttg	acagctactc	tggggggcc	ttggagaatg	tttgggtcga	cactctgtat	3300
ctagttaaatc	tagtggggac	gtggagaacc	tttgggtctca	gctcaggat	tgtaaacgca	3360
ccaatcagcg	ccctgtcaaa	acagaccact	cggctctacc	aatcagcagg	atgtgggtgg	3420
ggccagataa	gagaataaaa	gcaggctgcc	cgagccagca	gtggcaacgc	gcacaggtcc	3480
ctatccacaa	tatggcagct	ttttttttt	gtgtttgcg	ataaaatctt	ctactgctcg	3540
ctttttgggt	ccacactgct	tttatgagct	gtaacactca	ccacgaaggt	ctgcagcttc	3600
actcctgaag	ccactaagac	cacgagccca	ccgggaggaa	tgaacaactc	cggccgcgt	3660
gccttaagag	ctataacact	caccgcgaag	gtctgcagct	tcactcctca	gccagcgaga	3720
ccacgaaccc	accagaagga	agaaaactgcg	aacacatctg	aacatcagaa	ggaacaaaact	3780
ccagatgcac	caccttaaga	gctgtAACAC	tcactgcgag	ggtccgcggc	ttccttcttg	3840
aagtcaagtga	gaccaagcac	tcaccagtt	cggacacaag	cccaggagtt	tgagatcagc	3900
ctggcaaca	tgtgaaaatg	ccctctctgc	aaaaaaaaaa	aaaattacaa	aaattggcgg	3960
agcatggtgg	tccgtgcctg	tggtcccagc	tacgcgggag	gctaaagtgg	gaggatcgct	4020
tgagccttggg	aggtaagac	tgcagtgcgc	tgtgattgt	ccacagccct	ctaggctggg	4080
ggacagactg	agaccctgtt	tcccctccgc	aaaaaaaaatg	acaaaagtgt	aataagaggt	4140
gcctgatatg	gctaggcgca	gtggctcatg	cctgtatcc	cagcactttg	ggaagccgag	4200
gcggcggggt	cacctaagg	caggagtgt	agaccagct	ggccaacatg	gagaaagccc	4260
atctttctta	aaaataaaaa	attagccggc	tgtggggca	gtgggtggagc	atgcctgtaa	4320
tcccagctac	tcaggaggct	gaggcaggag	aatcaactga	acccaggagg	cggcggttgc	4380
agtgagccga	gatcgtccca	ttgcactcca	cccactccag	cctggcaac	aagagccaaa	4440
ctctgtctta	aaaaaaaaaa	aaaaaaagtgc	ctgacatata	agaggtgtgc	aatgcaatag	4500
ttgcccaggca	acatgtttaa	gaatgtggag	ctcctgcctt	ccatggctct	gttaaaaacc	4560
caccctcaag	gccaggtgca	gtggctcatg	cctataatcc	cagcactttg	ggaggcccgag	4620
gcgggtggat	cacctgaggt	caggagttcg	agaccagct	gaccaccaac	atggtaaaat	4680
cccacctcta	ctaaaaatac	aaaattagat	gagcatggtg	gtgcatgcct	gtaatcccac	4740
ctacttggga	ggctgaggca	ggaaaatcac	tagaaccagg	gaggcggagg	ttgttagtgag	4800
ccgagatcgt	gccattgcac	tccagcctga	gcaatgagcg	aaactccatc	tcaaaaaaac	4860
aacaacaaaa	accactctc	tactcccagg	gagctggta	cagagctggg	ccacatcagt	4920
gcaaggtgct	gagccacaga	gctaaggcgg	agctgcagga	ccgcggacca	gataacagtg	4980
tgtgagatca	gtgtgtgaga	tcagacgtcc	ctgccatgg	tgaccaccag	ggggccccca	5040
agcaccagag	atggccccc	ccagtcacca	catccacttc	tcatccagag	atgtctgttt	5100
cttggcacgc	tgggttaaat	taggacagaa	ggtgacagtc	ttgggtgtgg	tcagtcagac	5160
tgccttggc	aggccttgc	gcctgttagaa	aacgttcagg	cctaggccgg	gcacgggtgg	5220
tcacgcctgt	aatcccagca	ctttgggagg	ccgaggcgggg	tggatcacga	ggtcaggaga	5280
tcgtgaccat	cctggctaac	acggtaaaac	cccgctctca	ctaaaaatac	aaaaaattgg	5340
ccgggcattgg	tggcgggcac	ctgtagttcc	agctactcgg	gaggctgagg	caggagaatg	5400
gcgtgaaccc	gagaggcaga	gttgcagt	agccgagatc	gchccactgc	actccagcct	5460
ggggcgacaga	gcaagactcc	atctggaaaa	gaaaaagaaa	acgttcagg	ctgagccaga	5520
ggcccaggct	gtaattctgt	cacttaccat	gaccttggc	aaggcacttc	cttccctggc	5580
ccagttcacg	gggttggaaat	cgactccaag	gtcccttcca	gcattaacgc	tgcattgggtc	5640
taagatgaga	agatggggca	gttccccctc	tctcaccatca	gcccgtgtcc	acttcaaggt	5700
gaatgaccag	ggaagtcacg	tgtcccaatc	ccgcagttcc	aaagcccttg	gggaccctac	5760
tgtcagggtc	gtgcacgagg	aggtaaggt	caggtgagcc	aatgcctcg	aagggttcttg	5820
cctcattcgg	gacagacatc	cggtttccctc	tggctctacc	gggattctag	gggctttagc	5880
cgaatgagtc	atggggggcg	gggggttttc	tggggagtt	cccagcta	caacttggga	5940

11/11

tattagagcc aaagagagag atagacagac ccccatacaa taataactgg agacttcaac	1800
acccacttt cagcatttga cagatcatcc agacagaaaa ttaacaaaca tcaaatttca	1860
tctgcaccat aggtcaaatg gacctagtag atatcacag aacatttgat ccaacagctg	1920
tagaatacac attcttctcc tcagcacatg gataatttc aaggatatac caaatgctag	1980
gtcacaaaac aaatctaaa atttagaaaa aaagtgaat aatataaac gtttctctc	2040
accacagact aagaaaaaaa gaagtccaa ataaatacaa tctgagataa aaaaggagac	2100
gagacaacca ataccacaaa aaattaaagg atcattagaa gatactatga aactatatgc	2160
taataaattt gaaaacctga aaaaaataga taattcctag aacatacaa catactggc	2220
tgttcaggtt ttgtatttt tcatagtacc atgaagaaat acaagaattt tttctagaac	2280
catttttgta ttcttcatg gttttgtat ttcttcatgg aaccatgaag aaataaaaaa	2340
tgtgaacagg ccaataacaa gtaatgagac agaagccata ctaaaaagta tcccagaaaa	2400
gaactcagga tctgatggct tcactgatga attttgc当地 atataaaaa aactaataacc	2460
aatccaactc aaattattaa aaaaatagag gtggacagaa tctttccaaa tgtattctat	2520
gaggccagtg tttttctga ttgaatctcc cattatattt taatcacata taaaaccaga	2580
gaaagacaca taaaaagaa agaaaactgt aggccatat ctctgatgaa cattgatgca	2640
gaaatcctca acaacaaatt agcaaactga attcaagaac acattaaaac aatcattcat	2700
catgaccaag tggaaatttgc cctagagatt caagtgtgt taggtatgtg cagatcaatg	2760
ggtttaatgt tgtccaatga acataatgtc ctccagctcc atccatgttc ttgcaaattga	2820
caggatctca ttcttttta tggctaagta gtactccatt gtgtataagt gccatatttt	2880
cttatccat tcatactgtt gacacctaag ttgcttccaa atcttagcta ttgtgaatag	2940
tgctgcaata aacatgggag tgtaaatatt ttgttgacat actgatttca ttcccttgg	3000
ataaataaccc agtagtggga ttgctggatc ata	3033

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 September 2001 (20.09.2001)

PCT

(10) International Publication Number
WO 01/68882 A3

- (51) International Patent Classification⁷: C12N 15/63 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (21) International Application Number: PCT/US01/07870 (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (22) International Filing Date: 13 March 2001 (13.03.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
09/525,160 14 March 2000 (14.03.2000) US
- (71) Applicant (*for all designated States except US*): TRAN-SKARYOTIC THERAPIES, INC. [US/US]; 195 Albany Street, Cambridge, MA 02139 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): IVANOV, Evgenii [RU/US]; 390 East Foxboro Street, Sharon, MA 02067 (US).
- (74) Agents: MYERS, P., Louis et al.; Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110-2804 (US).
- Published:**
— with international search report
- (88) Date of publication of the international search report: 14 March 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

A3

WO 01/68882

(54) Title: METHODS FOR HOMOLOGOUS RECOMBINATION

(57) Abstract: The invention features a method of promoting an alteration at a selected site in a target DNA, e.g., in the chromosomal DNA of a cell. The method includes providing, at the site: (a) a double stranded DNA sequence which includes a selected DNA sequence; (b) an agent which enhances homologous recombination, e.g., a Rad52 protein or a functional fragment thereof; and (c) an agent which inhibits non-homologous end joining, e.g., an agent which inactivates Ku such as an anti-Ku antibody or a Ku-binding oligomer or polymer, and allowing the alteration to occur. The agent which inhibits non-homologous end joining, e.g., a Ku inactivating agent such as an anti-Ku antibody, is preferably provided locally. Component (a), (b), and (c) can be introduced together, which is preferred, or separately.

INTERNATIONAL SEARCH REPORT

Inte. l Application No

PCT/US 01/07870

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/63

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WO 00 12716 A (PIONEER HI BRED INT) 9 March 2000 (2000-03-09) abstract page 2, line 14 - line 24 page 3, line 10 - line 15 -----</p>	1-8
A	<p>TSUKAMOTO Y ET AL: "Hdf1, a yeast Ku-protein homologue, is involved in illegitimate recombination, but not in homologous recombination" NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 24, no. 11, 1996, pages 2067-2072, XP002170162 ISSN: 0305-1048 the whole document ----- -/-</p>	1-9

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

27 September 2001

Date of mailing of the international search report

12/10/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Panzica, G

INTERNATIONAL SEARCH REPORT

Inte. n. Application No

PCT/US 01/07870

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	PETRINI J H J: "The Mammalian Mre11-Rad50-Nbs1 Protein Complex: Integration of Functions in the Cellular DNA-Damage Response" AMERICAN JOURNAL OF HUMAN GENETICS, UNIVERSITY OF CHICAGO PRESS, CHICAGO,, US, vol. 64, 6 April 1999 (1999-04-06), pages 1264-1269, XP002150324 ISSN: 0002-9297 the whole document ---	1-9
A	CRITCHLOW S E ET AL: "MAMMALIAN DNA DOUBLE-STRAND BREAK REPAIR PROTEIN XRCC4 INTERACTS WITH DNA LIGASE IV" CURRENT BIOLOGY, CURRENT SCIENCE,, GB, vol. 7, no. 8, 1 August 1997 (1997-08-01), pages 588-598, XP002065034 ISSN: 0960-9822 the whole document ---	1-9
A	TOMKINSON A E ET AL: "STRUCTURE AND FUNCTION OF MAMMALIAN DNA LIGASES" MUTATION RESEARCH, AMSTERDAM, NL, vol. 407, no. 1, 1998, pages 1-9, XP002065035 ISSN: 0027-5107 the whole document ---	1-9
A	WO 98 30902 A (CRITCHLOW SUSAN ELIZABETH ;CANCER RES CAMPAIGN TECH (GB); JACKSON) 16 July 1998 (1998-07-16) abstract claims ---	1-9
A	WO 99 25829 A (NANDABALAN KRISHNAN ;YANG MEIJIA (US); CURAGEN CORP (US); SCHULZ V) 27 May 1999 (1999-05-27) ---	
A	WO 98 30903 A (CANCER RES CAMPAIGN TECH ;DOWNS JESSICA ANNE (GB); JACKSON STEPHEN) 16 July 1998 (1998-07-16) abstract disclosure claims ---	1-9
A	US 5 641 670 A (HEARTLEIN MICHAEL W ET AL) 24 June 1997 (1997-06-24) cited in the application the whole document ---	1,9,10, 26,27,75
A	US 5 272 071 A (CHAPPEL SCOTT C) 21 December 1993 (1993-12-21) cited in the application the whole document ---	1,9,10, 26,27,75
		-/-

INTERNATIONAL SEARCH REPORT

Inte. n. Application No

PCT/US 01/07870

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>TEO SOO-HWANG ET AL: "Lif1p targets the DNA ligase Lig4p to sites of DNA double-strand breaks." CURRENT BIOLOGY, vol. 10, no. 3, 10 February 2000 (2000-02-10), pages 165-168, XP002178014 ISSN: 0960-9822 the whole document ---</p>	1-9
A	<p>MILNE G TODD ET AL: "Mutations in two Ku homologs define a DNA end-joining repair pathway in <i>Saccharomyces cerevisiae</i>." MOLECULAR AND CELLULAR BIOLOGY, vol. 16, no. 8, 1996, pages 4189-4198, XP002178015 ISSN: 0270-7306 the whole document ---</p>	1-9
A	<p>KABOTYANSKI ELENA B ET AL: "Double-strand break repair in Ku86- and XRCC4-deficient cells." NUCLEIC ACIDS RESEARCH, vol. 26, no. 23, 1 December 1998 (1998-12-01), pages 5333-5342, XP002178016 ISSN: 0305-1048 the whole document ---</p>	1-9
A, P	<p>WO 00 68404 A (PIONEER HI BRED INT ; SHI JINRUI (US); MAHAJAN PRAMOD B (US)) 16 November 2000 (2000-11-16) the whole document -----</p>	1-9

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1, 25 and 75 relate to an extremely large number of possible methods. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the methods claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the methods, namely: a method to alter a given nucleic acid genomic sequence by inhibiting non-homologous end-joining factors Mre11, Rad50, Nbs1, Lig4, Xrcc4, Ku, and by enhancing the activity of homologous recombination agents as Rad51, Rad52, Rad54 (see claims 2 and 4).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/07870

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0012716	A	09-03-2000	AU EP WO US	5799599 A 1108032 A2 0012716 A2 6180850 B1	21-03-2000 20-06-2001 09-03-2000 30-01-2001
WO 9830902	A	16-07-1998	AU AU AU AU EP EP WO WO GB GB GB GB JP JP US	724108 B2 5568198 A 729066 B2 5568498 A 0966683 A1 0965040 A1 9830902 A1 9830903 A1 2321702 A ,B 2322193 A ,B 2329469 A ,B 2329248 A ,B 2001508868 T 2001508175 T 6242175 B1	14-09-2000 03-08-1998 25-01-2001 03-08-1998 29-12-1999 22-12-1999 16-07-1998 16-07-1998 05-08-1998 19-08-1998 24-03-1999 17-03-1999 03-07-2001 19-06-2001 05-06-2001
WO 9925829	A	27-05-1999	US AU EP WO	5986055 A 1522499 A 1030919 A2 9925829 A2	16-11-1999 07-06-1999 30-08-2000 27-05-1999
WO 9830903	A	16-07-1998	AU AU AU AU EP EP WO WO GB GB GB GB JP JP US	724108 B2 5568198 A 729066 B2 5568498 A 0966683 A1 0965040 A1 9830902 A1 9830903 A1 2321702 A ,B 2322193 A ,B 2329469 A ,B 2329248 A ,B 2001508868 T 2001508175 T 6242175 B1	14-09-2000 03-08-1998 25-01-2001 03-08-1998 29-12-1999 22-12-1999 16-07-1998 16-07-1998 05-08-1998 19-08-1998 24-03-1999 17-03-1999 03-07-2001 19-06-2001 05-06-2001
US 5641670	A	24-06-1997	AU AU BR CA CN CZ EP FI HU JP NO NZ SK WO US ZA	709058 B2 2550495 A 9507874 A 2190289 A1 1119545 A 9603258 A3 0759082 A1 964536 A 76844 A2 10500570 T 964802 A 285945 A 146196 A3 9531560 A1 5733746 A 9503879 A	19-08-1999 05-12-1995 19-08-1997 23-11-1995 03-04-1996 17-12-1997 26-02-1997 09-01-1997 28-11-1997 20-01-1998 09-01-1997 25-03-1998 04-02-1998 23-11-1995 31-03-1998 18-01-1996

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/07870

Patent document cited in search report	Publication date	Patent family member(s)		Publication date	
US 5641670	A	AU	689455 B2	02-04-1998	
		AU	5736294 A	22-06-1994	
		AU	5840198 A	04-06-1998	
		CA	2151032 A1	09-06-1994	
		EP	0672160 A1	20-09-1995	
		JP	8503856 T	30-04-1996	
		MX	9307623 A1	30-06-1994	
		NZ	259165 A	26-01-1998	
		NZ	329348 A	28-10-1999	
		SG	46476 A1	20-02-1998	
		TW	402639 B	21-08-2000	
		WO	9412650 A2	09-06-1994	
		US	5733761 A	31-03-1998	
		US	5968502 A	19-10-1999	
		AT	155810 T	15-08-1997	
		AU	669499 B2	13-06-1996	
		AU	3069892 A	07-06-1993	
		AU	710255 B2	16-09-1999	
		AU	6563196 A	28-11-1996	
		DE	69221168 D1	04-09-1997	
		DE	69221168 T2	26-02-1998	
		DK	649464 T3	02-03-1998	
		EP	0649464 A1	26-04-1995	
		EP	0750044 A2	27-12-1996	
		ES	2106891 T3	16-11-1997	
		GR	3025054 T3	30-01-1998	
		JP	7500969 T	02-02-1995	
		MX	9206376 A1	28-02-1994	
		NZ	245015 A	21-12-1995	
		NZ	270805 A	24-10-1997	
US 5272071	A	21-12-1993	AT	156189 T	15-08-1997
			AU	645294 B2	13-01-1994
			AU	7183691 A	24-07-1991
			BG	60624 B1	31-10-1995
			BR	9007937 A	17-11-1992
			CA	2071989 A1	23-06-1991
			DE	69031172 D1	04-09-1997
			DE	69031172 T2	12-03-1998
			DE	779362 T1	05-04-2001
			DK	505500 T3	25-08-1997
			EP	0505500 A1	30-09-1992
			EP	0779362 A1	18-06-1997
			ES	2104690 T3	16-10-1997
			ES	2151463 T1	01-01-2001
			FI	922863 A	18-06-1992
			GR	3025057 T3	30-01-1998
			HK	1000547 A1	03-04-1998
			HU	62657 A2	28-05-1993
			HU	217212 B	28-12-1999
			JP	5504682 T	22-07-1993
			KR	176693 B1	01-04-1999
			LT	1595 A ,B	25-07-1995
			LV	10655 A	20-04-1995
			LV	10655 B	20-08-1995
			NO	922436 A	19-06-1992
			OA	9594 A	30-04-1993
			RO	109864 B1	30-06-1995

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/07870

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 5272071	A	RU	2128227 C1	27-03-1999
		WO	9109955 A1	11-07-1991
		ZA	9010392 A	29-01-1992
WO 0068404	A 16-11-2000	AU	4975400 A	21-11-2000
		EP	1093523 A1	25-04-2001
		WO	0068404 A1	16-11-2000

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.